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CHAPTER 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: 
Siregar AYM, Komarudin D, Leuwol B, Afriandi I, Djuhaeni H, Baltussen R.  
Economic aspect of HIV/AIDS control and injecting drug use in Indonesia.  
Acta Medica Indonesiana 2009; 41 (suppl.1); 70 – 4 
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Background 
In Indonesia, the HIV epidemic is increasing, and among the fastest growing in 
Asia [1]. The epidemic is concentrated among injecting drug users (IDUs) and their 
sexual partners in most parts of the country, but generalised in the Papua province 
[2]. In 2011, an estimated 186,257 Indonesians were living with HIV, with HIV 
prevalence among the general Indonesian population age 15-49 of around 0,27% 
[3,4]. Total deaths in Indonesia because of HIV/AIDS were estimated at 5,430 in 
2011 [5].  
 
Needle-sharing, which is a very efficient way to transmit HIV, has been reported to 
be almost universal, while unprotected sex was found to be common, including 
having multiple partners (25%) and buying sex from sex workers (19%) among 
IDUs [6]. HIV prevalence among IDUs who have been injecting more than two 
years reached 60% in Jakarta, 54% in Surabaya, and 48% in Malang [6]. Even when 
the numbers of IDUs are relatively small, their contribution to the overall epidemic 
in a country can be considerable, because of further spreading sexually, creating a 
critical mass in sexual networks. As a response to growing numbers of IDUs and 
the risk of HIV transmission, the Indonesian government has launched harm 
reduction programs since 2007. As a consequence, the face of the HIV/AIDS 
epidemic started to change and it is now spreading more through heterosexual 
transmission, mostly to the IDUs’ partners and commercial sex workers. The 
percentage of HIV transmission through injecting drug use decreased from 53% in 
2001-2005 to 34% in 2011, and the heterosexual transmission increased from 37% 
to 71% during the same period [2]. The Indonesian government is developing and 
implementing HIV/AIDS control policies in response to the epidemic since 1997, 
and in 2010, a total of US$69 mln was spent from all sources [2,7].  
 
A number of important policy questions in HIV/AIDS control prevail, all related 
to the use of these resources to control the epidemic in Indonesia. The first 
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question relates to the absolute level of resources that is currently available, and 
how these compare with the health problem at hand now and in the future. In 
other words, is present funding sufficient to combat the epidemic? The second 
question relates to use of available funding, and whether these are being used 
adequately. That is, is present funding being targeted at the right interventions, at 
the right group of people, and in the right geographical areas? The third question 
relates to the financial sustainability of the present Indonesian HIV/AIDS control 
program – are such programs based on reliable sources of funding? These are 
vexing questions in a time where adequate policy measures are urgently needed in 
Indonesia to prevent the epidemic – which is now still concentrated in specific 
targets groups and / or geographic areas – to spread over to the general population 
in larger parts of the country.  
 
This chapter deals with the above questions, as such describes HIV/AIDS policy in 
Indonesia with special reference to the allocation of resources, and provides the 
framework for the entire thesis. To that aim, we first outline the context, i.e. the 
characteristics of the Indonesian health system that may affect HIV/AIDS control. 
Second, we discuss HIV/AIDS expenditure patterns in Indonesia. Next, we 
describe the potential role that economic analyses like costing and cost-
effectiveness analysis could play and conclude with a number of recommendations 
on future research on economic analysis on HIV/AIDS control in Indonesia. 
Finally, the chapter outlines the conceptual framework and structure of the thesis. 
 
Health policy and HIV/AIDS in Indonesia 
Health policy in Indonesia 
Indonesia has made significant progress in health outcomes over the last decades. 
For instance, infant mortality dropped from 118 deaths per thousand births in 1970 
to 25 in 2011, and life expectancy increased from 48 years to 69 years over the 
same period. This progress owed much to the expansion of public health provision 
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in the 1970s and 1980s. However, new challenges have emerged as a result of social 
and economic changes, and there are a number of additional major factors that 
make the careful allocation of health resources an imperative [8–13]. 
 
First, in recent years, Indonesia’s public expenditures on health have increased 
substantially. In real terms, total public spending on health has more than 
quadrupled from about US$1 billion in 2001 to over US$4 billion in 2007, 
surpassing for the first time 1 percent of GDP, and reached US$11 billion in 2010. 
Despite this increase, Indonesia still spends comparatively little on health. In total 
in 2010, Indonesia spends less than 3 percent of GDP on the health sector (split 
between private and public spending in a ratio of 2 to 1). In contrast, Vietnam, the 
Philippines, Malaysia and most of Indonesia’s other neighbors spend more. It is 
therefore critical that limited available public funds should be spent well [8–11].  
 
Second, health financing is not only low, but also inequitable. Health financing is 
overwhelmingly private, with individuals providing 65 percent of total health 
expenditure, and most of this is out-of-pocket (75 percent). The result is that the 
poor utilize and receive less publicly funded services and public subsidies than the 
rich: the poorest 20 percent of the population captures less than 10 percent of total 
public health subsidies while the richest quintile captures almost 40 percent. 
Publicly financed services should therefore be targeted to those who need them. In 
addition, there are important regional and socioeconomic inequities in the health 
system, i.e. people in rural areas, and the poor have less access to the health system 
[8–10,12,13].   
 
Third, decentralization came with new challenges and opportunities. Local 
governments have become the focal point for health care provision: their share in 
total public health spending has increased from 10 percent prior to 
decentralization, to 40 percent in 2009. Although this could make public spending 
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more responsive to local conditions and disease patterns, it may also cause the loss 
of economies of scale, increasing regional disparities and a lack of critical health 
information [8,9,13,14]. 
 
Policy responses to HIV/AIDS in Indonesia 
Indonesia’s first AIDS case was detected in 1994 and soon afterwards the country 
had developed its first AIDS strategy and established a national AIDS commission, 
provincial commissions and approximately 150 district commissions [15]. In 2003, 
the government endorsed Indonesia’s second AIDS national strategy from 2003 to 
2007, which reaffirmed the central importance of HIV prevention while 
acknowledging the need to expand care and treatment. The strategy emphasized 
policy reform, capacity building, coordination, surveillance, prevention, treatment 
and care and the same aspects [16]. The latest HIV/AIDS national strategies and 
action plans for 2010-2014 stressed prevention, treatment, support and care, impact 
mitigation, and establishing conducive environment [17]. 
 
The total spending on AIDS in Indonesia has increased from around US$ 57 mln 
(2006) to approximately US$ 69 mln (2010). Domestic public health expenditure on 
HIV/AIDS was only US$15 mln in 2006 (consumed as such only 0.36% of total 
public health budget in that year) and has increased considerably to around US$28 
mln in 2010. Within the same period, provincial and city/district budgets increased 
from about US$4 mln to roughly US$11 mln [2,3].  
 
From the domestic public health expenditure on HIV/AIDS in 2010, central 
government spent largest parts of this (64%) and local governments the rest (36%). 
HIV expenditure from international sources equaled US$41 mln in 2010, and as 
such was less than the double of domestic public health HIV expenditure. This 
included both bilateral and multilateral source of funds. Of total domestic and 
international health expenditure, the majority was spent on support, care and 
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treatment (35%), while less was spent on prevention (30%), program management 
(19%), and other HIV expenditures (16%) [2].  
 
 Table 1. HIV/AIDS Prevalence, expenditure, and per capita health expenditure 
To view Indonesia in international context, Table 2 compares health expenditure 
on HIV/AIDS in Indonesia with some countries which have approximately the 
same prevalence rate of HIV in young adults. The table reveals that Indonesia’s 
total health expenditure on HIV/AIDS is relatively large, while the health 
expenditure on HIV/AIDS per person living with HIV/AIDS (PLHIV) and the 
share of domestic funding in Indonesia is higher than in Pakistan and India. 
 
The above expenditure patterns give rise to three concerns. The first concern 
relates to the relatively low levels of funding of HIV/AIDS control/PLHIV in the 
country, higher only than India and Pakistan- although HIV/AIDS is still a 
relatively minor health problem in terms of infected cases and incurred deaths, it 
carries a high risk to spread to the general population in large parts of the country if 
no adequate measures are taken, as has already been occurring now in Indonesia[2]. 
Country Year 
HIV prevalence (%) 
in adults (15–49) 
Total health 
expenditure 
(in million US$) 
Total health 
expenditure 
spent on 
HIV/AIDS 
(in million US$) 
Total health 
expenditure spent 
on HIV/AIDS per 
PLHIV 
(US$) 
Domestic health 
expenditure per 
PLHIV for 
HIV/AIDS 
 (US $) 
Percentage of 
international 
fund for 
HIV/AIDS 
Indonesia 2010 0.3 (0.2-0.4)** 18,482 69 371 149 60% 
Pakistan 2010 0.1 (0.1-0.3)**  3,884 13 133 13 90% 
Iran 2010 0.2 (0.1-0.2)** 18,885 41 437 389 11% 
China 2010 0.1 (0.1-0.1)** 300,578 615 831 706* 15%* 
India 2008 0.29 49,062 140*** 62 15 75% 
Belarus 2010 0.4 (0.3-0.6)** 3,096 12 940 615 35% 
*estimated; **2011;***2009; ^ US$ may not be the best currency to use as comparison between countries as it does not capture the variability in 
purchasing power 
Source: National AIDS Commission (Indonesia); National AIDS Control, Pakistan; UNAIDS, Islamic Republic of Iran; National AIDS Committee 
Secretariat, Islamic Republic of Iran, MoH of the People’s Republic of China; UNAIDS; National AIDS Control organization, India; the 
Republic of Belarus; World Bank [2,18–25] 
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Hence, intensified control activities and associated increased funding are warranted 
in this context. The second concern is on the use of available funding. Indonesia’s 
health expenditure is said to be often misallocated, and to be spent on capital 
investment instead of as the urgently needed operating cost [8]. It is difficult, 
however, to judge whether this is also true for funding of HIV/AIDS control. The 
third concern relates to the financial sustainability of HIV/AIDS control activities 
in Indonesia given that the majority of funding is still coming from international 
sources despite the increase of HIV/AIDS domestic fund share from 27% in 2006 
to 40% in 2010 [2,7]. How will the programs against HIV/AIDS be sustained once 
the donor or international funding stops?  
 
Figure 1. The relationship between HIV/AIDS epidemic, health system, policy response, 
HIV/AIDS expenditure and interventions in Indonesia 
 
 
 
 
 
 
 
 
 
 
 
In summary, the Indonesian health policy response to HIV/AIDS faces a number 
of challenges. The nature of the Indonesian HIV epidemic (increasing overall 
prevalence, with different epidemic profiles); the characteristics of the Indonesian 
health system (decentralized policy making, need for efficient and equitable use of 
public funding), and the low and highly internationalized funding of HIV/AIDS 
(resulting in low service coverage and questions of sustainability) draw out a very 
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specific health environment of HIV/AIDS. Figure 1 illustrates how these factors 
are interlinked, and may influence HIV/AIDS control. 
  
Economic analysis of HIV/AIDS control 
The above sections have drawn out the specific context of HIV/AIDS in 
Indonesia. In such a context, reliable, objective evidence on the costs and likely 
effectiveness of interventions to reduce it, is a key input into policy debates. 
Without such evidence, policies and programmes to improve health are unlikely to 
achieve their potential for maximizing population health levels through strategic 
investments in intervention options. This section highlights the use of economic 
analysis to stimulate evidence-based policy in health, and specifically HIV/AIDS.  
 
Economic analysis includes both costing and cost-effectiveness analysis (CEA). 
Costing analysis provides detailed break-down of inputs and prices of interventions 
in HIV/AIDS control and can be used to improve programme management, or to 
predict budgetary outlays when scaling up interventions. CEA is an important tool 
in the priority setting process. In responding to the HIV/AIDS epidemic the costs 
and consequences of possible interventions in HIV/AIDS control must be known 
to the decision-makers to make best use of scarce resources [26]. Especially in the 
setting of Indonesia, with very limited funding available, the requirement for low-
cost, effective interventions is paramount. Policy-makers and planners are therefore 
faced with the challenge of allocating limited resources among programmes. Many 
factors contribute to decisions about resource allocation including concerns of 
sensitivity, acceptability, equity and efficiency. CEA informs policymakers on the 
relative costs and health effects of interventions, and can be used to improve the 
value for money, and as such the rationale of their investments in HIV/AIDS 
control. It can provide answers to some of the most frequently asked questions, 
such as is it better to invest resources in one intervention rather than another; 
which type or combination of services provides the best value from the budget 
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available; how should resources be allocated within the competing needs of AIDS 
control programmes; and how can extra investment best improve an intervention’s 
performance? 
 
At the start of this thesis, in 2008, very little information was available on costs and 
health effects of HIV/AIDS control in Indonesia to guide policy makers. A study 
by the World Health Organisation, through its WHO-CHOICE (Choosing 
Interventions that are Cost-Effective) program, evaluated costs and health effects 
of HIV/AIDS control in South-east Asia [27]. The conclusion was that reducing 
HIV transmission could be done most efficiently through mass media campaigns, 
interventions for sex workers and treatment of sexually transmitted infections 
where resources are most scarce. Prevention of mother to child transmission, 
voluntary counseling and testing, and school based education would yield further 
health gains at higher costs but would be regarded as cost effective or highly cost 
effective based on standard international benchmarks. Important insight was that 
antiretroviral therapy was at least as cost effective in improving population health 
as some of these interventions. This study, however, is of limited use as an 
evidence-base to health policy in HIV/AIDS in Indonesia as interventions 
targeting IDUs were not evaluated. Moreover, the analyses were performed for 
South-east Asia as a whole, whereas the epidemiology in Indonesia may be distinct. 
 
Rationale for thesis and research questions 
The previous section has pointed out the specific context of HIV/AIDS in 
Indonesia. This is characterized by an increasing overall prevalence with high risk 
groups as IDUs and sex workers, and a weak Indonesian health system. The low 
level of funding, mainly stemming from international sources, raises concerns on 
service coverage and their financial sustainability. It is therefore critical that limited 
available public funds should be spent well, and a number of important policy 
questions in HIV/AIDS control prevail related to the optimal use of available 
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limited resources [8–10,28]. In those situations of severe resource constraints, an 
effective and efficient use of resources becomes very important and are the main 
concerns addressed in this thesis through the broader application of economic 
analysis of HIV/AIDS control in Indonesia.  
 
The overall research question of this thesis is “what are the costs and effects of 
various strategies for HIV/AIDS control in Indonesia?”  
 
The sub questions following are: 
1. What are the costs and effects of providing hospital based methadone 
maintenance therapy (MMT)?  
2. What are the costs and effects of various voluntary counseling and testing 
(VCT) models? 
3. What are the costs of providing antiretroviral treatment (ART)? 
4. What are the implications of these findings for HIV/AIDS control in 
Indonesia? 
Figure 2 shows the outline of this thesis and the relation between the questions and 
chapters.  
 
Figure 2. Outline of thesis based on research questions 
 
 
 
 
 
 
 
 
 
 
What are the costs and 
effects of various strategies 
for HIV/AIDS control in 
Indonesia? 
Chapter II and III Chapter IV and V Chapter VI 
Question 3 
What are the costs 
of providing ART? 
Question 2 
What are the costs and 
effects of various VCT 
models?  
Question 1 
What are the costs 
and effects of 
providing hospital 
based MMT service?  
 
Question 4 
What are the 
implications of 
these findings for 
HIV/AIDS 
control in 
Indonesia? 
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Conceptual framework 
The following framework will be used throughout this thesis separately or in 
combination.  References to the specific chapter in which the method is used are 
provided within the explanation of each framework. 
 
Table 2. Types of economic evaluation 
Type of Study  Method  Measurement/
valuation of 
costs in both 
alternatives 
 Identification of 
effects 
 Measurement/ 
valuation of 
effects 
Cost analysis/cost-
minimization analysis 
 Costs are measured 
and the average or 
incremental cost is 
calculated 
 
 Currency  Identical in all 
relevant respects 
 None 
Cost-effectiveness 
analysis 
 Impact is measured 
using indicators 
related to the change 
in health status 
 
 Currency  Single effect of 
interest, common 
to both 
alternatives, but 
achieved to 
different degrees 
 
 Natural units (e.g. 
life years gained, 
disability days 
saved) 
Cost utility analysis  Impact is measured 
in terms of gains in 
the quality-adjusted 
life-years (QALYs) 
of an individual 
 
 Currency  Single or 
multiple effects, 
not necessarily 
common to both 
alternatives 
 Healthy years or 
(more often) quality-
adjusted life-years 
Cost benefit analysis   Impacts of the 
intervention are 
translated into 
monetary terms, in 
order to obtain a 
ratio 
 Currency  Single or 
multiple effects, 
not necessarily 
common to both 
alternatives 
 Currency 
Source: Drummond, et al; UNAIDS [26,30] 
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Economic evaluation (in health) 
Economic evaluation is the main method used throughout the thesis. Economic 
evaluation aims to maximizing social welfare by comparing the costs and effects of 
various alternative health programmes [29–31] (figure 3). Generally, there are four 
major techniques of economic evaluation (table 2), distinguished from each other 
according to how health effects are measured and valued [26,30]. We do not, 
however, distinguish CUA from CEA in this thesis as CUA is in itself a form of or 
a particular case of CEA and both share technical similarities [30–33].  
 
Figure 3. Economic evaluation framework 
 
 
 
 
 
 
Source: Drummond,  et al [30] 
 
Costs analysis and micro costing 
Cost analysis estimates the total direct and indirect costs of an intervention to the 
society. The basic approach is to estimate the number of cost-generating events for 
each patient and multiply them by relevant unit costs [34, 39]. This approach is 
used in chapter II, IV, and VI on the costing analysis of MMT, VCT and ART, and 
the result serves as the basis for the cost-effectiveness analyses of scaling up MMT 
and VCT presented in chapter III and V, respectively.  
 
Throughout this thesis, we differentiate two types of costs, namely costs of 
providing health interventions (health care cost), and costs of accessing health 
interventions (non-health care cost, including time/opportunity costs) [35]. We also 
assumed several viewpoints in conducting cost analysis, namely the provider, health 
Choice 
Programme of interest 
Comparator/alternative B* 
 
*This can be in a form of “doing 
nothing”. Even when the 
comparator is another form of 
program, comparing with “doing 
nothing” is still important as the 
comparator may not be efficient.  
The differences in costs 
and effects are compared 
in an incremental analysis 
Costs and effects 
Costs and effects 
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care systems, patient and societal perspective (table 3). The provider perspective 
only considers costs which are directly incurred by the medical provider, while the 
health care system perspective considers costs incurred by the medical providers as 
well as those incurred by government and/or donor (e.g. through grant or in-kind 
subsidy). The patient perspective encompasses costs borne by the patients in 
accessing health care service, and the societal perspective includes all costs incurred 
in each perspective (taking into account any potential double counting). Each 
chapter explicitly states the specific perspective(s) used.    
 
Table 3. Perspectives used in this thesis 
Type of perspective  Costs incurred 
by medical 
provider 
 Costs incurred by 
government/donor 
 Costs 
incurred by 
patient 
 Costs incurred 
by the society 
Provider perspective  √  -  -  - 
Health care system 
perspective 
 √  √  -  - 
Patient perspective  -  -  √  - 
Societal perspective  √  √  √  √ 
 
 
Where possible, we employed a micro-costing approach to costing analysis as this 
method gives the most precise estimates, e.g.  to estimate costs of personnel, drugs, 
and equipments. However, in case where detailed data was not available, we use 
one of the following methods: case-mix group approach or average per diem [30] 
(the explanation for each of this approach is presented in figure 4). For instance, we 
estimated laboratory costs in chapter VII  using the case-mix group  approach, 
while we estimated hospital hotel costs using the average per diem approach (on 
the basis of WHO CHOICE estimates [36]).  
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   Figure 4. Levels of precision in hospital costing 
 
 
 
 
 
 
 
   Source: Drummond, et al [30] 
 
Costs Effectiveness analysis (CEA) 
CEA involves identifying costs and health effects of certain intervention(s) or 
program(s) from a relevant perspective. The costs are then divided by the health 
effects to obtain a cost-effectiveness ratio which indicates the efficiency and is used 
to make comparison of economic attractiveness among interventions [26]. Some 
examples of health effects are years of life gained, number of children immunized, 
number of infections averted, or disability adjusted life years (DALY) [29]. Chapter 
III and V utilize CEA in exploring the effects of scaling up MMT and VCT in 
Indonesia, namely the number of HIV infection averted and DALY.  
 
Asian Epidemic Model (AEM) and Resource Needs Model (RNM) 
The cost effectiveness studies in this thesis employ two models, the AEM and the 
RNM, to calculate the population health effects of scaling up MMT and VCT 
against the current situation.  
 
The AEM is a dynamic, deterministic compartment model mathematically designed 
for macro simulation of populations and key processes driving HIV transmission, 
focused primarily on the most important transmission routes in Asia – sex work, 
marital sex, and injecting drug use. The output data include the number of new 
HIV infections, AIDS cases, deaths, and routes of transmission per year between 
MOST PRECISE 
LEAST PRECISE 
Micro-costing 
Each component of resource use (e.g. laboratory tests, days of stay by 
ward, drugs) is estimated and a unit cost derived for each. 
 
Case-mix group 
Gives the cost for each category of case or hospital patient. Takes 
account of length of stay. Precision depends on the level of detail 
specifying the types of cases. 
 
Disease-specific per diem (or daily cost) 
Gives the average daily cost for treatments in each disease category. 
These may still be quite broad (e.g. orthopedic surgery). 
 
Average per diem (or daily cost) 
Averages the per diem over all categories of patients. Available in most 
health care systems.  
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1975 and 2030, with the probability of HIV transmission as one of the 
determinants for new infections [37]. 
 
The RNM was used primarily in this thesis to estimate the resources needed for 
providing a certain intervention within a certain scenario in relation with 
HIV/AIDS by combining population sizes, coverage of intervention, and unit 
costs. The RNM was initially made to estimate the costs of achieving goals stated at 
the UNGASS on HIV/AIDS [38]. The RNM contains three sub costs models, 
namely prevention model, care and treatment model, and mitigation model where 
the final expenditure for any specific program is a summation of these three 
elements.  
 
Disability Adjusted Life Years (DALYs) 
The concept of DALYs is central to assess the global burden of disease, to the 
conduct of many cost effectiveness analysis, and to identify disease control 
priorities [39]. A DALYs is the sum of the present value of future years of lifetime 
lost through premature mortality, and the present value of years of future life time 
adjusted for the average severity of disability due to a disease or injury [40]. In its 
calculation, it combines an estimate of the duration of the time lost due to 
premature death, a weight representing the social value of time lived at different 
ages, disability weight and a discount rate [29].  
 
The measure was first introduced in the World Development Report [39] and the 
Disease Control Priorities Review [41]. Since 1993, DALYs have been used in cost-
effectiveness analysis at a micro level and in sectoral prioritization exercises [40]. A 
second version of DALYs was developed in 1996 and is used to replace the earlier 
version [42,43].  
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Thesis Outline 
Chapter 2 presents the costs of delivering hospital based MMT service for IDUs in 
Bandung Indonesia from four perspectives: hospital, health system, patient, and 
societal. The costing analysis addressed concerns of financial sustainability at the 
hospital level and financial accessibility and economic attractiveness at the health 
system level. It also addressed the costs of MMT to the patient on the basis of a 
survey among 48 MMT patients over the period 2006-2007. 
 
Chapter 3 relates the costs of MMT from Chapter 2 to perform a cost 
effectiveness analysis on the provision of MMT as HIV prevention in Indonesian 
settings .We used the Asian Epidemic Model [37] and the Resource Needs Model 
[46] for this purpose.  
 
Chapter 4 explores the costs and outcome of various VCT models. We estimated 
the costs of delivering VCT service from four clinical settings: hospital clinic, HIV 
community clinic, STI community clinic, and prison clinic, and analyzed the 
advantages and disadvantages of each clinic in terms of costs and outcomes. The 
analysis involved the use of primary data on utilization, costs, and outcomes of 
VCT services in a hospital clinic (568 patients), HIV community clinic (28 patients), 
STI  community clinic (784 patients), and prison clinic (574 patients) in Bandung, 
Indonesia, in the period of January 2008 – April 2009. 
 
Chapter 5 provides the costs-effectiveness analysis of scaling up community-based 
VCT in West-Java, Indonesia. In this chapter, the costs of delivering VCT in the 
HIV community clinic, as presented in Chapter 5, are combined with analysis of 
effectiveness to estimate the cost effectiveness analysis on scaling up VCT at 
community level.  The Asian Epidemic Model [37] and Resource Needs Model [46] 
were used to calculate incremental costs per HIV infection averted and per DALY.  
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Chapter 6 reports on an economic analysis of HIV care and treatment in Indonesia 
to assess the options and limitations of increasing efficiency, improving access, and 
scaling up services. We calculated the cost of providing HIV care and treatment in 
a main referral hospital in West Java, Indonesia from 2008 to 2010, differentiated 
by initiation of treatment at different CD4 cell count levels (0-50, 50-100, 100-150, 
150-200, and >200 cells/mm3); time of treatment; HIV care and opportunistic 
infections (OI) cost components; and costs of patients for seeking and undergoing 
care. 
 
Chapter 7 presents the overall study conclusions, as well as implications and 
recommendations within the context of health policy in Indonesia. In addition, the 
chapter points out how future studies may further complete the information 
needed to achieve efficient HIV/AIDS control in Indonesia.  
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Abstract 
 
OBJECTIVE: To assess the cost of hospital-based methadone maintenance 
treatment (MMT) for injecting drug users (IDUs) in Bandung, Indonesia; to 
address concerns of financial sustainability at the hospital level and financial 
accessibility and economic attractiveness at the health care policy level.  
 
METHODS: In a one year observation period in 2006-2007, MMT service delivery 
costs were estimated on the basis of a micro-costing approach. Patient costs were 
estimated on the basis of a survey among 48 methadone clients.  
 
RESULTS: A total number of 129 clients attended the MMT clinic, resulting in a 
total of 16,335 client-visits. Total annual societal costs of running the MMT clinic 
equalled Rp 1,130 mln (US$123,672), or Rp 69,206 (US$7.57) per client visit. Of 
total costs, patient costs established the largest share (65%), followed by that of 
central government (20%), and the hospital (15%). Present consultation tariffs 
already cover hospital costs and the patient costs of accessing MMT services 
constitute almost 70% of their income.  
 
CONCLUSION: Under current circumstances, MMT services are financially 
sustainable to the hospital. MMT services are subsidized by the central government, 
and this is warranted considering the important role of the program in HIV/AIDS 
among IDUs. Still, the present user fee seems a barrier to utilisation, and a higher 
level of subsidy might be justified to reduce the cost to the patient.  
 
Key words: Cost Analysis, Methadone Maintenance Treatment, Injecting Drug 
User, HIV/AIDS, Indonesia
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Introduction 
The HIV epidemic shows an increasing trend in Indonesia, and is even among the 
fastest growing in Asia [1]. A total of 6,066 HIV cases and 11,141 AIDS cases were 
registered between 1987 and 2007 [2]. The epidemic is mostly driven by the use of 
non-sterile needles among injecting drug users (IDUs) in many parts of the 
country. The HIV prevalence in IDUs rose from 26.76% (42,749 cases) in 2002 to 
41.09% (90,030 cases) in 2006, while the prevalence among other risk groups 
remained stable or decreased [3,4]. 
 
In response to the increase in drug-related HIV cases, Methadone Maintenance 
Treatment (MMT) has been provided on a limited scale in Indonesia since 2003 [5]. 
Its effectiveness to control the HIV epidemic has been reported from different 
countries in the world [6]. Because of the increasing HIV-seroprevalence rate, 
Indonesian national policy now aims to scale up MMT services to cover 19% of all 
IDUs by 2010 [7]. Besides issues of medical, ethical and/or political nature, 
important concerns prevail at different levels regarding the economic aspects of 
MMT service implementation. Firstly, the hospital management is concerned about 
the financial sustainability of MMT services, considering that MMT services in 
Indonesia are not fully funded by the government and hospitals need to cover 
some of their costs through the imposition of a user fee. It, therefore, requires 
information on the breakdown of costs in order to estimate the appropriate charges 
to cover costs as well as to assess the efficiency of service delivery. 
 
These demand analyses from the hospital’s perspective. Secondly, policy makers of 
the Ministry of Health (MOH) are concerned about the budgetary impact of 
scaling-up MMT services to the whole of Indonesia, which requires analyses from 
the health system’s perspective. Thirdly, the policy makers are also concerned about 
the affordability and consequently the financial accessibility of the services, and 
therefore on the level of appropriate subsidy they provide for hospitals (which 
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demands health system perspective analyses), and the costs that patients spend on 
obtaining MMT services (including MMT fee, but also travel cost and time cost) 
(which need patient's perspective analyses). Fourth, they are concerned about the 
benefits of investing in the MMT services, and how this compares to other 
investments in health sectors. The last concern requires societal perspective 
analyses.  
 
However, to our knowledge, there are no studies reporting data on the costs of 
providing MMT in low-income countries, including Indonesia. Most studies in the 
literature on the cost of MMT services were conducted in developed countries 
setting Barley et al [8], Zaric, et al [9],  Barnett and Hui [10], and Masson et al [11] in 
the USA, and Doran et al [12] in Australia. These studies have addressed some of 
the concerns raised above, but the results are context specific and difficult to 
generalize to the Indonesian setting. 
 
Against this background, this study aims to estimate the cost of providing a 
hospital-based MMT clinic in the Indonesian setting from the above-mentioned 
perspectives. The analyses all respond to the above concerns.  
 
Methods 
Study setting 
The study was conducted at the MMT clinic of Hasan Sadikin hospital, a teaching 
and provincial top-referral hospital for West Java (approximately 40 million 
populations). The hospital is a public hospital with a capacity of more than 1,100 
beds and all the main specialities are represented. The MMT clinic was established 
in May 2006 and has been running up to now. The clinic is one of the 24 MMT 
service points across the country and opens every day from morning to noon.  
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All newly attending clients receive a medical examination and are assessed for 
eligibility to receive MMT according to the 2006 National Guidelines Criteria for 
MMT [13]. Urine test is compulsory for every new client and strongly suggested for 
other clients who show signs of intoxication and/or withdrawal. The dosage of 
methadone dispensed to each client will be based on the result of the medical 
examination. New clients receive medical examination and follow-up visits mostly 
include only counseling and dispensing. MMT clients pay a fixed amount of 
Rp15,000 per visit (US$1.64) to the hospital which includes all services mentioned 
above except for other medical conditions.  
 
Data collection and cost estimation 
The health system costs data (which include the costs from hospital and 
government perspectives) was constructed from utilization and service delivery cost 
data. We retrieved data on service utilization from the clinic’s records for one 
calendar year (November 2006 - October 2007). Data collected included for each 
client visit, information on attendance, methadone dosage, laboratory and other 
investigations, and referrals to corresponding medical services. Service delivery 
costs were estimated using a micro-costing approach [14]. All resources consumed 
were listed and estimated on the basis of clinical records and interviews with 
medical staff working at the clinic. Costs to the clinic consist of recurrent and 
capital costs. Personnel recurrent costs were estimated on the basis of government 
salary scales (issued by Ministry of Finance in 2007 [15]) by recording the 
corresponding scale of all staff members. Other recurrent costs such as the cost of 
methadone, mineral water and syrup consumed during the one year period of 
observation were estimated using market prices. Capital costs included trainings 
and workshops attended by the clinic staff, and unit costs on organizing these 
activities were obtained from government records. Market prices were used to 
estimate other capital costs, which include the cost of equipment, furniture, space 
as well as start-up costs (e.g. initial renovation during the clinic establishment). 
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Capital costs were subsequently annualized on the basis of the life time of the 
capital items. We did not include the cost of utilities (i.e. water, electricity). 
 
The patient costs were estimated by conducting a survey to a consecutive sample of 
48 methadone clients attending the clinic in November 2007. We collected 
information on travel costs and travelling time, the monthly income of the client, 
and the average number of daily working hours. Additional observations were 
conducted to estimate average total time spent per client in the clinic.  
 
Table 1. Yearly Cost of MMT service provision from different perspectives (in US$, using 
2007 exchange rate) 
Type of Cost 
Hospital 
perspective 
Central 
government 
perspective 
Health care 
system 
perspective 
Patient 
perspective 
Societal 
perspective 
(a) (b) (c) = (a) + (b) (d) (e) = (c) + (d)* 
1. CAPITAL COST 
(Annualized) 
     
1.1 Personnel (trainings 
& workshops) 
- 3,795.40 3,795.40 - 3,795.40 
1.2 Building/Space 512.99 1,058.86 1,571.85 - 1,571.85 
1.3 Equipments 336.63 834.86 1.171,49 - 1.171,49 
Subtotal 849.61 5,689.13 6,538.74 - 6,538.74 
2. RECURRENT COST      
2.1 Personnel 16,776.32 13,056.07 29,832.39 - 29,832.39 
2.2 Methadone Supply - 5,991.62 5,991.62 - 5,991.62 
2.3 Other supplies 563.50 - 563.50 - 563.50 
2.4 Service charge - - - 26,789.40 - 
2.4 Estimated income 
loss  
- - - 57,228.79 
        
57,228.79 
2.5 Travel cost  - - - 9,220.94 
          
9,220.94 
Subtotal 17,339.82 19,047.69 36,387.51 93,239.13     102,837.24 
T o t a l 18,189.43 24,736.82 42,926.25 93,239.13 
      
109,375.98 
Unit cost per visit 1.11 1.51 2.63 5.71 6.70 
* The amount of service charge within the societal perspective is omitted to avoid double counting. 
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All costs were measured in Rupiah, and converted to US$ using the 2007 exchange 
rate [16]. Both the MMT service utilization and cost data were entered into and 
analysed with Microsoft Excel 2007 (Table 1).  
 
Finally, total costs from the societal perspective are the summation of the total 
costs from the health system and patient perspectives. We omitted the service 
charge to avoid double counting.   
 
Results 
Number of patients and visits 
A total number of 129 clients registered with the MMT clinic during the one-year 
observation period, resulting in a total of 16,335 client-visits. The number of 
attending clients ranged from 51 to 75 in a month with an average of 46 daily 
client-visits. In the observation period, the median attendance rate of the clients 
was 80.8% (Inter Quartile Range (IQR) = 42.0% to 94.3%), while the monthly 
drop-out rate was 18.9%.  
 
Table 2. Characteristics of clients receiving MMT (n = 48) 
Variable  Statistics 
1. Male, no.   45 (93.8%) 
2. Age, median  27 (25 – 30) 
3. Occupation, no.     
- Employed   40 (83.3%) 
- Unemployed and not in labor force  8 (16.7%) 
4. Mode of transportation to MMT clinic, no.    
- Motorcycle  36 (75%) 
- Others  12 (25%) 
5. Travelling time to MMT clinic, minutes, median   20 (10 – 30) 
6. Client’s income (n=40), USD, median  246.14 (109.40 – 546.99) 
Source: Author's construct 
 
In our sample, the average age of the client was 27.7 years (SD = 4.31; median = 
27; IQR = 25 – 30). More than half of the clients attended university or college. 
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The median of monthly income per patient was Rp 2,250,000 or US$246 (IQR = 
Rp 1,000,000 – Rp 5,000,000). Further information on patient characteristics in our 
sample can be seen on Table 2. 
 
Cost of MMT services from different perspectives  
From the societal perspective, the total annual costs of the MMT clinic was 
Rp999,805,823 (US$109,376), with an average cost per client visit equal to 
Rp61,206 (US$6.70). Of total costs, the share of costs incurred by the patient was 
the largest (61%), followed by that of the central government (23%), and the 
hospital (17%).   
 
Total cost from the hospital’s perspective equals Rp 116,269,637 (US$18,189), with 
an average cost per client visit of Rp 10,179 (US$1.11). Personnel costs account for 
the largest share of total expenses (91%) and the rest of the hospital costs are 
building/space (i.e. renovation), equipment and other supplies (i.e. syrup and 
water). The total cost from central government’s perspective equals Rp 226,119,210 
(US$24,737), with an average cost per client visit of Rp 13,843 (US$1.51). Also 
here, personnel costs constitute the largest portion of costs (68%), followed by 
methadone supply (24%), and costs of building/space and most of equipments 
(7%). Total costs from the health care system perspective are the sum of both 
hospital and central government perspective, and equalled Rp 392,388,848 
(US$42,926). The share of central government and hospital within this perspective 
was respectively 58% and 42%. The cost per client-visit for health care system 
perspective equalled Rp 24,021 (US$2.63).   
 
From the patient’s perspective, the average cost per visit includes a consultation fee 
of Rp 15,000 (U$1.64) and travel costs of Rp 5,160 (US$0.56). The loss of income 
due to seeking and utilizing MMT services was equal to Rp 32,025 (US$3.50). As a 
result, the average patient costs per visit were Rp 52,185 (US$5.71). The total 
Costs of hospital-based MMT in Indonesia 
 
Page | 37 
 
annual cost to the whole of patients visiting the clinic in a year is calculated by 
multiplying the yearly number of visits with the average patient cost per visit, and 
totals Rp 852,441,975 (US$93,239). On a monthly basis, total costs to MMT clients 
in terms of paying charges (Rp 450,000/US$49), travel cost (Rp 154,800/US$17) 
and income loss (Rp 960,750/US$105) amount to Rp 1,565,550 (US$171), and 
constitute almost 70% of the median of client’s income (Rp 2,250,000/US$246). 
 
Discussion 
This paper, to our knowledge, is the first study that estimated the cost of providing 
MMT in a developing country setting in the context of HIV/AIDS control. It has 
offered a costing model that provides cost information from five hierarchical 
perspectives, i.e. hospital, central government, health care system, patient, and 
societal perspective. As such, it responds to a number of economic concerns at 
different institutional and policy levels on MMT services.  
 
In response to the hospital management concerns on the appropriate tariff, our 
analysis shows that the current charge of Rp 15,000 (US$1.64) very well covers the 
cost of Rp 10,179 (US$1.11) per client visit from the hospital point of view, and 
thus seems financially sustainable. Also, the study shows that personnel costs 
constitute the largest cost share, and therefore offer potential for efficiency gains. 
For example, increasing the number of client visit is one way to achieve such 
efficiency gains as it will decrease the unit cost per client visit.  
 
Responding to health care system policy concerns on the costs of scaling up MMT 
services in the country, our analysis shows that, on average, one client visit costs Rp 
24,021 or US$2.63 (from the health care system’s perspective). The total cost of 
scaling up to cover 19% of all IDUs in Indonesia (with the total estimated IDU 
population of 219,130 and assuming 67.5% individual adherence rate as observed 
in our study), would then amount to about Rp 246 billion (around US$27 million). 
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Obviously, (dis)economies of scale need to be taken into account to obtain more 
detailed and reliable estimates [17]. 
 
From the health care system’s perspective, the level of the subsidy is another 
concern. Our analysis indicates that the central government provides subsidy as 
much as 40% from the cost per client visit, and such direct involvement from 
government seems warranted considering the nature of the MMT services. MMT 
services do not only protect its clients from unsafe needle injecting behavior, but 
also carry positive externalities in a sense that it prevents the further spread of 
HIV/AIDS through contaminated needle sharing. In this context, MMT service 
can be categorized as merit goods, a type that exists between private and public 
goods [18–20]. Given this nature of MMT services, the role of government within 
the MMT services is well justified and should be maintained or even expanded, and 
in the latter case, government could decide to exempt the consultation fee 
completely. The large contribution and subsidy from the central government to the 
MMT program proves that the central government has a certain commitment to 
control the HIV epidemic in Indonesia. Maintaining this situation will generate a 
positive impact on decreasing the spread of HIV/AIDS.   
 
Closely related to this is the question whether or not the current patient cost of 
accessing the services is a potential barrier to the client. Our study revealed that 
patient costs constitute almost 70% of the median client’s income. A study 
conducted on MMT service patient’s satisfaction reveals that half of patients indeed 
complain on the service charge being too expensive [21]. In addition, from the 
societal perspective, the MMT service clients already bear around 60% of the total 
costs. Therefore, from the patient’s perspective, increasing the subsidy level is 
warranted. To determine the appropriate level of subsidy, however, policy maker 
should also take into account the other competing health programs as the 
government resources are limited. Currently, the expenditure amount on harm 
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reduction programs only constitutes 0.83% of public health expenditure on 
HIV/AIDS [22]. 
 
Policy makers are also concerned about the relative cost-effectiveness of MMT 
services compared to other interventions. While our study does not provide 
information on the cost-effectiveness of MMT, the cost estimates can be used for 
future cost-effectiveness analyses. Such studies will be valuable in informing the 
policy makers on the value for money of MMT services vis-à-vis other (competing) 
investments in health.  
 
This study has a number of limitations. First, it was limited to one hospital-based 
MMT clinic in Indonesia. Cost structures and levels are likely to vary from clinic to 
clinic. Costing studies in other settings, such as other hospitals, primary health 
centers and the delivery of MMT at the prison level, should be considered. Also, 
the 48 clients sample represents only the clients attending the clinic and, thus, 
cannot be generalized to represent Bandung, West Java, or Indonesia. 
 
Second, several market prices were used in the calculations, rather than the actual 
price paid during transaction. Nevertheless, this limitation is unlikely to create 
significant bias of the estimation as it constitutes only small proportion of the 
overall costs. Third, we did not include the costs of utilities in our calculations. 
However, as these costs are small, we do not believe it would change study 
conclusions. Fourth, we did not include any cost savings related to the social 
impact of MMT (e.g. decreasing criminalities, increasing productivity). Fifth, in 
calculating the patient costs, time lost seeking and undergoing MMT were valued at 
the patient wage rate, but it is not sure whether actual income losses were realized. 
This may then have overestimated the total patient costs. However, ignoring 
income losses all together would undervalue the economic cost borne by the clients 
or society. Sixth, the total personnel costs were based on existing staffing of the 
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MMT clinic and may include inefficiencies in personnel time required to deliver 
MMT service, and this may have resulted in overestimation of total personnel 
costs. As such, a further time motion study is warranted to give a clear picture of 
the service capacity of the clinic.   
 
Seventh, we based our assessment of the financial sustainability of the MMT 
program from the hospital’s perspective solely on the difference between unit cost 
and service charge. Other important factors such as the sustainability of 
government subsidies have not been addressed. Eighth, we concluded that the 
present user fee seems a barrier to utilization. However, we realize that this can 
only be confirmed in a study among patients who are eligible but not receiving 
MMT service.  
 
Conclusion  
This study has provided information on utilization and costs of providing hospital-
based MMT service in a developing country setting. Important concerns on tariff 
setting, financial sustainability and the estimated cost for scaling up have been 
addressed. Most importantly, it is also clear that the current tariff is potentially a 
barrier and a higher level of subsidy might be justified. 
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Abstract 
 
BACKGROUND: Indonesia faces an HIV epidemic that is in rapid transition. 
Injecting drug users (IDUs) are among the most heavily affected risk populations, 
with estimated prevalence of HIV reaching 50% or more in most parts of the 
country. Although Indonesia started opening methadone clinics in 2003, coverage 
remains low. 
 
METHODS: We used the Asian Epidemic Model and Resource Needs Model to 
evaluate the long-term population-level preventive impact of expanding Methadone 
Maintenance Therapy (MMT) in West Java (43 million people). We compared 
intervention costs and the number of incident HIV cases in the intervention 
scenario with current practice to establish the cost per infection averted by 
expanding MMT. An extensive sensitivity analysis was performed on costs and 
epidemiological input, as well as on the cost-effectiveness calculation itself. 
 
RESULTS: Our analysis shows that expanding MMT from 5% coverage now to 
40% coverage in 2019 would avert approximately 2,400 HIV infections, at a cost of 
approximately US$7,000 per HIV infection averted. Sensitivity analyses  
demonstrate that the use of alternative assumptions does not change the study 
conclusions. 
 
CONCLUSION: Our analyses suggest that expanding MMT is cost-effective, and 
support government policies to make MMT widely available as an integrated 
component of HIV/AIDS control in West Java. 
 
Key words: cost-effectiveness, HIV, methadone maintenance therapy, Indonesia 
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Introduction 
Apart from sub-Saharan Africa, HIV epidemics are mainly concentrated among 
most-at-risk populations [1]. Injecting drug users (IDUs) constitute an important 
risk group, estimated at 15.9 million individuals globally, of whom 3 million are 
HIV-infected. The size of the IDU population and the prevalence of HIV in this 
population have increased in the past decade [2]. 
 
Indonesia has significantly contributed to this increase. HIV increased considerably 
in Indonesia from the mid-1990s onwards, paralleling the rapid rise of opioid use. 
Indonesia currently faces an HIV epidemic in rapid transition: there has been a 
rapid rise in HIV incidence among IDUs, followed by a heterosexual epidemic 
among female sex workers (FSWs) and their clients, and subsequently among men 
having sex with men (MSM) [3]. By 2007, approximately 50% of IDUs were 
infected (in Jakarta 55%, Bandung 43%, Medan 56%, and Surabaya 56%) [4,5], 
contributing to at least 40% of new HIV infections. In 2015, it is expected that one 
million Indonesians will be HIV-infected and 350,000 will have died because of 
AIDS [6,7].  
 
Acknowledging the important role of injecting drug use, Indonesia adopted 
legislation in 2004 supporting harm reduction activities, including methadone 
maintenance therapy (MMT) [8]. Despite ambitious policy targets, MMT coverage 
remains low, mainly because of its high costs, lack of capacity to expand 
continuously, and the recent tightening of drug laws. In 2003, a pilot study in 
Jakarta showed that MMT significantly reduces injection frequency and IDU-
associated HIV risk behaviours [9]. However, many IDUs continue to inject, and 
therefore remain at risk of transmitting HIV or becoming infected themselves. This 
situation raises questions regarding the population-level preventive impact of 
MMT. Do intermediate behavioural outcomes also translate into final outcomes as 
infections averted at the populational level? In this sense, what are the long-term 
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effects of MMT? Van den Berg et al. [10] showed that full participation in harm 
reduction (both MMT and NSP) programs is associated with a reduced HIV 
transmission in the Netherlands, but it is questionable whether these results are also 
applicable to the Indonesian context. Moreover, the resource requirements for 
harm reduction in Asia in 2009 were estimated at $500 million and MMT 
accounted for a significant share of these resources [11]. Therefore, careful 
assessment of both the costs and effects of prevention measures is warranted to 
further inform decisions about whether to expand MMT to higher coverage levels. 
The research question in this paper is: from the societal perspective, what are the 
costs and effects of expanding MMT compared with current practice? This paper is 
the first to address the cost-effectiveness of MMT as an HIV prevention measure 
in a low-income setting. We chose a modeling design to study the effects of MMT 
on long-term HIV transmission at the populational level. We used the Asian 
Epidemic Model (AEM), a well validated and widely used HIV transmission model. 
Most importantly, the AEM comprises all relevant risk groups and allows 
behaviour to change over time [12,13]. We describe HIV transmission in the West 
Java province, explore the role of IDUs, and relate this role to cost-effectiveness 
analysis. West Java is Indonesia’s most populous province (43 million people) and 
has one of the highest populations of HIV-infected individuals in Indonesia. 
 
Methods 
HIV transmission model 
We used the AEM [12,13] to simulate the epidemiology of HIV among the various 
risk groups in West Java. Our starting point of analysis was the AEM model as 
fitted for West Java by AIDsina and the East-West Centre, two local specialised 
institutes on HIV/AIDS epidemiology and modeling that developed the model and 
also calculated the national HIV/AIDS projections [7]. The parameters were varied 
to find the model fit as shown in table 1, and risk behaviour was assumed constant 
after 2007.  
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The current practice scenario assumed a coverage of MMT of 1.5% in 2008 [14], 
extrapolated to 5% in 2010 and remaining constant thereafter. The intervention 
scenario assumed a similar MMT coverage till the end of 2009 followed by a linear 
increase to 40% in 2019, following UNAIDS recommendations [15]. In both 
scenarios, the impact of MMT was modeled through changes in the prevalence and 
frequency of unsafe injecting drug use (the frequency of injections and percentages 
of needle-sharing) and condom use among IDUs, derived from the intervention 
impact matrix of the Resource Needs Model (RNM) [16] (Table 2).  
 
To estimate the impact of our intervention scenario, we ran current practice and 
intervention scenarios and compared the resulting annual numbers of new 
infections. We performed extensive one-way sensitivity analysis on all IDU-related 
parameters. Additionally, to cope with uncertainty in surveillance studies, we 
changed (±25%) functionally related clusters of both sexual and injecting behaviour 
parameters and single key parameters (based on our own data search). These 
scenarios were again fitted with observed HIV prevalences and used for alternative 
cost-effectiveness calculations. 
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 Table 1. Parameters baseline values, sensitivity ranges and references used in adapted Asian Epidemic Model for West-Java Province 
 
  
Parameter Baseline value  Reference 
AEM fitting parameters 
Transmission probability    
 Male to female (Pm_f) 0.00125  Fitting 
 Male to male (Pm_m) 0.01790  Fitting 
 Needle stick 0.03  Fitting 
Ratio of male to female versus female to male 
transmission 
3.80  Fitting 
IDU network parameter (%) 80%  Fitting 
STI cofactor    
 Female to male 16.00  Fitting 
 Male to female 20.00  Fitting 
 Male to male 1.00  Fitting 
Circumcision factor 2.55  Fitting 
Epidemic start year    
 IDU 2002  Fitting 
 Heterosexual 1989  Fitting 
 MSM 1992  Fitting 
Population sizes in West-Java in 2006   
 FSW 0.32%  [17] 
 FSW who are direct FSWs (%) 62.20%  [17] 
 IDU  0.08%  [17] 
 MSM higher risk 0.13%  [17] 
 MSM lower risk 1.1% [17] 
 MSW 0.02% [17] 
 Clients of FSWs  1.7%  [17] 
 Males age 15+ 14,596,400  [18] 
 Females age 15+ 14,152,600  [18] 
Parameter Baseline value  Reference 
HIV prevalence (% in 2007, used for fitting) 
 Direct FSW (%) 10.35  [4] 
 Indirect FSW (%) 3.29  [4] 
 IDU 43.00  [4] 
 MSM 2.00 [4] 
 General population 0.00  [4] 
Hetero sexual behavior and STIs   
Direct female sex workers   
 Direct to indirect FSW behavior movement each year 
(%) 
1  Default value 
 Number of clients per day  1.7 [4] 
 Days worked per week  5.3 [4] 
 Condom use with clients (%) 62 [4] 
 Average duration of sex work (years) 2.5 [4] 
 STI prevalence (% neisseria gonorrhea)  44  [4] 
Indirect female sex workers   
 Number of clients per day  0.86 [4] 
 Number of clients per day  5.5 [4] 
 Condom use with clients (%) 60 [4] 
 Average duration of sex work (years) 2.0 Local expert opinion1 
 STI prevalence (% neisseria gonorrhea)  22  Local expert opinion 
Clients of sex workers   
 Males age 15-49 visiting sex workers (%) 1.7 [17] 
 Average duration of being a client (years) 11 Local expert opinion 
 Adult males circumcised (%) 87  [19] 
  
 
Table 1. Parameters baseline value, sensitivity ranges references used in adapted Asian Epidemic Model for West-Java Province (cont’d) 
P
a
g
e
 |
 4
9
 
 
C
o
st-effectiv
en
ess o
f M
M
T
 as H
IV
 p
rev
en
tio
n
 
 
  
Parameter Baseline value  Reference 
Male and female casual sex 
 Males having casual sex in last year (%) 0.3 Local expert opinion 
 Females having casual sex in last year (%) 0.1 Local expert opinion 
 Condom use in casual sex (%) 21  [4] 
 Average number of casual contacts in last year 
(male) 
1 Default value  
Sex with spouses or regular partners   
 Number of weekly sexual contacts with 
spouse/regular partner  
1.4 Local expert opinion 
 Condom use with spouses or regular partners 
(%) 
10 Local expert opinion 
 Adult population with STI (%) 0.5 Local expert opinion 
IDU injecting and sexual behavior   
 IDU mortality (% additional mortality per 
year) 
1.0 Default value 
 IDU sharing (%) 32  [4], percentage sharing 
needle last week 
 Injections shared, by those in sharing group 
(%) 
70 [4] 
 Number of injections each day 0.74 [4], the number of 
injections last week 
divided by 7.  
 Average duration of injecting (years) 8.0  [4], a stable population 
is assumed. As 12% of 
IDUs started injecting 
drugs less than one 
year ago, the average 
duration is 1/12%.  
 Parameter Baseline value  Reference 
 Sharing to non-sharing movement in a year (%) 20 Local expert opinion 
 Visiting FSWs (%) 41 [4], percentage visiting 
sex workers last year 
 Condom use with direct FSW (%) 54  [4], condom use at last 
commercial sex  
 Condom use with indirect FSW (%) 54  [4], condom use at last 
commercial sex  
 Condom use with spouse or regular partner (%) 34  [4], condom use at last 
sex 
 Number of contacts with regular partners (per 
week) 
1  Default value 
Injecting sex workers (ISW)2   
Injecting behaviors - higher frequency injecting SWs   
 Percent of higher frequency sex workers who 
inject 
0.1 [4] 
 Percent of higher frequency ISW in high risk 
networks 
0 Default value 
 Percent of higher frequency ISW sharing 0 Default value 
 Percent of all injections shared (Sharing hi 
frequency SW) 
0 Default value 
 Number of daily injections for higher frequency 
ISW 
0.7 [4] 
 Average duration of injecting for higher freq ISW 
(years) 
2.5 [4] 
 Percent condom use with clients (hi frequency 
ISWs) 
62 [4] 
Injecting behaviors - lower frequency injecting SWs   
 Percent of lower frequency sex workers who 
inject 
0.1 [4] 
 Percent of lower frequency ISW in high risk 
networks 
0 Default value 
 Percent of lower frequency ISW sharing 0 Default value 
 Percent of all injections shared (Sharing low 
frequency SW) 
0 Default value 
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Parameter Baseline value  Reference 
 Percent of Lo MSM with other female partners 20 Local expert 
opinion 
 Percent condom use in anal sex with other Lo MSM 48 Local expert 
opinion 
 Percent Lo MSM with anal STI 5.4 Local expert 
opinion 
MSM sexual behavior with commercial partners  
 Percent of Hi MSM visiting male sex workers 13 Local expert 
opinion 
 Percent of Lo MSM visiting male sex workers 2 Local expert 
opinion 
 Ratio of frequency of visiting MSW (Lo MSM/Hi 
MSM) 
0.1 Default value 
 Percent of Hi MSM visiting female sex workers 6 Local expert 
opinion 
 Percent of Lo MSM visiting female sex workers 0 Local expert 
opinion 
 Condom use in anal sex with male sex worker (%) 50 Local expert 
opinion 
 Condom use direct FSW (%) 62 [4] 
 Condom use indirect FSW (%) 60 [4] 
Male sex workers (MSW)3  
MSW size and duration   
 Average duration of male sex work (years) 6.3 Local expert 
opinion 
 Shifts from Hi MSM to MSW 1 Default value 
 Shifts from Lo MSM to MSW 1 Default value 
Sexual behaviors and STI with clients   
 Percent of MSW reporting anal sex with clients in last 
year 
93 Local expert 
opinion 
 Number anal sex contacts last week (for MSW w/anal 
sex) 
1.0 Local expert 
opinion 
 Percent MSW with anal STI 23 Local expert 
opinion 
    
Parameter Baseline value  Reference 
 Number of daily injections for lower 
frequency ISW 
0.7 [4] 
 Average duration of injecting for lower 
freq ISW (years) 
2.5 [4] 
 Percent condom use with clients (low 
frequency ISWs) 
60 [4] 
MSM sexual behavior3   
Higher risk MSM (Hi MSM) sexual behavior   
 Reporting anal sex last year (%) 93 Local expert 
opinion 
 Number anal sex contacts last week 0.5 Local expert 
opinion 
 Average duration of same-sex behavior 
(years) 
12.7 Local expert 
opinion 
 Shift from Hi MSM to Lo MSM 25 Default value 
 MSM having sex with other female 
partners (%) 
34 Local expert 
opinion 
 Condom use in anal sex with other hi 
MSM (%) 
45 Local expert 
opinion 
 Prevalence hi MSM with anal STI (%) 21 Local expert 
opinion 
Lower risk MSM (Lo MSM) sexual behavior  
 Percent of Lo MSM reporting anal sex in 
last year 
53 Local expert 
opinion 
 Number anal sex contacts last week (for 
MSM w/anal sex) 
0.1 Local expert 
opinion 
 Average duration of same-sex behavior 
(years) 
18.1 Local expert 
opinion 
    
  
 
Table 1. Parameters baseline value, sensitivity ranges references used in adapted Asian Epidemic Model for West-Java Province (cont’d) 
P
a
g
e
 |
 5
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Baseline value  Reference 
Female partners of MSW   
 Percent MSW visiting female sex 
workers in last year 
9 Local expert 
opinion 
 Percent MSW with other female 
partners in last year 
43 Local expert 
opinion 
IDU = injecting drug users, FSW = female sex workers, MSM = men having sex with men, STI = sexual transmitted infections 
1 Local expert opinion was given by researchers from East West Center and AIDSIna 
2 The parameter values for Injecting sex workers are copied from both FSW and IDU parameter values.  
3 The IBBS 2007 report does not discriminate between MSM hi, MSM lo and MSW, but the raw IBBS data were used by local experts for parameter estimates.   
Note: order and categorization of parameters are in line with presentation in Asian Epidemic Model. 
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Table 2. MMT intervention impact matrix. 
Source: Bollinger et al. [16] 
 
 
Cost analysis 
We also employed the RNM to estimate the cost of our intervention, and linked 
unit cost estimates to the number of people utilising MMT. Unit costs of MMT, 
from the societal perspective, were taken from Afriandi et al. [20]., which was also 
conducted in West Java. To summarise the findings of Afriandi et al. [20], this study 
provides full details about the costs of MMT. MMT service delivery costs were 
estimated using a micro-costing approach. Data regarding service utilisation (such 
as attendance, methadone dosage, laboratory and other investigations, and referrals 
to medical services) were retrieved from the clinic’s records from November 2006 
to October 2007. Capital costs and other recurrent costs (such as personnel, 
training, and other resources used) were calculated on the basis of financial 
administrative data. Patient costs were estimated on the basis of a survey among 48 
methadone clients. This survey included information about travel costs and 
travelling time, monthly income, and the average number of daily working hours. 
This information was combined with the average total time spent per client in the 
clinic. All capital costs (including training and workshops), personnel costs, 
methadone supply, and other supplies were included in the health care system 
perspective. The societal perspective also included patient costs. 
 
The unit cost estimates ($6.70 and $2.63 per client visit for the societal and health 
care system, respectively, with a mean of 126 visits per client per year) were altered 
 
Non-condom use 
Prevalence of injecting 
drug use 
Frequency of injection 
Prevalence of needle 
sharing 
Low -22% -46% -64% -30% 
Average -32% -47% -79% -63% 
High -42% -53% -88% -89% 
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(±25%) in the sensitivity analysis. We ran sensitivity analysis including only costs 
from the health care system perspective. 
 
Cost-effectiveness analysis 
We compared costs and effects of the intervention scenarios to those of the current 
practice scenario. The incremental costs of the intervention scenarios were divided 
by their incremental effects to establish the incremental cost per HIV infection 
averted. We discounted both costs and effects at a 3% discount rate for both costs 
and effects; this value was altered to 1% and 5% for effects and costs, and to 0% 
for effects in our sensitivity analysis. The time horizon of this study was 10 years, 
and was changed to 20 years in the sensitivity analysis. 
 
Figure 1. Reported and simulated HIV prevalence among high risk groups in West Java, 
Indonesia. *  
 
* West-Java projection for high risk groups (% older than 15 years, living with HIV) at current 
practice (5% coverage from 2010-2019) MMT.  
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Results 
The HIV epidemic in West Java and the role of injecting drug use 
Our model simulations show a reasonably good fit with the observed prevalence of 
HIV among important risk groups (Figure 1). Our current practice scenario 
predicts that in West Java, without any change in risk behaviours, the HIV 
prevalence in the overall adult population will not reach 0.3% before 2020. HIV 
prevalence among IDUs steadily approaches approximately 50% in the period from 
2010 until 2020. Although HIV prevalence among FSWs is expected to grow 
considerably, the MSM prevalence only grows moderately. 
 
 
Figure 2: Predicted HIV/AIDS prevalence among IDUs in West Java, current practice 
and intervention scenario  
 
Intervention impact and cost-effectiveness 
Figure 2 depicts the expected impact of different MMT expansion programs on 
HIV prevalence among IDUs. When MMT is expanded to a coverage level of 40% 
in 2019, the number of IDUs receiving MMT will increase from approximately 500 
in 2010 to approximately 4,600 in 2019. The HIV prevalence among IDUs is 
expected to decrease to 40% in 2019. Compared with current practice, 2,400 
undiscounted HIV infections are expected to be averted by 2020, at an 
undiscounted cost of US$16 million. Of these averted infections, 56% would be 
among IDUs, 24% among FSWs, 11% among clients, 9% among lower-risk 
populations, and just one averted infection would be among MSM. However, to 
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put this into perspective, in the same period there would still be 95,600 HIV 
infections in the overall population. Expanding MMT to 40% is expected to reduce 
the number of infections among IDUs by 18%, while the effect on FSWs, clients, 
and MSM is expected to be negligible. 
 
Table 3: Results of sensitivity analysis on cost-effectiveness of MMT.  
Parameter 
ICER1 current practice compared to 
no intervention 
Lower end Higher end 
ICER2 6,817 
Time horizon is increased to 20 years 3,767 
Unit cost lower end =-25%, higher end=+25% 5,113 8,522 
Unit costs taken from health care system perspective 2,676 
Discount rate lower end=1%, higher end=5% 6,661 6,974 
Discount rate for effects = 0%, costs 3% 5,638 
IMPACT of intervention3, lower end: low impact, higher end: high impact.  8,551 5,313 
IMPACT of intervention – no effects on condom use 8,654 
IMPACT of intervention – no effect on condom use, neither on prevalence 
of injecting drug use 
11,813 
 
CEAs on alternative scenarios  
Alternative 1: PWID increased sexual risk behavior (all parameters +25% 
for risk behavior, -25% for protective behavior). 
5,580 
Alternative 2: PWID decreased sexual risk behavior (all parameters -25% 
for risk behavior, +25% for protective behavior). 
8,521 
Alternative 3: All injecting behaviors + 25% (except for additional mortality 
parameter). 
6,313 
Alternative 4: All injecting behaviors - 25% (except for additional mortality 
parameter). 
7,027 
Alternative 5: An enlarged (multiplied by 7) clients of sex workers 
population size and smaller (divided by 1.15) FSW population size. 4  
6,699 
Alternative 6: Increased (multiplied by 1.75) injection frequency.5,6 6,775 
Alternative 7: Enlarged (multiplied by 3.14) IDU population size.5  7,913 
1: ICER: incremental cost-effectiveness ratio: costs in US$ per infection averted. 
2: Assumptions in the CEA: time horizon is 10 years, an average impact of MMT is assumed (table 1), discount rate both for costs 
and effects is 3%, unit costs are 848.41$ per IDU on MMT per year. Costs from 2010 until 2019 and effects from 2010 until 2019 
were included 
3: In table 1 (methods), the different impacts are shown.  
4: To reduce the ‘Number of sex acts per IDU with FSWs per year’ and in this way testing the link between IDU and FSW and 
the effect on CEA. Reductions and multiplications follow alternative population size estimations.  
5: More dramatically than in alternative 3 and thereby testing the impact of this specific parameter on CEA.  
6: Using another indicator for injection frequency from IBBS 2007[4]  
 
 
Table 3 shows that, in our baseline analysis, MMT costs approximately US$7,000 
per HIV infection averted. We performed extensive sensitivity analysis regarding 
the costs, epidemiological input, and the cost-effectiveness analysis calculation 
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itself, and all incremental cost-effectiveness ratios (ICERs) fall within a factor two 
of US$7,000 per HIV infection averted, with one exception. When adopting the 
health care system perspective, the ICER equals US$2,676 per infection averted. 
When neither effects on condom use nor effects on the prevalence of injecting 
drug use were modeled, the ICER increased to almost US$12,000 per infection 
averted. 
 
Discussion 
In this study, we analysed the cost-effectiveness of MMT and the role of injecting 
drug use in the West Javan HIV epidemic. Our analysis suggests that MMT costs 
approximately US$7,000 per HIV infection averted, and we found this value to 
vary within a factor of two in the sensitivity analysis. The relevant question here is 
whether MMT in West Java is an economically attractive intervention, and would 
merit further investment from the Indonesian government to make the services 
widely available. The World Health Organisation, through its WHO-CHOICE 
program, defines interventions that cost less than the gross domestic  product 
(GDP) per capita per disability-adjusted life year (DALY) averted as very cost-
effective, and those with a ratio that falls between one and three times the GDP 
per capita as cost-effective [21]. Assuming that one averted HIV infection equates 
to approximately 26 averted DALYs [22], MMT would cost approximately US$269 
per DALY averted. Given that Indonesia’s GDP per capita is US$2,858 [23], MMT 
can be considered very cost-effective. A comparison with other interventions is 
more difficult to make: MMT compares favorably to other HIV-preventive 
interventions, such as school-based education [24,25], but less so to a multifaceted 
harm reduction program (including Needle and Syringe Programs and others) in 
Bangladesh [26]. These studies have been conducted in different contexts and are 
therefore difficult to compare. However, our study results confirm findings from 
Ukraine, where expanding MMT was also found to be a cost-effective intervention 
(costing US$530 per quality-adjusted life year gained) [27]. Our results show that 
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expanding MMT to 40% in 2019 will avert approximately 2,400 HIV infections by 
2020. Strikingly, only 56% of these infections will be prevented among IDUs. Two 
factors are of importance: the proportion of IDUs who share needles and the 
impact of IDUs on the epidemic as a whole. These two factors are discussed below 
in more detail. 
 
In our one-way sensitivity analysis, we found ‘% of IDU sharing’ to be the most 
important IDU-related parameter affecting the cost-effectiveness estimates. This 
parameter, together with movement in and out of this group, more or less 
determines the stable equilibrium of HIV prevalence among IDUs. Because IDUs 
inject frequently and HIV is transmitted very effectively via needles, almost all 
IDUs who share needles become infected and the rapid spread of HIV among 
IDUs is common (for an overview, see Saidel et al. [13]). This also implies that 
when the epidemic has reached equilibrium among IDUs, only those who start to 
share needles will be likely to acquire new infections. New needle sharers comprise 
a small proportion of a relatively stable cohort (in our study, the average duration 
of being an IDU was 8 years), especially when an intervention reduces the 
percentage of IDUs who share needle IDUs have played a significant role in the 
West Javan HIV epidemic, and may continue to do so in the future. The link 
between IDUs and FSWs is strong: in our West Java projection, 41% of IDUs 
reported visiting sex workers. Our West Java projection confirms the findings of 
Saidel et al. [13] for a hypothetical population: despite high-risk behavior by FSWs 
and their clients, their HIV prevalence remained low until the introduction of HIV 
among IDUs.  
 
HIV initially spread rapidly among IDUs, and provided a boost to the HIV 
epidemic among FSWs. Because of this strong link between IDUs and FSWs, many 
infections among FSWs and their clients would be averted when HIV incidence 
and prevalence among IDUs is reduced by MMT. Overall, our analysis suggests 
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that the proportion of incident cases caused by injecting drug use is expected to 
decrease and to be replaced by infections caused by heterosexual transmission. This 
is an important insight, and indicates the limitations of interventions like MMT: 
although they may offer value for money and are therefore worthwhile, they are 
only able to reduce incidence slightly (2.5% in our analysis). Our analyses 
demonstrate a steady rise of HIV prevalence among MSM, yet at a relatively low 
level. More profound analysis of the HIV epidemic among MSM is beyond the 
scope of this article. Although our results appear soothing, given the MSM 
epidemics in Asia, HIV among MSM certainly requires further investigation, 
including cost-effectiveness analyses of interventions among MSM. 
 
The present analysis has a number of limitations. First, our study was limited by the 
availability and quality of input parameters, especially size of population groups and 
MMT coverage rates. Also, we assumed that most behavioural parameters would 
remain constant after 2007, and neglected trends such as the increased 
consumption of methamphetamines, which may replace heroin use and for which 
MMT is not an effective treatment option. Yet our extensive sensitivity analyses 
showed that study conclusions are robust towards alternative assumptions on key 
variables, which also supports the extrapolation of our findings to epidemics other 
than the West Java epidemic.  Second, our analysis focused on MMT and its impact 
on IDUs. The evaluation of other interventions (such as the social marketing of 
condoms among IDUs) was beyond the scope of our study, and also impossible 
considering the absence of reliable cost information. Nor did we evaluate 
interventions targeting FSWs or MSM. We acknowledge FSWs and MSM as 
increasingly important risk groups (as reflected in our simulations), and we call for 
more research on HIV among FSWs and MSM in Indonesia, including cost-
effectiveness analyses of interventions that target these risk groups. 
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Third, our estimates regarding the impact of MMT were based on international 
evidence, as summarized in the impact matrix of the RNM [16], and may not 
necessarily reflect reality in Indonesia. However, the assumed impact compares well 
with evidence from pilot studies of MMT at eight sites, including Jakarta [9]. In 
Jakarta, opiate use dropped from 2.5±1.4 to 0.43±1.2 daily occasions of use after 
three months, and to 0.51±1.2 daily occasions of use after six months. Blood 
Borne Virus Transmission Risk Assessment Questionnaire injecting risk scores 
(which indicate unsafe injecting behavior) dropped from 19.05±17.9 to 5.23±13.1 
after three months and to 3.83±9.3 after six months. Self-reported abstinence rates 
varied between 69100% at six months. In addition, a recent international 
systematic review [28] of the impact of MMT supports the RNM matrix. Because 
of the absence of any Indonesian data to support reductions in condom non-use 
and the prevalence of injecting drug use after the implementation of MMT, we ran 
a sensitivity analysis excluding these reductions and found that study conclusions 
did not change. Fourth, the present analysis considers the role of current IDUs in 
HIV epidemics, but ignores the impact of recreational and former IDUs. While 
MMT is not indicated for these groups, they may play a role in the HIV epidemic in 
West Java; both populations may be important bridges to transfer HIV infections 
originating from injecting drug use to the general population through sexual 
transmission. In a recent survey from Indonesia, 44% of IDUs were classified as 
former IDUs, of whom 66% were HIV-seropositive [29]. 
 
Fifth, our analysis is somewhat limited in scope because we did not consider 
antiretroviral treatment of IDUs. Treatment incurs costs and reduces the 
transmission of HIV; however, because only a small minority of all IDUs receives 
treatment, we do not expect treatment outcomes to change our study conclusions. 
Furthermore, our analysis did not value reductions in addiction-related crimes and 
risk behaviors, regular contact of IDUs with medical services, reestablishment of 
social and societal functioning, or collateral health effects. These aspects are 
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difficult to measure and are seldom included in cost-effectiveness analyses. Sixth, 
we present the cost-effectiveness of one intervention only, and use international 
cost-effectiveness thresholds to classify the interventions as very cost-effective. 
Ideally, all possible interventions to control HIV/AIDS in West Java should be 
ranked on the basis of their cost-effectiveness, and investments should be geared 
towards the most cost-effective interventions until the budget is exhausted. 
 
Seventh, our analysis shows that an expansion of MMT is warranted, but it does 
not tell us how the expansion should be performed. IDUs are a stigmatized group, 
and harm reduction programs often lack political support or face legislative 
problems. A lack of national capacity to expand harm reduction programs, 
including issues of funding, has been observed throughout Southeast Asia [14]. 
Expanding MMT to 40% would require full commitment from the entire public 
health system (staff commitment, infrastructure, materials) and political and 
legislative support. Therefore, to successfully expand MMT, careful consideration 
and continuous attention to the political and organizational challenges are needed.  
 
In sum, our analyses suggest that MMT is a cost-effective HIV prevention measure, 
and support government policies to make MMT services widely available as an 
integrated component of HIV/AIDS control in West Java. 
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Abstract 
OBJECTIVE: To evaluate costs and outcomes of VCT service delivery models in 
an urban setting in Indonesia 
 
METHODS: We collected primary data on utilization, costs, and outcomes of VCT 
services in a hospital clinic (568 clients), HIV community clinic (28 clients), STI 
community clinic (784 clients), and prison clinic (574 clients) in Bandung, 
Indonesia, in the period January 2008 – April 2009. 
 
RESULTS: The hospital clinic diagnosed the highest proportion and absolute 
number of HIV infections, but with the lowest average CD4 cell count and with 
the highest associated travelling and waiting time. The prison clinic detected fewer 
cases, but at an earlier stage, and all enrolled in HIV-care. The community clinics 
detected the smallest number of cases, and only 0-8% enrolled in HIV care. The 
unit cost per VCT was highest in the hospital clinic (US$74), followed by the STI 
community clinic (US$65), the HIV community clinic (US$39) and the prison 
(US$23).  
 
CONCLUSION: We propose a reorientation of the delivery models for VCT and 
related HIV/AIDS treatment in this setting. We call for the scaling up of 
community clinics for VCT to improve access, promote earlier detection and to 
perform (early) treatment activities. This would reduce the burden of the hospital 
clinic to orient itself towards the treatment of AIDS patients. This is one of very 
few studies addressing this issue in Asia and the first of its kind in Indonesia, which 
has a rapidly growing HIV-epidemic. The conceptual framework and overall 
conclusions may also relevant to other low-income settings.  
 
Key words: Cost Analysis, Voluntary Counselling and Testing, Injecting Drug 
User, HIV/AIDS, Indonesia 
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Background 
The HIV epidemic in Indonesia is among the fastest growing in Asia [1]. It is 
concentrated among injecting drug users (IDUs) and their sexual partners in most 
parts of the country, with exception of parts of Papua where the epidemic is 
generalized. As of 2009, the cumulative death toll due to HIV/AIDS amounted to 
nearly 17,000, of whom 42% were reported to be IDU-related, while hetero and 
homosexual transmission accounts for 48% and 4%, respectively [2]. HIV/AIDS 
control efforts have increased considerably in Indonesia in recent years [3], with 
voluntary counselling and testing (VCT) being a key component in the national 
strategic plan [4]. VCT offers an entry point to treatment of HIV-positive 
individuals, and is instrumental to prevent the further spread of the disease by 
reducing risk behaviour of tested individuals [5]. As of now, VCT services are only 
accessed by approximately 30% of all high risk groups [1], and scaling up of 
services is warranted.  
 
Various delivery models of VCT exist, ranging from integration in primary health 
services, specialised STD-clinics, to tertiary level hospital services. In Indonesia, 
VCT is typically delivered by tertiary level hospitals as this is where most 
individuals present themselves for testing, while it has been stressed that more 
efforts are needed to increase early testing at community level [6]. Integration of 
VCT in primary health care in Tanzania shows that this may lead to improved VCT 
uptake, reduced stigma, and improvement of general  health service delivery [7]. 
 
However, it is not clear which delivery models are most appropriate in which 
context. Different aspects may be important, such as VCT costs, the outcomes of 
services including the number of positive cases identified and follow-up with 
treatment, the sustainability of the services, its accessibility for clients, the provider 
capacity to accommodate scaling up of services, and the target population of the 
specific delivery model.  
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This paper concentrates on the former two aspects, and presents the costs and 
outcomes of four different VCT delivery models – as delivered at the hospital 
clinic, the HIV community clinic, the STI community clinic, and the prison clinic - 
in an urban setting in Indonesia. It thereby responds to the almost complete 
paucity of evidence on the costs of VCT services in Asia [8] – as of now, the 
evidence-base only includes two studies on costs of VCT in Thailand [9,10], one 
study at the south-east Asian sub-regional level [11], and one in India [12]. The 
present costing study is unique for three reasons. Firstly, it provides the first 
costing study on VCT in Indonesia, which is an important input for rational 
decision-making on the scaling up of service delivery [3]. Secondly, the study does 
not only estimate costs of VCT service delivery, but also costs of implementing 
VCT as incurred at the more administrative level (so called programme costs)– 
these costs are typically ignored in economic analysis [13]. Thirdly, the study also 
estimates costs of clients of seeking and undergoing VCT. Both programme costs 
and patient costs are also important criteria when making decision on scaling up 
VCT services. 
 
The analyses of costs and outcomes of VCT delivery models serves as a basis for a 
broader elaboration of scaling up the respective models – taking into account all 
other aspects as well. The objective of the paper is to inform policy makers on the 
options and limitations of scaling up alternative VCT delivery models in Indonesia.  
 
Methods 
Study setting 
The study was conducted at four different sites in Bandung, capital city of West 
Java. The first site is a hospital clinic located at Hasan Sadikin hospital, a teaching 
and provincial top-referral public hospital for West Java (with a population of 
approximately 40 million people). The clinic delivers HIV related services such as 
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VCT, ART, and STI services, and general medical services, and is frequented by 
both the general population and all kind of high risk groups, mostly IDUs. As this 
clinic resides at a top-referral hospital and it is one of the few clinics which deliver 
ART within the city, the number of HIV service related visits is very high and the 
clinic operates at full capacity. The clinic generates its own revenues through user-
fees and otherwise relies on government, hospital and donor-funding. The second 
site is a newly established HIV-community clinic which is integrated with a public 
community health centre, targeting both general and high risk populations, but 
currently mainly frequented by IDUs. The third site is an STI-community clinic, 
owned by an NGO. The clinic delivers mostly STI and VCT services and is visited 
by high risk groups other than IDUs (e.g. female sex workers, transgenders, and 
men having sex with men), with smaller number of visits by general population. 
The STI case load in this clinic is high (around 2,000 cases within a year) and it is 
the only clinic with its own outreach team which also performs pre- test counselling 
for VCT in Bandung. The clinic charges a highly discounted price for its services to 
improve access for high risk groups from every income level. The funding for the 
clinic is mostly covered by donor with limited support from the government. The 
fourth site is a HIV-clinic in a prison for drug users including IDUs. The VCT in 
this clinic is also performed as part of the screening test for new prisoners. At the 
moment, this clinic mostly relies on donor funding. 
 
All clinics have their own complete VCT package, including pre- and post- test 
counselling and HIV testing, except for the prison clinic which sends all blood 
samples to the Hasan Sadikin hospital laboratory. The HIV-community-based 
clinic refers samples for confirmatory tests at the hospital-clinic if the screening test 
is positive result. Each site has its own distinct characteristics of clients, VCT 
procedures, HIV positive cases, and settings (Table 1). 
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HIV antibodies are measured using different commercially available rapid tests, the 
hospital laboratory also uses immunoassays, with external quality control showing 
100% accuracy (National Serology Reference Laboratory, Australia). CD4 cell 
measurements are performed at the hospital laboratory using Facscount 
flowcytometry (BD Biosciences, Jakarta, Indonesia). 
 
Data collection and cost estimation 
We distinguished health care costs (costs related to the consumption of resources 
in the health care system), and non-health care costs (costs falling on the patient for 
seeking and undergoing care). Health care costs were estimated on the basis of 
service utilization and service cost data for each clinic (Table 1).  
 
We retrieved data on service utilization from each clinic’s records including 
information on number of VCT and resources used. Service costs were estimated 
using a micro-costing approach [14]. All resources consumed and salaries were 
listed and estimated on the basis of clinical records, interviews with medical staff, 
government standard, or market price. Costs to the clinic consist of recurrent and 
capital costs. Personnel recurrent costs were estimated on the basis of their actual 
Table 1. Overview of study sites 
Variable  Hospital clinic  HIV community 
clinic 
 STI community 
clinic 
 Prison clinic 
Number of VCT  568  28  784  574 
Type of high risk groups  All high risk 
groups 
 Mostly IDUs  Mostly sex 
workers and 
transgenders 
 Prisoners 
Service charge (US$)  2.13   0.32   3.72   n/a 
Type of VCT offered  Complete  Complete  Complete  Incomplete† 
Period of study  Jan – Dec 2008  Dec 2008 – Sept 2009  Oct 2007 – Sept 
2008 
 May 2008 – 
April 2009 
HIV (+) detected, no. (% of VCT 
conducted) 
 214 (38%)  4 (14%)  26 (3%)  39 (7%) 
CD 4 cell count on HIV (+), median 
(IQR) 
 129 (26 – 338)  n/a  292 (189 – 397)††  290 (165 – 382) 
Enrolled in HIV care (%)  88  0  8  100 
† Only includes pre- and post-test counseling; HIV blood- testing is conducted at Hasan Sadikin hospital.  
†† n = 9, HIV (+) clients with traceable CD 4 cell count. 
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wage whenever possible, or estimated by using government salary scales (issued by 
Ministry of Finance in 2007 [15]). Other recurrent costs such as the cost of medical 
and administration goods consumed during the one year period of observation 
were estimated using both actual and market prices. Laboratory cost was estimated 
using the current service charge. Capital costs included trainings and workshops 
attended by the clinic staff, and unit costs on organizing these activities were 
obtained from their actual budget or government records. Market prices were used 
to estimate other capital costs, which include the cost of equipment, furniture, as 
well as start-up costs (such as renovation cost, if applicable). Capital costs were 
subsequently annualized on the basis of the life time of the capital items, using a 
3% discount rate [14]. We omitted the cost of utilities (i.e. water, electricity). 
Although HIV tests administered in the clinic were sent to a lab outside the prison 
for diagnosis, associated costs were included in the prison clinic costing analysis. 
 
Non-health care costs (i.e. patient costs) were estimated by conducting a survey 
among a sample of high risk group clients utilizing the VCT service at the hospital 
and STI clinic between September - October 2009. For the HIV community clinic 
patient costs were obtained from another survey conducted between June – August 
2009. We collected information on, among others, travel costs, travelling time, the 
monthly income of the client, the average number of daily working hours, and 
monthly expenditures. Such study was not conducted at the prison. All costs were 
measured in Rupiah, and converted to US$ using the 2008 exchange rate [16]. Both 
the utilization and cost data were entered into and analysed with Microsoft Excel 
2007.  
 
In addition, we collected the data on the number of HIV positive clients and their 
CD4 cell count from each site. We also performed interviews with the clinic 
managers to put the observed data in context. 
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Results 
Number of patients and visits 
The number of conducted VCT ranged considerably between settings. Most of the 
VCT were conducted at the STI community, but most positive cases were found at 
the hospital clinic (Table 1). The median CD4 cell count at time of HIV diagnosis 
was relatively low in the hospital clinic, higher in the STI community clinic and 
prison and unavailable for the HIV community clinic. In the hospital clinic and 
prison most patients diagnosed through VCT enrolled in HIV-care after VCT, 
whereas very few did so in the community clinics (Table 1). Table 2 provides the 
characteristics of the sampled clients for each of the clinic. Most clients were young 
and employed. Travelling and waiting time were the highest for the hospital clinic, 
lower for the community clinics and not applicable for the prison clinic.  
 
Cost of VCT services from different clinic sites  
Table 3 summarizes the results of VCT costing analysis. The unit cost per VCT was 
highest in the hospital clinic (US$74), followed by the STI community clinic 
(US$65), the HIV community clinic (US$39) and the prison (US$23). Personnel 
recurrent cost was the largest cost component for both hospital and STI 
 
Table 2. Characteristics of sampled high risk group clients getting VCT (excluding 
inmates)  
Variable / clinic  
Hospital clinic 
(n=66) 
 
HIV community clinic 
(n=57) 
 
STI community clinic 
(n=61) 
Male, no.   37 (56%)  52 (91%)  32 (53%) 
Age, mean  28  28  25 
Occupation, no.        
 Employed   58 (93%)
 †  46 (81%)  57 (93%) 
 Unemployed and/or not in labor force  4 (7%)
 †  11 (19%) (n=22)  4 (7%) 
Mode of transportation to clinic, no.        
 Public transport  33 (50%)  4 (18%)  23  (38%) 
  Motorcycle  29 (44%)  17 (77%)  24 (39%) 
 Others  4 (6%)  1 (5%)  14 (23%) 
Travelling time to the clinic, minutes, 
mean  
 45  39 (n=22)  20 (n=60) 
Spent time at the clinic, minutes, mean  94  n/a  38 
Client’s monthly estimated income, USD 
(median) 
  48 (36 – 72)  77 (36 – 128)  124 (52 – 246)  
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community clinic (70% and 41%). At the HIV community clinic, equipment costs 
constituted the largest portion of costs (30%), while the estimated laboratory cost 
was the largest cost item for the prison clinic (34%). Non-health care costs (i.e. 
patient costs), per VCT were the lowest at the HIV community clinic, and 
approximately five times higher at the STI community clinic. Interviews with 
managers of the clinics reveal that the hospital clinic is operating at full capacity (i.e. 
cannot always treat clients promptly), the HIV community clinic is operating at low 
capacity, and the STI community clinic is operating at a capacity between the 
previous two clinics. 
Table 3. Annual cost of delivering VCT service for different settings 
(US$, 2008 exchange rate) 
 
 
Type of cost / clinic  
Hospital 
clinic 
 HIV 
community 
clinic 
 STI 
community 
clinic 
 
Prison 
clinic 
Health care costs         
 Capital costs (annualized)         
 
Personnel (trainings & 
workshops) 
 145 
 
207 
 
4,220 
 
4,194 
 Building/Space  657  181  266  1,624 
 Equipments  657  298  351  30 
 Subtotal  1,459  685  4,837  5,848 
 Capital costs per VCT  3  24  6  10 
          
 Recurrent costs         
 Personnel  21,633  57  21,051  2,116 
 Supplies  2,591  263  10,007  539 
 Outreach team activities  -  -  6,186  - 
 Laboratory  3,255  31  -††  4,439 
 Subtotal  27,479  351  37,244  7,093 
 Recurrent cost per VCT  62  11  48  12 
Non-health care costs         
 Patient costs  2,157  46  8,862  n/a 
 Access costs per VCT  1  0.3  3  n/a 
 
Estimated productivity loss 
per VCT† 
 4 
 
1.3 
 
8 
 
n/a 
 Patient costs per VCT  5  2  11  n/a 
 
 
Total Annual Cost 
 31,095 
 
1,083 
 
50,942 
  
12,941 
          
 Number of VCT  421  28  784  574 
 Unit costs per VCT  74  39  65  23 
 
Unit costs per HIV positive 
case 
 178 
 
271 
 
1,959 
 
332 
 
† Productivity losses signify income losses because of seeking and undergoing VCT 
†† Not costed separately, but included in the capital and recurrent cost items. 
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Discussion 
There is a need to scale up VCT services in Indonesia, and a variety of service 
delivery models have been developed, each with its own characteristics in terms of 
its clients and services. The findings of this paper are summarized in Table 4 in 
dimensions of economic aspects (costs and accessibility), clinical aspects (VCT 
performed, % HIV positive, CD4 cell count, enrolment in HIV care) and other 
aspects (VCT target group), and lead to the following observations. As such, 
further economies of scale from scaling up services along with cost reductions may 
not be possible. The clinic is also not as physically accessible as the other clinics as 
indicated by the relatively long travelling and waiting time. The role of the clinic 
merely seems to be that of a referral centre for treatment of late and/or 
complicated cases, and for treatment of opportunistic infections. The clinic is 
currently already adopting this role, given  that the hospital clinic is frequented by 
individuals presenting for testing with symptomatic and late stage disease (as 
indicated by the relatively low CD4 count among HIV positive-tested patients) [6].  
 
 
The HIV community clinic holds potential to function as an entry point to VCT 
for the broader population, and the following observations in the present study 
qualify this perspective. The clinic has the lowest costs per VCT performed 
(US$39) compared with the hospital clinic and STI community clinic. Considering 
Table 4. Economic, clinical and other aspects of VCT delivery models † 
Service delivery 
model 
 Economic Aspects  Clinical aspects  Other aspects 
 
Unit cost per VCT (US$)  
Physical 
Accessibility 
 
VCT 
performed 
% HIV 
positive 
CD4 
count 
Enrollment 
in HIV care 
 VCT target group 
 At present If scaled up        At present If scaled up 
Hospital clinic  High High Low  Many Many Low High  Symptomatic  Symptomatic  
HIV community 
clinic 
 
Low Low High  Few Few NA Low  Mostly IDU All 
STI community 
clinic 
 
High High High  Many Few High Low  
Mostly sex 
workers and 
transgenders 
All 
Prison clinic  Low NA NA  Many Few High High  Prisoners Prisoners 
† Perceptions of these aspects as relative to other clinics. Perceptions relate to present situation, unless indicated otherwise.   
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its recent establishment and currently low capacity utilization, cost reductions can 
be expected when these services are scaled up. Also, the HIV community clinic is 
relatively physically accessible as indicated by the short travelling time, and this 
holds potential for a high uptake of VCT when scaled up. However, as the present 
clinic is now mainly frequented by IDUs, more efforts are needed to target and also 
attract the (symptomatic and asymptomatic) population as a whole in scaling up. 
Concerns are the (present) absence of HIV-care or a good referral system to a 
clinic with HIV care, and its current inability to cover all costs by collecting fees 
(nor does it receive financial support from the government).  
 
The STI community clinic could play an important role in scaling up VCT services, 
specifically by continuing its focus on high-risk groups as it does now. The clinic 
appears to be able to detect HIV-positive cases in an early stage, as indicated by the 
relatively high CD4 cell count of HIV positive clients tested. The  clinic’s outreach 
activities and the resulting network with high-risk groups probably contribute to its 
success. The present clinic is located near the area of where the sex workers live 
and work, which improves physical accessibility, as indicated by relatively low travel 
and waiting time. Moreover, the clinic’s active campaign on delivering STI services 
gives them good access to other high risk groups such as transgenders and MSM. 
This holds potential for a high uptake of VCT when this decentralised service 
model is scaled up. In relation, the focus of the clinic on the provision of STI 
services may also reduce HIV transmission [17,18]. The absence of a good referral 
system to a clinic with HIV care is a matter of concern, and currently the 
discounted price charged cannot cover the full cost of delivering the services (the 
clinic relies heavily on donor funds).  
 
The VCT services as delivered in the prison clinic hold potential to be scaled up to 
other prisons. During the period of study, both the number of VCT performed and 
the CD4 cell counts of the HIV positive clients were relatively high, as was the 
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enrolment in HIV-care. This demonstrates the ability of the clinic to identify and 
treat HIV infection in prison at an early stage, although one should realise that 
HIV-care for prisoners after release might pose a bigger challenge. Furthermore, 
the delivery of VCT in the prison clinic is relatively cheap (US$23). Personnel costs 
are relatively low and patient cost of seeking and undergoing the service are absent. 
Currently, the prison clinic is relying on donor funding for its VCT services. 
Whether the VCT services should also be implemented in other  prisons targeting 
other groups is difficult to answer in the present study and warrants further 
investigation.  
 
Table 5. Recommendation on role of clinics in VCT and treatment† 
Service delivery model VCT uncomplicated 
ART 
complicated 
ART 
Treatment of 
opportunistic 
infections 
Hospital clinic +/- +/- + + 
HIV community clinic + + - - 
Community clinic + + - - 
Prison clinic + + - - 
† '+' and '-' denote respectively a role of high and low importance for the clinic in the specified activities 
in HIV/AIDS control. ART = anti-retroviral treatment   
 
Based on our study findings we can make several recommendations (Table 5). VCT 
services may best be scaled up in community-based clinics to the broader 
population, to improve its uptake and hence early detection of HIV/AIDS. These 
clinics may also initiate treatment of early / uncomplicated cases. A system should 
be developed for referral of late cases and those with opportunistic infections to 
the hospital. The HIV-clinic in the hospital should be less oriented towards 
conducting VCT. We also emphasize the need for measures that address the 
general barriers to VCT such as (travel) costs, lack of confidentiality of test results, 
and perceived lack of benefit of conducting HIV test [19]. 
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Our results should be interpreted with some caution. First, this study has evaluated 
highly contextualised VCT service delivery models, which hampers their 
generalizibility. Yet, the conceptual decision framework can be applied to other 
settings. Second, we estimated patient costs of seeking and undergoing care on the 
basis of (assumed) productivity losses – these may not be realized in practice and 
we may then have overestimated the total patient costs. Differences in these patient 
costs are related to income levels of the clinic’s clients and do therefore not 
necessarily reflect differences in access to the different clinics. 
 
Third, personnel costs in clinics may include inefficiencies in the delivery of VCT 
services, and we may have overestimated total costs - a time motion study is 
warranted to assess the required resources to scale up VCT services in further 
detail. 
 
In conclusion, we propose a reorientation of the delivery models for VCT in 
Indonesia, which would improve access and promote earlier detection, and reduce 
the burden of the hospital clinic to orient itself towards the treatment of 
complicated HIV/AIDS cases. Whereas this study is specific to Bandung, 
Indonesia, the conceptual framework and overall conclusions may also hold 
relevance to other low-income settings.  
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Abstract 
 
AIM: to evaluate the costs-effectiveness of scaling up community-based VCT in 
West-Java.  
 
METHODS: the Asian epidemic model (AEM) and resource needs model (RNM) 
were used to calculate incremental costs per HIV infection averted and per disability-
adjusted life years saved (DALYs). Locally monitored demographic, epidemiological 
behavior and cost data were used as model input.  
 
RESULTS: scaling up community-based VCT in West-Java will reduce the overall 
population prevalence by 36% in 2030 and costs US$ 248 per HIV infection averted 
and US$9.17 per DALY saved. Cost-effectiveness estimation were most sensitive to 
the impact of VCT on condom use and to the population size of clients of female 
sex workers (FSWs), but were overall robust. The total costs for scaling up 
community-based VCT range between US$1.3 and 3.8 million per year and require 
the number of VCT integrated clinics at public community health centers to increase 
from 73 in 2010 to 594 in 2030.  
 
CONCLUSION: scaling up community-based VCT seems both an effective and 
cost-effective intervention. However, in order to prioritize VCT in HIV/AIDS 
control in West-Java, issues of budget availability and organizational capacity should 
be addressed. 
 
Key words: HIV infections, voluntary counseling and testing, cost-effectiveness 
analysis, decision maker. 
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Introduction 
In most Asian countries national HIV epidemics are stabilizing, but Indonesia’s is 
growing [1]. The epidemic is concentrated among risk groups, such as injecting 
drug users (IDUs) and female sex workers (FSWs), except in Papua province, 
where it is generalized [2]. In 2009, the prevalence of people living with HIV/AIDS 
(PLWHA) was estimated at 353,173 (0.3%) and long-term projections vary between 
500,000-1,000,000 in 2015. Importantly, these projections indicate a shift of the 
epidemic towards the general population [3,4]. 
 
Indonesia’s national response focuses on a wide range of services, mainly for most-
at-risk populations: e.g. harm reduction programs, condom distribution, and 
voluntary counselling and testing (VCT) [3]. Unfortunately, coverage of VCT 
remains low, approximately 30% among most-at-risk populations in 2009 [3]. As a 
result, HIV patients present themselves at hospitals and at a very late stage, 
reflected in extremely low median CD4 cell counts (33/ml among IDUs and 84/ml 
among non-IDUs) [5]. VCT functions as an entry point for care and counsellors 
aim to reduce the risk behavior of tested individuals by providing information 
about routes of HIV transmission and about prevention methods [6]. Because VCT 
is able to prevent the spread of HIV, it is a key component in Indonesia’s 
HIV/AIDS control. Based on WHO guidelines, VCT services in Indonesia consist 
of HIV rapid testing combined with pre- and post-test counseling. In line with the 
WHO/UNAIDS goals for universal access to VCT in 2010, the National AIDS 
Commission (NAC) proposes in their National Strategy 2010-2014 to scale up 
VCT to 80% among most-at-risk groups in 2014 [3,7]. 
 
To date, VCT is mainly delivered at hospitals, but several researchers stress the 
need for a community-based approach to promote early detection and treatment 
and to reduce case loads at hospitals [8,9]. Moreover, Siregar et al. [8] showed that 
in Indonesia community health centers provide VCT at significantly lower costs 
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than hospitals. However, the total costs and health effects of scaling up VCT at 
community level are not yet clear. The rise in costs caused by the increasing 
number of people covered might be largely offset by a decrease in unit costs of 
VCT. In addition, the cost-effectiveness of VCT is largely unknown. 
 
The Indonesian government substantially increased economic efforts to combat the 
HIV epidemic: the allocation from the national budget rose from US$11 to 73 
million between 2006 and 2009 [3]. This is encouraging, but it will not be enough 
to implement every intervention for every target group at full scale, emphasizing 
the urgent need for setting priorities for HIV/AIDS interventions [10]. Cost-
effectiveness is proposed as a leading criterion in setting such priorities, but 
evidence on the cost-effectiveness of HIV/AIDS interventions is largely 
unavailable in Indonesia [10]. In addition, international literature is difficult to 
generalize and focuses mainly on Africa [11]. 
 
Against this background, our study aims to evaluate the costs, effects, and cost-
effectiveness of scaling up community-based VCT in West-Java in order to support 
the national strategy as well as policy makers in setting priorities for HIV/AIDS 
interventions. Our study is an integrated component of a broader project on the 
economic analysis of HIV/AIDS control in Bandung, West-Java that also includes 
cost [12] and cost-effectiveness studies on methadone maintenance treatment 
(MMT) [13]. 
 
Methods 
Study Setting 
Our area of analysis is the province of West Java, with 40 million inhabitants and a 
high HIV prevalence in most-at-risk populations: 42.8% in IDUs, 11.6% in direct 
FSWs, and 3.3% in indirect FSW (direct FSWs are those working in brothels and 
indirect FSWs are those working in bars and hotels), and 2.0% in men having sex 
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with men (MSM), according to most recent estimates in 2007. In 2010, West-Java 
reported a prevalence of 2,168 HIV infections and 3,512 AIDS cases [14], although 
mathematical models (Asian Epidemic Model for West-Java) had projected 35,294 
and 3,856, respectively. At time of research in West-Java, 167 VCT clinics are 
integrated in hospitals, public and private community health centers, and prisons. 
 
Between April 2006 and November 2009 these clinics provided VCT services to 
27,807 people. However, in 2009 overall coverage was only 30% among the 
majority of most-at-risk populations and 2% among clients of FSWs (Table 1) [3,7]. 
Because many stakeholders agreed upon a strategy of scaling up community-based 
VCT services, advocacy and capacity building has recently begun to successfully 
integrate more VCT clinics in existing public community health centers (i.e. 
Puskesmas) [7]. So far, these clinics provide VCT services to 30 people per year, but 
have the capacity to test and counsel 300 people per year, as estimated by the 
Ministry of Health (MoH) [1]. 
 
Scaling up Community-based VCT versus Current Practice  
We compare the costs and effects of scaling up community-based VCT versus a 
base case of current practice, over the years 2010-2030, from a government 
perspective. We calculated incremental cost-effectiveness ratios (ICER) per HIV 
infection averted and disability adjusted live years (DALYs). The base case and 
scaling up strategy were defined as follows: 
 
Current practice (base case). In this situation, VCT services target only most-at-
risk populations: indirect and direct FSWs, IDUs, higher risk MSM, transgenders, 
clients of FSWs, prisoners, and partners of IDUs. We assumed that VCT coverage 
among risk populations in 2009 (Table 1) remains stable until 2030 and that 60% of 
the people targeted receive VCT at hospitals, 20% at private community health 
centers, 10% at public community health centers, and 10% at prisons, reflecting  
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Table 1. VCT coverage and population size covered per risk population for West-Java province, based on national strategy 2010-2014 [7] 
  2009  2010  2011  2012  2013  2014 
Most-at-risk 
populations (size in   
West-Java province 
in 2009)§ 
 Coverage 
(%) 
Population 
covered 
 Coverage 
(%) 
Population 
covered 
 Coverage 
(%) 
Population 
covered 
 Coverage 
(%) 
Population 
covered 
 Coverage 
(%) 
Population 
covered 
 Coverage 
(%) 
Population 
covered 
IDUs (9,596)  37.0[2] 3,551  44.0 4,313   64.0 6,403   68.0 6,940   72.0 7,496  80.0 8,490  
FSWs (37,422)  33.4[2] 12,498  48.0 18,337   56.0 21,798   64.0 25,387   68.0 27,472   72.0 29,614  
Higher risk MSM 
(15,117) 
 22.8[2] 3,447  22.8 3,521   36.0 5,674  48.0 7,718   56.0 9,184   64.0 10,700  
Transgender (1,769)  85.6[2] 1,514  85.6 1,538  85.6 1,560   85.6 1,581   85.6 1,602  85.6 1,622  
Clients of FSWs 
(204,200) 
 2.2# 4,492  15.0 31,293   23.0 48,971   30.0 65,159   35.0 77,540   40.0 90,334 
Prisoners (20,199)  11.4# 2,304  48.0 9,851   64.0 13,318   68.0 14,344   72.0 15,389   80.0 17,303  
Partners IDUs 
(5,829) 
 0.0# 0,0  2.0 119  4.0 243  8.0 496  12.0 759  20.0 1,289 
Total (294,132)  9.5 27,806   23.0 68,972   32.0 97,967   38.9 121,625   43.8 139,442   49.1 159,352  
IDUs = injecting drug users, FSWs = female sex workers, MSM = men having sex with men.  
# VCT coverage data for West-Java province not available and therefore based on national data (outside Papua province), as reported in National Strategy 2010-
201410 
Note: population size increases over the years by overall West-Java population growth, § population size in 2009 was based on adaptation of size in 2006 by 
population growth  
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current practice [15]. Unit costs of VCT per client depend on where the client is 
tested and counselled (i.e. health centers, hospitals, or prisons). 
 
Scaling up VCT at the community level. In this situation, VCT will be scaled up 
at public community health centers according to the National Strategy 2010-2014, 
as specific targets for West-Java province are not available [7,16]. “Community 
level” is defined as providing services at close distance to the living area of the 
target group, in public community health centers (i.e. Puskesmas) in both urban and 
rural areas. Coverage among most-at-risk populations will increase from 
approximately 30% in 2009 to 80% in 2014 and will remain stable until 2030 (Table 
1). We assumed that hospitals will no longer offer VCT services, that the number 
of people tested and counselled at private community health centers and prisons 
remains stable, and that the additional people covered receive VCT at public 
community health centers. In this situation, 85.4% of the targeted people receive 
VCT at public community health centers, 3.2% at private community health 
centers, 11.4% at prisons and 0% at hospitals. The most-at-risk populations 
targeted, the VCT unit costs, and the capacity of public community health centers 
are similar as the defined base case.  
 
Study Model 
We projected costs and effects using a combined Asian epidemic model (AEM) 
[17,18] and Resource needs model (RNM) [19]. Both models are widely published 
and are the primary and only source of data on the HIV/AIDS epidemic for the 
Ministry of Health in Indonesia [4,7]. A detailed description of the models and the 
data sources used can be found in the online Appendix 
(www.niche1.nl/publications). 
 
Because of model limitations we only modelled the impact of a reduction of 
condom use in contacts between direct and indirect FSWs and their clients, IDUs 
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and FSWs and their spouses or regular partners, and between MSM and their male 
partners. In our sensitivity analysis we anticipated on the over- or underestimation 
of the effectiveness of VCT, as the impact matrix does not capture studies from 
Indonesia on the impact of VCT. However, in the literature we found one 
qualitative study on the impact of VCT on 40 IDUs in Bali that reported that of 
those who tested positive, 50% reported decreased risky drug use and 37.5% 
decreased risky sex. The individuals with negative test results showed the same 
changes [20]. In addition, we assumed equal impact of VCT over risk groups, as we 
found no evidence for differences in the literature [21]. The costs of VCT coverage 
were included for all most-at-risk populations. 
 
Estimate of DALYs Saved 
AEM output (number of new HIV infections, AIDS cases, and deaths of men and 
women) was used to estimate DALYs for both the base case and the strategy of 
scaling up VCT, based on the following Global Burden of Disease formulas [22]:  
DALY = YLL + YLD 
 
Years of lives lost (YLL) due to AIDS related death: 
 
𝑌𝐿𝐿𝑠|𝑟, 𝐾, 𝛽|
=
𝐾𝐶𝑒𝑟𝑎
(𝑟|𝛽)2
[𝑒(𝑟|𝛽𝐾𝐿|𝑎|)][𝑟|𝛽][𝐿||𝑎]1|−𝑒(𝑟|𝛽|𝑎|)| − (𝑟 + 𝛽)𝑎 − 1|)
+
1 − 𝐾
𝑟
(1 − 𝑒𝑟𝐿) 
 
K=age weighting modulation factor; C=constant; r=discount rate; a=age of death; 
β=parameter from age weighting function; L=standard expectation of life at age. 
 
Years lived in disability (YLD) (separated for disease stages of HIV-infection and 
AIDS): 
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𝑌𝐿𝐷𝑠|𝑟, 𝐾, 𝛽|
= 𝐷|
𝐾𝐶𝑒𝑟𝑎
(𝑟|𝛽)2
[𝑒(𝑟|𝛽𝐾𝐿|𝑎|)][𝑟|𝛽][𝐿||𝑎]1|−𝑒(𝑟|𝛽|𝑎|)| − (𝑟 + 𝛽)𝑎 − 1|)
+
1 − 𝐾
𝑟
(1 − 𝑒𝑟𝐿) 
 
K=age weighting modulation factor; C=constant; r=discount rate; a=age of onset 
of disability; β=parameter from age weighting function; L=duration of disability; 
D=disability weight. 
 
For men and women disability weights were 0.136 for HIV infection (0.123 until 15 
years old) and 0.505 for AIDS, the average duration in the HIV and AIDS states 
were 7.49 and 3.0 years respectively,2,23 the discount rate was 0.03, and no age-
weighting was applied. The average age of infection was estimated using the Asian 
Epidemic Model. The mortality and AIDS disability that will take place after 2030 
(and relate to HIV infections that occurred between 2010-2030) were included in 
the DALY estimates. 
 
Estimate of Costs 
Siregar et al. [8] estimated the costs of VCT in different delivery settings (public 
and private community health centers, hospitals, and prisons) in Bandung, West-
Java (Table 2). Health care costs were estimated on the basis of data on service 
utilization retrieved from clinic records and unit costs, including all resources 
consumed and valued using a micro-costing approach. All costs were measured in 
rupiah, and converted to US$ using the 2008 exchange rate. Based on a MoH 
workshop with HIV/AIDS experts in West-Java, the health care costs for public 
community health centers were adjusted from 28 to 300 people per year to reflect 
normal capacity [23]. In all settings the VCT service is in line with the standard 
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VCT delivery procedure instructed by the MoH: VCT includes a separate room for 
counselling and well-trained counsellors. Differences among clinics in capital  
 
Table 2. Annual costs of delivering VCT service for different clinic 
settings (US$, 2008 exchange rate)8 
Type of cost/clinic 
setting 
 Public 
community 
health center† 
 Private 
community 
health center 
 Hospital 
 
 Prison 
 
 Capital costs 
(annualized) 
        
 Personnel training, 
& workshops 
 207 (4.6§)  4,220 (10.0)  145 (0.5)  4,194 
(32.4) 
 Building/space  181 (4.0)  266 (0.6)  657 (2.3)  1,624 
(12.5) 
 Equipment  297 (6.6)   351 (0.8)  657 (2.3)  30 (0.2) 
 Subtotal  685   4,837   1,459  5,848  
 Capital cost per VCT  2  6  3  10 
 Recurrent costs         
 Personnel  615 (13.8)  21,051 (50.0)  21,633 
(74.9) 
 2,116 
(16.4) 
 Supplies  2,297 (51.4)  10,007 (23.8)  2,591 
(9.0) 
 539 (4.2) 
 Outreach team 
activities 
 -  6,186 (14.7)  -  - 
 Laboratory  874 (19.5)  - ¥  3,255 
(11.2) 
 4,439 
(34.3) 
 Subtotal  3,787   37,244   27,479  7,093 
 Recurrent cost per VCT  12  48  65  12 
Total annual cost   4,472  42,080  28,938  12,941 
Clinic capacity 
(number of VCTs per 
year) 
 300  784  421  574 
Unit cost per VCT   14.91  53.37  68.74  22.55 
† Adapted to 300 patients per year 
§ Percentage of total costs  
¥ Not costed separately, but included in the capital and recurrent cost items 
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personnel training and workshop costs are explained by differences in training 
quality and number of staff trained. Differences in recurrent personnel costs are 
caused by differences in number of admin staff, salary and time spend per VCT 
service. We assumed that only private community health centers have outreach 
teams. Additional costs for scaling up services were not included as the unit costs 
include capital costs reflecting costs for new buildings and training costs for new 
VCT counsellors. 
 
Sensitivity Analyses 
We examined the robustness of baseline incremental cost-effectiveness ratios to 
parameter variations in a one-way sensitivity analysis. For the impact of VCT on 
the reduction in non-condom use the uncertainty ranges as provided by the 
GOALS matrix were used. We varied coverage assumptions in the strategy of 
scaling up VCT and all costs components using a -/+ 25% approach. Other 
parameters, like AEM fitting variables, years of projection, clinic capacity, and most 
importantly epidemiological and behavioral variables were varied according to 
known uncertainty or a -/+25% approach. All uncertainty ranges are presented 
between brackets in an additional table in the online Appendix 
(www.niche1.nl/publications). 
 
Results 
Between 2010 and 2014, scaling up VCT will increase condom use for direct FSWs 
from 62% to 69%, for indirect FSWs from 60% to 67%, for MSM from 45% to 
55%, for sexual contact between IDUs and FSWs from 54% to 62%, and for 
sexual contact between IDUs and spouses from 34% to 46%. Compared with the 
base case, scaling up VCT will decrease the overall HIV prevalence by 36%, from 
0.44% to 0.28%, in West-Java in 2030. This reduction varies between most-at-risk 
populations: a decrease from 42.9% to 41.2% for IDUs, 34.0% to 21.7% for FSWs, 
and 15.7% to 9.8% for MSM. Up to 2030, scaling up VCT will avert more than 
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94,000 HIV infections (Figure 1), 41,000 AIDS cases and 26,000 deaths, and this 
corresponds to more than 2.5 million DALYs averted in West-Java. 
 
 
Figure 1. Impact of scaling up VCT on cumulative and current number of HIV infections 
in West-Java 
 
 
Unit costs of VCT delivery settings range between US$14.91 at public community 
health centers and $68.74 at hospitals (Table 2). Over the period 2010-2030, scaling 
up VCT at the community level will cost US$60 million, compared to US$37 
million if current practice is maintained. Scaling up VCT will cost US$1.3 million in 
2010, US$3.0 million in 2015, and US$3.8 million in 2030. The number of clinics 
integrated at public community health centers would need to increase from 73 in 
2010 to 594 in 2030 in order to provide VCT services to more than 180,000 
thousand people in West-Java in 2030.  
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maximum value minimum value 
Scaling up VCT (compared to the base case) costs US$248 per HIV infection 
averted and US$9.17 per DALY averted. As presented in Figure 2, ICER estimates 
were most sensitive to the impact of VCT on condom use, population size of 
clients of FSWs, HIV prevalence in the general population, population size of 
FSWs, and condom use between FSWs and clients. Costs per HIV infections 
averted range between US$104 and US$1,758 and cost per DALY saved range 
between US$5 and US$65. 
 
Figure 2. Results of one-way sensitivity analysis of incremental costs per DALY saved 
 
 
Discussion 
Our estimates show that implementation of the national strategy of scaling up 
community-based VCT to 80% of the most-at-risk populations in West-Java could 
reduce the overall population prevalence by 36% in 2030 (from 0.44% to 0.28%) 
and could avert a substantial amount of HIV-related morbidity and death. This 
strategy costs US$248 per HIV infection averted and US$9.17 per DALY saved. 
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According to international thresholds put forward by WHO [24], this intervention 
seems very cost-effective as it falls within the one-time per capita gross domestic 
product (i.e. US$2,963 in 2010) [25]. Although our estimates are sensitive to 
parameter changes in the model, they do not exceed the threshold mentioned and 
therefore conclusions can be considered robust. Because the nature of the HIV 
epidemic is similar across Indonesia, with the exception of Papua province, study 
results can be generalized with caution. 
 
Although scaling up community-based VCT is very effective and cost-effective it 
raises concerns: West-Java province will need between US$1.3 to US$3.8 million 
per year to spend on VCT; in 2010 the national HIV/AIDS   expenditure for all 
programs in all 33 provinces together was US$50.8 million and 61% was financed 
by international sources [3]. However, the prioritization of VCT over other 
interventions could partially address this concern. Scaling up community-based 
VCT requires a substantial rise in the number of public community health centers 
that deliver VCT (from 73 in 2010 to almost 600 in 2030) and it is not certain 
whether this is feasible, although first steps in this process have already been taken 
successfully [7]. Because of these budget and organizational constraints, cost-
effectiveness alone should not guide priority setting in HIV/AIDS control in West-
Java [26]. 
 
Scaling up VCT is more cost-effective than MMT in West-Java. Wammes et al. [13] 
estimated that scaling up MMT to 20% in West-Java costs $269 per DALY saved. 
Unfortunately, we cannot compare these results to the cost-effectiveness of other 
HIV/AIDS interventions in Indonesia due to a lack of data. Compared to other 
countries our estimates are in the same order of magnitude. In India and Kenya, 
VCT costs, respectively, US$665 and US$249 per HIV infection averted. In Peru, 
VCT costs US$116 per DALY saved [27–29]. 
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This study has a number of limitations. First, the AEM and RNM were not 
originally developed to conduct cost-effectiveness analysis and could not precisely 
reflect VCT in West-Java as some risk populations were not included. In addition, 
the effectiveness data in the impact matrix (i.e. the impact of VCT on condom use) 
was not based on Indonesian evidence and the exclusion of some populations 
caused an underestimation of the effectiveness. However, our effectiveness 
assumption was validated by the literature and sensitivity analysis showed that 
conclusions are robust. Second, VCT was evaluated as a single intervention and the 
impact of increased need for antiretroviral treatment (ART) on budget and health 
effects was not included. We excluded ART because its implementation is a 
separate decision for the government; if we included it then the overall intervention 
would probably be even more cost- effective, as ART can reduce HIV transmission 
and therefore has large population effects. In addition, we analyzed costs from a 
governmental perspective and did not include patient costs, although a recent study 
in three settings in Indonesia showed a substantial financial burden of HIV/AIDS 
care for patients.30 Third, economies of scale, cost inflation, indirect costs 
(productivity loss due to disability and early death), and interactions between 
interventions were not taken into account, because accurate data was not available. 
Fourth, scaling up VCT could face feasibility constraints, e.g. a lack of VCT 
counsellors and political and cultural support, but this can be partially resolved by 
training community workers and by advocacy for prioritizing HIV/AIDS services. 
Fifth, we assume that high coverage of risk groups can be achieved although it is 
difficult to reach out to these populations. However, we see this assumption as a 
limitation of cost-effectiveness analysis in general.  
 
  
Cost-effectiveness of scaling up VCT 
Page | 95 
Conclusion 
Scaling up community-based VCT seems an effective and cost-effective 
intervention. However, in order to prioritize VCT in HIV/AIDS control in West-
Java, issues of budget availability and organizational capacity should be addressed.  
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APPENDIX. Description of AEM and RNM models and data sources used 
 
Asian Epidemic Model (AEM) 
The AEM is a dynamic, deterministic compartment model designed for macro 
simulation of populations and key processes driving HIV transmission; it is 
described in detail elsewhere [1,2]. The AEM considers HIV transmission within a 
population aged ≥ 15 years and divides the population in nine compartments: 1) 
clients of FSW; 2) males who are not clients of FSW; 3) lower risk, general 
population females; 4) direct FSWs; 5) indirect FSWs; 6) IDUs in higher risk 
sharing networks; 7) IDUs in a lower risk or not sharing network; 8) male sex 
workers; and 9) MSM who are not sex workers. Each compartment is divided into 
those infected with HIV and not infected. Movement between compartments is 
determined by the average duration of sex work, or death, or infection with HIV. 
The AEM includes data on factors such as demography, population size, injecting, 
sexual behavior, and epidemiology for the years 1975-2030. The most important 
model output data are the number of new HIV infections, AIDS cases, deaths, and 
routes of transmission per year between 1975 and 2030. The number of new 
infections is calculated based on the prevalence in the partner population, the 
frequency of sex acts or injections, and the probability of HIV transmission. 
Corrections are made for increased HIV transmission due to the presence of other 
sexually transmitted infections (STIs) or the lack of male circumcision by adding 
co-factors that increase the effective transmission probability by a fixed amount. 
Finally, a correction is made for protective behaviors such as condom use. To fit 
the model, the AEM fitting parameters (e.g. probabilities of transmission, Table A) 
are adjusted in order to obtain a reasonable match between the prevalence reported 
and the prevalence calculated by the AEM.   
 
We used the West-Java baseline model as defined by local leading experts from 
AIDsina (Portal for Indonesia AIDS community) and the East-West Center 
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(EWC), and as is compatible with data used by the MoH. This model is based on 
the National Indonesian AEM and adapted with local data for West-Java and 
assumptions made by EWC and AIDsina, who consulted experts in MoH and 
AIDS commissions. Data sources were retrieved to verify the data used in the 
model and only minor adaptations were made. Table A presents an overview of the 
model parameters, and their baseline values and references. The AEM uses these 
data to project HIV prevalence for most-at-risk-populations. We adjusted AEM 
fitting parameters so that projected HIV prevalence fits the observed HIV 
prevalence among IDUs, FSWs, and MSM from surveillance studies in West-
Java.HIV prevalence among the general population was not used for model fitting. 
Data on population sizes, and on epidemiological and behavior variables were 
sourced from government monitoring and evaluation systems and the International 
Biological Behavior Surveillance System (IBBS); no change in behavior parameters 
was assumed after 2007 (last year data of IBBS) [3]. The AEM was used, first, to 
reflect current practice of VCT delivery (base case) and second, to reflect the 
impact of increased condom use among most-at-risk populations caused by scaling 
up VCT. This increase in condom use was estimated by the RNM, described below, 
and altered in the AEM. As the AEM does not represent transgenders, prisoners, 
and partners of IDUs, these groups were excluded in our effectiveness analysis 
because we expected these groups to have minor impact on the spread of the 
epidemic. 
 
Resource Needs Model 
The RNM [4] was used primarily to estimate the resources needed for both the 
base case and the strategy of scaling up VCT, by combining population sizes, 
coverage of VCT, and unit costs. The RNM also calculated the impact of VCT on 
risk behavior, based on the RNM impact matrix (originally part of GOALS model 
[5]). This matrix is based on a literature review of VCT effectiveness on risk 
behavior [6] and differentiates the impact of VCT on the reduction in non-condom 
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use for low-, middle-, and high-risk populations. We assumed that all populations 
targeted by VCT in the scaling up strategy are high-risk populations and used a 
baseline VCT impact value of 44% reduction in non-condom use.  
 
Table A. Baseline values, sensitivity ranges and references of parameters used in Asian 
Epidemic Model adapted for West-Java Province 
Parameter 
Baseline value  
(sensitivity range) 
Reference 
AEM fitting parameters 
 Transmission probability    
 Male to female (Pm_f) 0.00125 (-/+ 25%) Fitting 
 Male to male (Pm_m) 0.01790 (-/+ 25%) Fitting 
 Needle stick 0.03 (-/+ 25%) Fitting 
Ratio of male to female versus female to male transmission 3.80 (-/+ 25%) Fitting 
IDU network parameter (%) 80.00 (-/+ 25%) Fitting 
STI cofactor    
 Female to male 16.00 (-/+ 25%) Fitting 
 Male to female 20.00 (- 25%) Fitting 
 Male to male 1.00 (+25%) Fitting 
Circumcision factor 2.55 (1.91-3.19) Fitting 
Epidemic start year    
 IDU 2002 (1996-2004) Fitting 
 Heterosexual 1989 (1985-1993) Fitting 
 MSM 1992 (1988-1996) Fitting 
Population sizes (2006) 
 FSWs   37,422 (24,970-47,190) [7] 
FSWs who are direct FSWs (%) 62.20 (-/+ 25%) [7] 
IDUs  9,596 (6,380-11,900) [7] 
Higher risk MSM 15,117 (14,361-15,872) [7] 
Lower risk MSM 133,220 [7] 
 Male sex workers 2,062 [7] 
Prisoners  20,199 (15,149-25,249) [7] 
Transgender  1,769 (1,568-1,733) [7] 
Clients of FSWs  204,200 (121,009 - 287,378) [7] 
Partners of IDUs  5,829 (5,537-6,120)    [7] 
Males age 15+ 14,596,400 [8] 
Females age 15+ 14,152,600 [8] 
HIV prevalence (% in 2007, used for fitting) 
 Direct FSW   11.60 (-/+25%) [3] 
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Parameter 
Baseline value  
(sensitivity range) 
Reference 
 Indirect FSW  3.29 (-/+25%) [3] 
 IDUs 42.80 (-/+25%) [3] 
 MSM 2.00 (-/+25%) [3] 
 General population 0.00 (0.00-3.00) [3] 
Heterosexual behavior and STIs (2007) 
 Direct female sex workers   
 Direct to indirect FSWs behavior movement each year 
(%) 
1 Default value 
 Number of clients per day  1.7 [3] 
 Days worked per week  5.3 [3] 
 Condom use with clients (%) 62 (-/+25%) [3] 
 Average duration of sex work (years) 2.5 [3] 
 STI prevalence(% neisseria gonorrhea)  44 (-/+25%) [3] 
 Indirect female sex workers   
 Number of clients per day  0.86 [3] 
 Days worked per week 5.5 [3] 
 Condom use with clients (%) 60 [3] 
 Average duration of sex work (years) 2.0 Local expert opinion¥ 
 STI prevalence (% neisseria gonorrhea)  22 (-/+25%) Local expert opinion 
 Clients of sex workers   
 Males age 15-49 visiting sex workers (%) 1.7 [7] 
 Average duration of being a client (years) 11 Local expert opinion 
 Adult males circumcised (%) 87 (-/+25%) [9] 
 Male and female casual sex   
 Males having casual sex in last year (%) 0.3 Local expert opinion 
 Females having casual sex in last year (%) 0.1 Local expert opinion 
 Condom use in casual sex (%) 21 (-/+25%) [3] 
 Average number of casual contacts in last year (male) 1 Default value 
 Sex with spouses or regular partners    
 Number of weekly sexual contacts with spouse/regular 
partner  
1.4 Local expert opinion 
 Condom use with spouses or regular partners (%) 10 Local expert opinion 
 Adult population with STI (%) 0.5 Local expert opinion 
IDUs injecting and sexual behavior(2007) 
 IDU mortality (% additional mortality per year) 1.0 Default value 
 IDUs sharing (%) 32 (-/+25%) [3] 
 Injections shared, by those in sharing group (%) 70 (-/+25%) [3] 
 Number of injections each day 0.74 (-/+25%) [3] 
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Parameter 
Baseline value  
(sensitivity range) 
Reference 
 Average duration of injecting (years) 8.0 (-/+25%) [3] 
 Sharing to non-sharing movement in a year (%) 20(-/+25%) Local expert opinion 
 Visiting FSWs (%) 41 (-/+25%) [3] 
 Condom use with direct FSW (%) 54 (-/+25%) [3] 
 Condom use with indirect FSW (%) 54 (-/+25%) [3] 
 Condom use with spouse or regular partner (%) 34 (-/+25%) [3] 
 Number of contacts with regular partners (per week) 1 (-/+25%) Default value 
Injecting sex workers (ISW) (2007)Ω 
 Injecting behaviors - higher frequency injecting SWs   
 Percentage of higher frequency sex workers who inject 0.1 [3] 
 Percentage of higher frequency ISW in high risk networks 0 Default value 
 Percentage of higher frequency ISW sharing 0 Default value 
 Percentage of all injections shared (sharing higher 
frequency SW) 
0 Default value 
 Number of daily injections for higher frequency ISW 0.7 [3] 
 Average duration of injecting for higher frequency ISW 
(years) 
2.5 [3] 
 Percentage condom use with clients (higher frequency 
ISWs) 
62 [3] 
 Injecting behaviors - lower frequency injecting SWs   
 Percentage of lower frequency sex workers who inject 0.1 [3] 
 Percentage of lower frequency ISW in high risk networks 0 Default value 
 Percentage of lower frequency ISW sharing 0 Default value 
 Percentage of all injections shared (sharing low frequency 
SW) 
0 Default value 
 Number of daily injections for lower frequency ISW 0.7 [3] 
 Average duration of injecting for lower frequency ISW 
(years) 
2.5 [3] 
 Percentage condom use with clients (low frequency ISWs) 60 [3] 
MSM sexual behavior (2007)§ 
 Higher risk MSM (Hi MSM) sexual behavior   
 Reporting anal sex last year (%) 93 Local expert opinion 
 Number anal sex contacts last week 0.5 Local expert opinion 
 Average duration of same-sex behavior (years) 12.7 Local expert opinion 
 Shift from Hi MSM to Lo MSM 25 Default value 
 MSM having sex with other female partners (%) 34 [3] 
 Condom use in last anal sex (%) 45 (-/+25%) [3] 
 Prevalence Hi MSM with anal STI (%) 21 [3] 
 Lower risk MSM (Lo MSM) sexual behavior   
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Parameter 
Baseline value  
(sensitivity range) 
Reference 
 Percentage of Lo MSM reporting anal sex in last year 53 Local expert opinion 
 Number anal sex contacts last week (for MSM w/anal 
sex) 
0.1 Local expert opinion 
 Average duration of same-sex behavior (years) 18.1 Local expert opinion 
 Percentage of Lo MSM with other female partners 20 Local expert opinion 
 Percentage condom use in anal sex with other Lo MSM 48 Local expert opinion 
 Percentage Lo MSM with anal STI 5.4 Local expert opinion 
 MSM sexual behavior with commercial partners   
 Percentage of Hi MSM visiting male sex workers 13 Local expert opinion 
 Percentage of Lo MSM visiting male sex workers 2 Local expert opinion 
 Ratio of frequency of visiting MSW (Lo MSM/Hi MSM) 0.1 Default value 
 Percentage of Hi MSM visiting female sex workers 6 Local expert opinion 
 Percentage of Lo MSM visiting female sex workers 0 Local expert opinion 
 Condom use in anal sex with male sex worker (%) 50 Local expert opinion 
 Condom use direct FSW (%) 62 [3] 
 Condom use indirect FSW (%) 60 [3] 
Male sex workers (MSW) 
 MSW size and duration   
 Average duration of male sex work (years) 6.3 Local expert opinion 
 Shifts from Hi MSM to MSW (%) 1 Default value 
 Shifts from Lo MSM to MSW (%) 1 Default value 
 Sexual behaviors and STI with clients   
 Percentage of MSW reporting anal sex with clients in last 
year 
93 Local expert opinion 
 Number anal sex contacts last week  1.0 Local expert opinion 
 Percentage MSW with anal STI 23 Local expert opinion 
 Female partners of MSW   
 Percentage MSW visiting female sex workers in last year 9 Local expert opinion 
 Percentage MSW with other female partners in last year 43 Local expert opinion 
Intervention characteristics (2010 onwards) 
 Impact of VCT on reduction in non-condom use (%) 44 (6-93) [6] 
 Distribution delivery settings    
 Current practice (base-case)   
  Hospitals (%) 60 (-/+25%) [10] 
  Community health centers 
(%) 
10 (-/+25%) [10] 
  Private health centers (%) 20 (-/+25%) [10] 
  Prison (%) 10 (-/+25%) [10] 
 Scaling up VCT   
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Parameter  
Baseline value  
(sensitivity range) 
Reference 
  Hospitals (%) 0 (-/+25%) Assumption 
  Community health centers 
(%) 
85.4 (-/+25%) Assumption 
  Private health centers (%) 3.2 (-/+25%) Assumption 
  Prison (%) 11.4 (-/+25%) Assumption 
 Clinic capacity, number of VCT per year   
 Hospitals  421 (-/+25%) Current practice 
 Community health centers 300 (-/+25%) [11] 
 Private health centers 784 (-/+25%) Current practice 
 Prison 574 (-/+25%) Current practice 
 Projection period (years) 2010-2030 (2010-2020) Assumption 
Disability adjusted life years 
 Discount rate 0.3 (0) Assumption 
 Age weighting 0 (1) Assumption 
IDUs = injecting drug users, FSWs = female sex workers, MSM = men having sex with men, STI = sexual transmitted 
infections 
¥ Local expert opinion was given by researchers from East West Center and AIDSIna 
ΩThe parameter values for injecting sex workers are copied from both FSW and IDU parameter values. 
§The IBBS 2007 report does not discriminate between higher risk MSM, lower risk MSM and MSW, but the raw IBBS 
data were used by local experts for parameter estimates.   
 Note: order and categorization of parameters are in line with presentation in Asian Epidemic Model. 
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CHAPTER 6 
Costs of HIV/AIDS treatment in Indonesia according to length of 
treatment and disease severity 
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Abstract 
OBJECTIVE: We report economic analysis of HIV care and treatment in 
Indonesia to assess the options and limitations of increasing efficiency, improving 
access, and scaling up services.  
METHODS: We calculated the cost of providing HIV care and treatment in a 
main referral hospital in West Java, Indonesia from 2008 to 2010, differentiated by 
initiation of treatment at different CD4 cell count levels (0-50, 50-100, 100-150, 
150-200, and >200 cells/mm3); duration of treatment; HIV care and opportunistic 
infections (OI) cost components; and costs of patients for seeking and undergoing 
care. 
RESULTS: Before ART initiation, costs were dominated by laboratory tests 
(>65%), and after initiation, by antiretroviral drugs (≥60%). Average treatment 
costs per patient decreased with duration on treatment. Higher CD4 cell counts at 
initiation resulted in lower laboratory and OI treatment costs. Transportation cost 
dominated the costs of patients for seeking and undergoing care (>40%). 
CONCLUSIONS: Costs of providing ART are highest during the early phase of 
treatment. Efficiency gains can likely be realized by early treatment initiation, 
applying alternative laboratory tests, and providing alternative delivery models with 
involvement of community health services or less frequent hospital visits. Although 
scaling up ART at the community level may improve early uptake and adherence, 
its implementation requires further study given the current low general HIV 
prevalence and required HIV expertise.  
Key words: Cost Analysis, Antiretroviral Therapy, HIV, Indonesia 
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Background 
The face of the HIV/AIDS epidemic in Indonesia is changing. While the epidemic 
started among injecting drug users, now it seems to shift towards the general 
population. The percentage of HIV transmission through injecting drug use 
decreased from 53% in 2001-2005 to 34% in 2011, and heterosexual transmission 
increased from 37% to71% during the same period [1]. 
 
Indonesia’s national response to the epidemic focuses on a wide range of programs, 
including continuing support for care and treatment programs [1].The need for 
antiretroviral therapy (ART) is expected to increase from approximately 30,000 
patients in 2008 to almost 87,000 patients in 2014 [2]. However, only 24% of HIV 
patients who are eligible for treatment in Indonesia receive ART which indicates 
the need for the government to increase ART service, and puts pressure on the 
already-constrained budget for HIV/AIDS control in Indonesia [3]. 
 
There is an urgent need to address the following research questions. First, what are 
the present treatment unit costs by time of treatment and stage of disease, and is 
there any potential to increase efficiency? Although there is (limited) international 
evidence that initiating treatment early is more efficient than late treatment [4], and 
that delivery of ART is less costly at the community level than the hospital level [5], 
these have not been substantiated for Indonesia, and have only limited studies in 
Asia [6,7]. There is also limited Indonesian data to suggest that the use of less 
intense diagnostic and treatment procedures might lead to cost savings [8–10]; 
however, this data has not been placed in the context of total treatment costs.  
 
Second, what are the costs of scaling up ART? International evidence suggests that 
cost increases stemming from increased patient numbers can partly be offset by 
reduced average treatment costs as patients are treated earlier [11]; however, there 
is no specific evidence for Indonesia to support this hypothesis. 
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Third, what is the financial burden of patients accessing care? Although 
international studies have shown that the financial burden on patients may 
constitute a barrier to treatment [12] and may affect adherence and retention to 
treatment [13–15], available evidence from Indonesia stems from a single study 
only [16]. 
 
This paper presents an economic analysis of the provision of ART and care for 
HIV/AIDS patients. It presents a cost profile differentiated by initiation of 
treatment at different CD4 cell count levels; time on treatment; cost components 
(e.g., drug and personnel costs) for HIV care and opportunistic infections (OIs); 
and finally patient costs of seeking and undergoing care. We believe our approach 
is unique in the context of Indonesia and Asia and can be generalized to other 
settings with similar HIV/AIDS epidemics and health system profiles.  
 
Methods 
Study setting and study population 
The study was conducted in Bandung, at an HIV/AIDS clinic in the largest public 
referral and teaching hospital (Hasan Sadikin) in West Java province (43 million 
inhabitants). The clinic is visited by highly at-risk groups and the general 
population, and delivers HIV-related services such as voluntary counseling and 
testing, ART, and sexually transmitted infections services. The clinic operates at full 
capacity because it is among the few clinics that deliver ART in Bandung. The 
clinic generates its own revenues through government, hospital, and private 
funding; ART-related services are free, excepting hospitalization and the 
registration fee. 
 
The study included all inpatients and outpatients starting ART in the clinic between 
2008 and 2010. The study population was divided into five groups by CD4 cell 
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count: 0–50, 50–100, 100–150, 150–200, and >200cells/mm3. The starting point of 
every patient initiating ART was uniformed as month 1, and patients were analyzed 
at 6, 12, 18, and 24 months of ART. We also observed the pre-ART period when 
patients received HIV care and treatment but had not yet initiated ART, which 
ranged from one week to 6 months before treatment initiation. Based on these 
starting points, each patient’s treatment pattern was tracked from available medical 
and financial records and all costs were calculated. Patients were required to visit 
the clinic monthly to take their antiretroviral drugs (ARVs), and undergo CD4 cell 
count, viral load, and routine laboratory tests approximately every 6 months. 
 
Data collection and cost estimation 
The cost estimation was divided into health care costs (costs related to the 
consumption of resources in the health care system) and non-health care costs 
(costs falling on the patient for seeking and undergoing care). Health care costs 
were divided into hospitalization, outpatient visits, OI treatment, and ARVs, as well 
as CD4 cell count, viral load, and routine laboratory test costs. The micro-costing 
approach [17] was used to calculate the unit cost of an outpatient visit and OI 
treatment. All resources consumed, prices, and salaries related to service utilization 
were listed and estimated based on clinical records, pharmacy databases, staff 
interviews, government price standards, and hospital or market prices. 
 
Outpatient costs were calculated based on the recurrent and capital costs of the 
clinic. Recurrent personnel costs were estimated based on actual wages or 
government salary scales [18]. Other recurrent costs (e.g., administration goods 
consumed during the observation period) were estimated using both actual and 
market prices. Capital costs included trainings and workshops attended by the clinic 
staff, and unit costs for organizing these activities were obtained from the actual 
budgetary or governmental records. Market prices were used to estimate other 
capital costs, including equipment, furniture, and start-up costs (e.g., renovation 
Costs of HIV/AIDS treatment 
 
Page | 113 
costs, if applicable). Capital costs were subsequently annualized on the basis of the 
lifetime of the capital items, using a 3% discount rate [17]. We omitted the cost of 
utilities (i.e., water and electricity). This result was then multiplied by the proportion 
of time allocated by the clinic to deliver ART, calculated through a separate time 
motion study in which we observed clinical activity and calculated the amount of 
time spent on ART-related duties per week by the clinic staff. The total outpatient 
visit cost was then divided by the number of total outpatient visits to obtain the 
unit cost per outpatient visit. Patients registered as outpatient were never also 
registered as inpatient in the same period. For example, a patient who is registered 
as inpatient in a certain month may be registered as outpatient in the next month, 
but never at the same month. The details of outpatient cost is presented in 
Appendix (Table A).  
 
OI treatment cost was calculated based on the medical resources consumed by OI 
treatment (e.g., drugs and equipment), excluding hospitalization. Medical records 
and the physician’s patient database were used to estimate resource utilization, and 
the official hospital prices issued in 2011 were used to calculate the unit costs of 
drugs and equipment. We obtained the unit cost of OI treatment by dividing the 
total cost of OI treatment for each CD4 cell count group by its population. We 
were unable to retrieve data regarding the specific OIs that drugs and equipment 
were used to treat. The average unit cost of OI treatment is presented in Appendix 
(Table B). 
 
Because the data was limited, we did not perform micro-costing when calculating 
the costs of hospitalization, ARVs, or laboratory tests. We used the World Health 
Organization’s Choosing Interventions that are Cost Effective (WHO-CHOICE) 
estimates [19] to estimate the per day inpatient hotel cost, which we then used to 
calculate the total hospitalization cost. The WHO CHOICE estimates for inpatient 
cost include items such as personnel, capital, and food costs, and exclude drugs and 
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diagnostic test costs. The prices of ARV drugs (except for Tenofovir) issued by 
Kimia Farma (a national pharmaceutical corporation) were used as the unit costs of 
ARVs, while the price of Tenofovir was based on Bender et al. [20]. The unit costs 
of laboratory tests (CD4 cell count, viral load, and other laboratory tests) were 
derived from the 2011 official hospital price for each test. The summary of all unit 
costs used is presented in Appendix (Table C). 
 
The non-health care costs comprised the patient costs, which were estimated by 
conducting a survey among 41 patients undergoing ART at the hospital. We 
collected information including (but not limited to) clinic service fee, travel costs, 
travelling time, the patient’s monthly income, the average number of daily working 
hours, and monthly expenditures. Next, we estimated patients’ monthly incomes 
based on their monthly expenditures. Patients did not have to pay for ARV, ARV 
monitoring, other lab tests, or OI medication/treatment. The patient cost 
estimation does not, at any rate, collide with the calculation of provider cost as it is 
calculated separately using different cost items specific to the patients. Therefore, 
there is no issue of double counting in this respect.  
 
All costs were measured in Rupiah, and converted to US$ using the 2010 exchange 
rate [21]. Both the utilization and cost data were analyzed using Microsoft Excel 
2007. We report costs from both health care system and patient perspectives. 
 
Results 
Patient characteristics 
Patient characteristics are presented in Table 1. The majority of patients with a 
CD4 cell count of 0–150 cells/mm3 are male, while females dominate the >150 
cells/mm3 group. All patients are in their productive age and the majority are 
married, employed, and have experience with injecting drug use. The highest 
education level attained by patients was the secondary level (high school). 
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Resource utilization and costs of providing ART 
Table 2 presents the resources used to provide ART. Hospitalization occurred only 
before ART and up to 6 months after treatment was initiated; the duration ranged 
from 3 to 20 days. The switch to second line ART occurred in 5% of patients with 
a CD4 cell count of 050 cells/mm3and 15% of those with 50100 cells/mm3. Few 
patients with CD4 cell counts >200 cells/mm3were hospitalized and received OI 
treatment. Details regarding unit costs per item are summarized in the appendix. 
  
Table 1. Characteristics of clients on ART 
  
   CD 4 cell count at time of starting ART 
 
Overall 
   0-50        50-100   100-150   150-200   >200         
No. of observation at the 
start of ART 
 96  33  22  17  10  178 
CD4 level at the start of ART , 
mean (CI) 
19  
(16 – 22) 
 71  
(66 – 76) 
 124  
(118 – 130) 
 177  
(170-184) 
 275  
(252 – 298) 
 39**   
(13-110) 
Sex (male)   80%  82%  59%  41%  40%  72% 
Age, mean (CI)  30  
(29 - 31)   
 30 (28-32)  29 (28-30)  27 (26-28)  27 (25 – 29)  30 (29-31) 
History of injecting drug use  69%  70%  55%  41%  70%  65% 
Marital 
status 
Married  52%  58%  45%  35%  60%  51% 
Not married  36%  24%  41%  29%  10%  33% 
Widowed/ 
divorced 
 10%  15%  14%  29%  30%  15% 
Occupation 
status 
Employed  67%  82%  86%  82%  80%  74% 
Student  2%  -  -  6%  -  2% 
Unemployed  30%  15%  14%  12%  20%  23% 
Highest 
education 
Primary  3%  -  -  -  -  2% 
Secondary  58%  51%  59%  77%  80%  60% 
Tertiary  36%  48%  41%  24%  20%  37% 
*CI=Confidence interval, 95% 
** Median (IQR) 
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Table 2. Resource utilization of patients on ART, per specified period 
   Period 
CD4 cell 
count at the 
start of ART 
Item  
Before 
ART 
 
1 - 6 
months 
 
7 - 12 
months 
 
13 - 18 
months 
 
19 - 24 
months 
0-50 Number of patients  96  96  95  84  61 
 %  hospitalized*  14%  22%  -  -  - 
 Average days of 
hospitalization (CI)** 
 6 (4-8)  15 (10-20)  -  -  - 
 Number of outpatient visit  95  47  75  63  41 
 % of patients treated for OI*   2%  63%  27%  18%  8% 
  % of patients switched to 2nd 
line ARV regiment*  
 -  -  1%  2%  3% 
 Number of CD 4 tests   95  47  75  63  41 
 Number of viral load tests   -  6  16  9  4 
 Number of routine lab tests   87  45  74  62  40 
50-100 Number of patients  33  33  33  32  25 
 %  hospitalized*  3%  12%  -  -  - 
 Average days of 
hospitalization (CI)** 
 3  6 (5-7)  -  -  - 
 Number of outpatient visit  36  13  29  20  10 
 % of patients treated for OI*   3%  36%  21%  13%  4% 
 % of patients switched to 2nd 
line ARV regiment*  
 -  3%  3%  6%  12% 
 Number of CD 4 tests   36  13  29  20  10 
 Number of viral load tests   0  5  6  4  0 
 Number of routine lab tests   30  14  28  20  9 
100-150 Number of patients  22  22  22  18  13 
 %  hospitalized*  -  14%  -  -  - 
 Average days of 
hospitalization (CI)** 
 -  7  -  -  - 
 Number of outpatient visit  29  8  18  13  7 
 % of patients treated for OI*   -  45%  18%  11%  15% 
 % of patients switched to 2nd 
line ARV regiment*  
 -  -  -  -  - 
 Number of CD 4 tests   29  8  18  13  7 
 Number of viral load tests   1  1  4  3  - 
 Number of routine lab tests   21  8  17  13  7 
150-200 Number of patients  16  16  13  13  11 
 %  hospitalized*  12%  6%  -  -  - 
 Average days of 
hospitalization (CI)** 
 5  3  -  -  - 
 Number of outpatient visit  26  9  9  11  7 
 % of patients treated for OI*   -  47%  14%  21%  - 
 % of patients switched to 2nd 
line ARV regiment*  
 -  -  -  -  - 
 Number of CD 4 tests   26  9  9  11  7 
 Number of viral load tests   1  4  4  1  - 
 Number of routine lab tests   16  8  9  11  7 
>200 Number of patients  10  10  10  7  4 
 %  hospitalized*  -  -  -  -  - 
 Average days of 
hospitalization (CI)** 
 -  -  -  -  - 
 Number of outpatient visit  17  5  6  4  4 
 % of patients treated for OI*   -  10%  -  -  - 
 % of patients switched to 2nd 
line ARV regiment*  
 -  -  -  -  - 
 Number of CD 4 tests   17  5  6  4  4 
 Number of viral load tests   -  -  -  -  - 
 Number of routine lab tests   9  5  6  4  4 
*for the whole sample within the indicated period 
**CI = Confidence Interval, 95% 
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Table 3. Health care costs of patients on ART, per specified period (US$^) 
CD4 cell 
count at 
the start 
of ART 
Item 
 Period 
 
Before ART   
(% of TC**) 
 
1 - 6 months           
(% of TC) 
 
7 - 12 
months         
(% of TC) 
 
13 - 18 
months         
(% of TC) 
 
19 - 24 
months         
(% of TC) 
0-50 Number of clients  96  96  95  84  61 
 Hospitalization  1,483 (10%)  6,161 (9%)  -  -  - 
 Outpatient visits  1,110 (8%)  6,707 (10%)  6,462 (12%)  5,247 (11%)  3,517 (11%) 
 OI treatment  86 (1%)  10,867 
(16%) 
 2,163 (4%)  564 (1%)  1,538 (5%) 
  ARV drugs  -  40,012 
(60%) 
 41,281 
(78%) 
 37,724 (81%)  26,915 (81%) 
 CD 4 test  1,254 (9%)  620 (1%)  990 (2%)  832 (2%)  541 (2%) 
 Viral load test  -  396 (1%)  1,056 (2%)  594 (1%)  264 (1%) 
 Routine lab test  10,452 
(73%) 
 1,488 (2%)  1,289 (2%)  1,548 (3%)  363 (1%) 
 Total costs  14,385   66,252  53,240  46,508  33,139 
 Average costs per 
client (CI*, 95%)  
 150  
(139 – 160) 
 690  
(593-787) 
 560  
(522-599) 
 554  
(515-592) 
 543  
(481-606) 
50-100 Number of clients  33  33  33  32  25 
 Hospitalization  57 (1%)  418 (2%)  -  -  - 
 Outpatient visits  421 (9%)  2,337 (12%)  2,232 (11%)  1,951 (11%)  1,110 (11%) 
 OI treatment  12 (0.3%)  725 (4%)  2,099 (10%)  13 (0.1%)  9 (0.1%) 
 ARV drugs  -  14,694 
(77%) 
 15,360 
(73%) 
 14,763 (83%)  9,058 (87%) 
 CD 4 test  475 (10%)  172 (1%)  383 (2%)  264 (1%)  132 (1%) 
 Viral load test  -  330 (2%)  396 (2%)  264 (1%)  - 
 Routine lab test  3,608 (79%)  478 (2%)  494 (2%)  508 (3%)  104 (1%) 
 Total costs  4,573  19,154  20,963  17,763  10,413 
 Average costs per 
client (CI, 95%)         
 139  
(126-151) 
 580  
(568-593) 
 635  
(622-648) 
 555  
(542-568) 
 417  
(404-429) 
100-150 Number of clients  22  22  22  18  13 
 Hospitalization  -  418 (4%)  -  -  - 
 Outpatient visits  339 (10%)  1,566 (14%)  1,391 (13%)  1,157 (13%)  771 (14%) 
 OI treatment  -  815 (7%)  77 (0.7%)  29 (0.3%)  2 (0.04%) 
 ARV drugs  -  8,147 (72%)  8,587 (79%)  6,858 (79%)  4,661 (83%) 
 CD 4 test  383 (11%)  106 (1%)  238 (2%)  172 (2%)  92 (2%) 
 Viral load test  66 (2%)  66 (1%)  264 (2%)  198 (2%)  - 
 Routine lab test  2,547 (76%)  222 (2%)  293 (3%)  317 (4%)  63 (1%) 
 Total costs  3,335  11,340  10,849  8,730  5,590 
 Average costs per 
client (CI, 95%)        
 159  
(144-173) 
 515  
(501-530) 
 493  
(479-508) 
 485  
(470-500) 
 430  
(415-445) 
150-200 Number of clients  17  17  14  14  11 
 Hospitalization  190 (7%)  57 (1%)  -  -  - 
 Outpatient visits  304 (11%)  1,133 (14%)  982 (15%)  935 (14%)  654 (14%) 
 OI treatment  -  66 (1%)  3 (0.05%)  5 (0.1%)  -  
 ARV drugs  -  6,188 (77%)  4,865 (76%)  5,162 (77%)  3,717 (82%) 
 CD 4 test  343 (12%)  119 (1%)  119 (2%)  145 (2%)  92 (2%) 
 Viral load test  66 (2%)  264 (3%)  264 (4%)  66 (1%)  - 
 Routine lab test  1,969 (69%)  200 (2%)  195 (3%)  362 (5%)  63 (1%) 
 Total costs  2,872  8,028  6,428  6,676  4,526 
 Average costs per 
client (CI, 95%)          
 169  
(136-202) 
 472  
(440-505) 
 459  
(427-492) 
 477  
(444-509) 
 411  
(379-444) 
^except for number of clients 
*Confidence interval (CI), **Total Cost (TC) 
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Table 3. Health care costs of patients on ART, per specified period (US$^) (cont'd) 
CD4 cell 
count at the 
start of ART 
Item 
     Period     
 
Before ART   
(% of TC**) 
 
1 - 6 months           
(% of TC) 
 
7 - 12 
months         
(% of TC) 
 
13 - 18 
months         
(% of TC) 
 
19 - 24 
months         
(% of TC) 
>200 Number of clients  10  10  10  7  4 
 Hospitalization  -  -  -  -  - 
 Outpatient visits  199 (13%)  701 (15%)  608 (13%)  363 (12%)  257 (20%) 
 OI treatment  -  1 (0.02%)  -  -  - 
 ARV drugs  -  3,637 (79%)  3,797 (83%)  2,715 (84%)  938 (73%) 
 CD 4 test  224 (15%)  66 (1%)  79 (2%)  53 (2%)  53 (4%) 
 Viral load test  -  -  -  -  - 
 Routine lab test  1,119 (73%)  223 (5%)  92 (2%)  68 (2%)  35 (3%) 
 Total costs  1,542  4,628  4,576  3,221  1,283 
 Average costs per 
client (CI*, 95%)         
 154  
(114-195) 
 463  
(422-503) 
 458  
(417-498) 
 460  
(420-501) 
 321  
(280-361) 
^except for number of clients 
*Confidence interval (CI), **Total Cost (TC) 
 
Table 3 details the costs associated with providing ART. Before ART initiation, 
costs were mainly dominated by laboratory tests (including the CD4, viral load, and 
routine laboratory tests). After the initiation of ART, costs were dominated by 
ARV, regardless of patients’ CD4 levels. Both total costs and per patient average 
costs decreased over time after ART initiation. The one anomaly was the OI 
drugs/treatment cost for patients with a CD4 level of 50100 cells/mm3, which 
increased from US$725 in 1-6 months to 2,099 in 7-12 months. A relatively high 
CD4 cell count at treatment initiation relates to relatively low costs of ARVs, 
laboratory tests, and OI drugs/treatment. Figure 1 shows the average costs per 
patient for different CD4 cell count levels and over time. The highest total costs for 
24 months of ART per patient were for patients with a CD4 cell count <50 
cells/mm3. The distribution of cost for patients with CD 4 cell count under 150 
cells/mm3 is provided in the Appendix (Figure A). 
 
Non-health care costs per visit 
Table 4 presents non-health care costs. The average patient’s non-health care costs 
per visit are US$10 and US$11, for patients with CD4 cell counts below and above 
200 cells/mm3, respectively. Transportation cost and the clinic fee dominated the 
costs, while productivity loss accounted for less than 25% of the total cost per visit. 
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Per visit, almost all patients spent US$2 for the registration fee and US$5  US$6 
for transportation. The mean time to reach the clinic was approximately 1 hour 
(most patients lived < 20 km away) and the average time spent in the clinic was 
approximately 100 min. There were no major differences in non-health care costs 
between patients with CD4 cell counts less than or greater than 200 cells/mm3 (we 
did not perform significance test for this due to our small sample size) 
 
Figure 1. Average service costs per client per specified period, health care system 
perspective (US$) 
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Table 4. Patient costs of accessing ART (patient’s perspective) (US$) 
 
  
 
CD4 level at 
the start of 
ART 
 Average per visit access costs  Estimated 
monthly average 
household 
income 
 Average 
transportation 
cost 
 Average 
estimated 
productivity 
loss 
 Average 
fee for 
clinic 
 Average per 
visit total 
costs 
 
0 – 200 (n=17)  6 (0-12)*  1 (0.5-2)*  2.4 (2-3)*   10 (3 – 16)*  71 (42 – 101)* 
>200 (n=23)  5 (2-7)*  3 (2-5)*  2   11 (4 – 18)*  147 (72 – 221)* 
*confidence interval, 95% 
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Discussion 
To our knowledge, this study is the first in Indonesia and among the few in Asia 
[22,23] to estimate the cost of providing ART. The overall cost profile shows that 
the total costs and average costs per client are reduced when patients’ CD4 levels 
are higher at the time of clinic enrollment and ART initiation. In most instances, 
hospitalization, OI treatment, and ART average costs per patient decrease with 
longer use of ART. During the early phase of the treatment, the highest costs are 
the costs of hospitalization, OI treatment, and ART initiation; these costs decrease 
over time as a result of patients’ improved health. This trend is comparable with 
the results of a study conducted in Southern Africa [24]. 
 
These findings lead to several observations in response to the research questions. 
Regarding the cost of treatment and potential efficiency gain, the study confirms 
the hypothesis that the following measures have potential to improve efficiency in 
ART delivery:  
 Early ART initiation. Most cost items are lower when patients’ CD4 cell 
counts are higher at ART initiation and especially the total cost share of 
hospitalization and OI treatment was reduced. CD4 cell counts can predict 
the likelihood of OIs; patients with CD4 cell counts >200 cells/mm3appear 
to be at lower risk for the majority of OIs, compared with patients with 
<200 cells/mm3  [25–28] and this explains our study results. Additionally, 
early treatment also reduces (1-year) mortality in Indonesia and its cost-
effectiveness in resource-limited settings as well as its impact on the global 
epidemic have been proven [4,29,30] 
 Alternative diagnostics. Before ART initiation, costs are dominated by 
laboratory tests (CD4, viral load, and routine laboratory tests) followed by 
outpatient visits and hospitalization. After ART initiation, costs were 
dominated by ARV drugs followed by laboratory tests. Although efficiency 
gains in hospitalization and ARV use might be difficult, gains are possible 
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for laboratory test costs, as is found in the DART trial in four African 
countries [31], which showed that ART can be delivered safely without 
routine laboratory monitoring for toxicity. A recent study within the same 
hospital clinic with our study demonstrated that the total lymphocyte count 
(TLC) is a good alternative for CD4 testing as it is much cheaper and easier 
to implement in rural settings. Combining TLC test results with an algorithm 
of simple patient characteristics could save US$14 per patient compared with 
the current scenario [8]. Also, De Jong et al. [9] in Indonesia (study 
conducted at the same clinic as our study) and Kumarasamy et al. [32] in 
India found that TLC may reduce the need for routine CD4 measurements 
during ART (excepting the first year of treatment). In Indonesia, another 
method to reduce laboratory costs is proposed by Indrati et al. [10], who 
found that a dual-test or single rapid-test algorithm (instead of a serial three-
test algorithm) may be just as accurate and more cost-effective, although the 
single rapid-test should be interpreted carefully. Although these alternative 
laboratory testing methods may lead to efficiency gains, additional study is 
needed to determine the cost savings. 
 
Regarding our second research question about scaling up ART, the study indicates 
that although increased ART coverage may cause a large increase in health 
expenditure in the short run [23,33], it could also save costs in the long run. By 
reaching more people in need of ART, assuming that these are detected at earlier 
stages, costs related to opportunistic infections and hospitalization may be avoided 
as has been shown in our study. Importantly, providing ART can also act as 
HIV/AIDS prevention [34,35] because ART treatment reduces transmission rates. 
Universal voluntary HIV testing and early ART could therefore have a major effect 
on the HIV/AIDS epidemic and could be cost saving [4,36]. The costs of 
treatment of new HIV infections will be averted and may potentially free resources 
to prevent even more infections [11]. Considering these findings, we suggest 
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further study regarding advantages (e.g., health benefits of early treatment) and 
disadvantages (e.g., budget impact) of scaling up ART in Indonesia from both the 
short run and long run perspective. 
 
In terms of the location for scaling up ART, we cannot draw strong conclusions on 
the basis of the costing analysis in the hospital only. Yet, there seem advantages in 
scaling up ART at the community level as this may potentially increase early 
detection and reduce the burden in hospital clinics [37]. Also, the shorter waiting 
and travel time to the clinic may lead to lower patient’s costs and better uptake and 
adherence of ART [13–15,37]. In this scenario, the hospital and community health 
centres will have different roles (Table 5). The hospital will be a referral centre for 
complicated AIDS cases and treatment of OIs just as current practice [37,38]. 
Because patients become relatively stable over time (indicated by decrease in 
hospitalization and OI treatment over time) they could continue ART at 
community clinics, reducing the hospital burden. Patients that initiate ART at >200 
cell/mm3 could also obtain ART at the community health care center, as our 
analysis suggests that hospitalization and OIs are rare in this population. In 
addition, patients mostly utilize first line ARV, and no patients with CD4 cell 
counts >100 cells/mm3 switch to second line ARV (Table 2), indicating a low rate 
of treatment failure within this group [39]As such, the ARV distribution (in terms 
of medicine type) in community/primary health care centres for patients with CD4 
cell counts >100 cells/mm3 might not be too complex, as most patients are likely 
to require only first line ARV. Currently, there are only two primary health care 
centers in Bandung that provide ART, which presents considerable potential to 
increase the service to other community clinics.  
 
However, providing ART at all community health clinics in Indonesia at this stage 
seems inefficient due to the low HIV prevalence in the general population which 
will result in a low patient load per clinic for which all community staff will require 
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training [40]. Therefore, providing HIV services through clinics in certain high 
prevalence settings such as prisons or cities may be preferable [41,42], although this 
strategy requires further study.  
 
However, providing ART at all community health clinics in Indonesia at this stage 
seems inefficient due to the low HIV prevalence in the general population which 
will result in a low patient load per clinic for which all community staff will require 
training [40]. Therefore, providing HIV services through clinics in certain high 
prevalence settings such as prisons or cities may be preferable [41,42], although this 
strategy requires further study.  
Regarding our third research question about patients’ financial burden, the study 
shows that patient’s non-health care costs per visit are US$10 and US$11, for 
patients with CD4 cell counts below and above 200 cells/mm3. This relates to 
approximately 14% and 7% of their monthly income, respectively. Especially for 
patients with CD4 cell counts <200 cells/mm3 these costs could be a barrier, as it 
exceeds 10% of their monthly income and can be considered to be catastrophic for 
a household economy [43]. 
Table 5. Recommendation on role of clinics in delivering ART†  
Costs items 
 Type of clinic  
 Hospital  Community/Primary Health care 
centre 
Hospitalization  +  - 
Outpatient visits  +/-  + 
OI treatment   +*  + 
ARV drugs  +/-  + 
CD 4 test  +  - 
Viral load test  +**  - 
Routine lab test  +  +/- 
†  '+' and '-' denote respectively a role of high and low importance for the clinic in the specified activities in 
HIV/AIDS control. ART = antiretroviral treatment   
*for severe cases 
**if necessary 
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Transportation comprises the highest proportion of costs: 62% and 43% for 
patients with CD4 cell counts below and above <200 cells/mm3, respectively, and 
this is comparable with the finding of Riyarto et al. [16] in Indonesia. A study by 
Haroen et al. [15] in Bandung, Indonesia, and international studies by Portelli et al. 
[13], Brinkhof et al. [14], and Posse et al. [12] have shown that transportation costs 
are a common reason why patients cease ARV. This information provides another 
reason to scale up ART at community level, as it likely reduces transportation costs 
for clients and may increase the uptake of ART, especially of patients with CD4 cell 
counts <200 cells/mm3. 
 
Study limitations 
Our results should be interpreted with some caution. First, this study has evaluated 
a contextualized ART service delivery model, which may hamper the 
generalizability of its results. Cost structures and levels as well as patient 
populations are likely to vary between clinics, and specific costing studies for other 
settings (e.g., other hospitals, community/primary health centers, and prisons) 
should be considered. Regardless, we believe that our approach is of relevance also 
to other resource-limited settings. Second, we may have overestimated the total 
patient costs of seeking and undergoing care as this was based on assumptions 
regarding patients’ labour productivity losses, and not on empirical data collection 
on these losses per se. Third, although we have conducted a time motion study to 
control for inefficiency in ART delivery in the clinic (e.g., related to personnel and 
equipment), discrepancies may still exist, and we may have over- or undervalued 
the total costs. Fourth, we did not perform any comparison between WHO 
CHOICE estimates (that we used for calculating inpatient cost) and any local data. 
Although this is an important aspect, currently there is very limited local data 
available to do this comparison.  
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Conclusion 
Three main conclusions can be derived from our study. First, we show that the 
costs of providing ART are highest during the early phase of treatment, and will 
decrease and stabilize as treatment progresses. Second, our findings suggest that 
efficiency gains can be realized by early treatment initiation (which may reduce 
hospitalization, OI drug/treatment costs, and patient mortality) and by applying 
alternative laboratory tests. Third, scaling up ART at the community level has 
potential to save costs and improve uptake and adherence. However, provision of 
ART at all community clinics seems inefficient due to the low prevalence in the 
general population and options to select certain clinics in high prevalence areas 
need further investigation.  
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APPENDIX 
Table A. Yearly Cost of ART outpatient  service  
Type of Cost  US$ (2010)  % 
1. CAPITAL COST (Annualized)     
1.1 Personnel (trainings & workshops)  111.37  0.5 
1.2 Building/Space  477.24  2.0 
1.3 Equipments  510.72  2.1 
Subtotal  1,099.33   
2. RECURRENT COST     
2.1 Personnel (number)  21,123.40  91.7 
Medical doctor (4)  6,701.66   
Nurse (2)  5.370.67   
Laboratory (1)  1,196.22   
Administration and cleaning service (6)  15,178.81   
2.2 Supplies  895.13  3.7 
Subtotal  23,018.54   
T o t a l  24,117.86   
Unit cost per visit  11.69   
 
Table B.  Average unit costs of OI treatment (US$) 
CD 4 cell count at 
the beginning of 
ART 
 Period 
 Before ART 
(CI*) 
1 - 6 
months (CI) 
7 - 12 
months (CI) 
13 - 18 
months (CI) 
19 - 24 
months (CI) 
0-50  1 (0-2) 113  
(48-179) 
23 (3-42) 7 (0-16) 25 (0-60) 
50-100  0.4 (0-1) 22 (1-43) 64 (0-170) 0.4 (0-1) 0.3 (0-1) 
100-150  - 37 (0-94) 3 (0.1 – 7) 2 (0-3) 0.2 (0-0.4) 
150-200  - 4 (0-9) 0.2 (0-1) 0.4 (0-1) - 
>200  - 0.1 (0-0.3) - - - 
*Confidence interval (CI) 
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Table C.  Unit Costs per Cost Item (US$) 
Costs Item  Unit Cost  Source 
Inpatient day  19.2  WHO CHOICE 
Outpatient visit  11.6  Own calculation 
Average unit costs of ARV drugs (min-
max) 
    
First line  28 (7-79)  Kimia Farma 
Second line  90 (56-117)  Kimia Farma and Bender et al. [20]  
CD 4 test  13.2  Hospital Decree 
Viral load test  66  Hospital Decree 
Average unit costs of laboratory tests 
(confidence interval) 
 6 (4-8)  Hospital Decree 
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Figure A. HIV treatment total costs per patient, over 24 months 
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CHAPTER 7  
General discussion 
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This thesis has presented a number of economic analyses exploring the costs, 
effects, efficiency, and scale up of HIV/AIDS control in Indonesia. This last 
chapter addresses the main research question: “What are the costs and effects of 
various strategies for HIV/AIDS control in Indonesia?” and the research questions 
presented in Chapter I. In doing so, this chapter reports on the general implications 
of our studies for HIV/AIDS policy in Indonesia, presents the limitations of the 
thesis, and discusses the value of the integrated IMPACT (Integrated Management 
for Prevention and Control and Treatment of HIV/AIDS) program approach, on 
which this thesis is built on.         
 
Table  1 presents a summary of our study results [1–6]. For the sake of comparison, 
the table also includes results from other Asian studies originating from the 
“HIV/AIDS unit cost database” of the Futures Institutes [7] and the international 
literature [8–16]. All results are reported in U.S. dollars (USD) for the year 2011, 
and reflect costs from the health care system perspective.  
 
What are the costs and effects of providing hospital-based methadone 
maintenance therapy (MMT)? (Chapters 2 and 3) 
Our study showed that the total cost of MMT per client visit is $7.50, of which 
65% is covered by the patients and the rest is covered by the central government 
and hospital. The total costs of accessing MMT constituted almost 70% of a 
patient’s income, an important barrier to utilization. We concluded that the present 
government subsidy (40% of the clinical fee) or even higher subsidies seem justified 
as MMT is a well-known and proven strategy to prevent HIV transmission among 
IDUs and creates positive externalities by preventing the further spread of 
HIV/AIDS through contaminated needle sharing. 
 
Scaling up MMT from 5% coverage now to 40% coverage in 2019 could avert 
2,438 HIV infections at a cost of approximately $7,000 per HIV infection averted 
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or around $269 per DALY. Based on WHO criteria [17], this can be considered 
cost-effective as it is less than Indonesia’s one-time GDP per capita, which was 
$3,495 in 2011 (using 2012 U.S. dollars) [18]. 
 
Our estimated annual costs of MMT, $347 per client, are higher than reported for 
Vietnam ($261) and for China ($182) (Table 1) [7]; probably because of the higher 
client load in those two studies [11,14]. Scaling up MMT was also found to be cost 
effective in Vietnam (costing $1,964 per QALY saved or $3,224 per HIV infection 
averted [12]) and in China (costing $2,509-4,609 per HIV infection averted) [19–
21]. This means that MMT seems to not only be an economically attractive 
intervention in Indonesia, but also in other Asian countries as well.  
What are the costs and effects of providing hospital-based methadone maintenance therapy (MMT)? 
Key messages: 
1. A high proportion of the cost of providing MMT from the societal perspective are covered by 
the patients. This may limit access to this intervention for substantial numbers of patients; 
2. Further government subsidy to make MMT widely available and more easily affordable is 
urgently needed as injecting drug use is still an important factor in the HIV epidemic in 
Indonesia; 
3. Scaling up MMT is cost effective. 
 
  
 
Table 1. Comparison of several HIV intervention unit costs per patient in Asia, health care system perspective (2011 US$ exchange rate) 
    Country 
Intervention  Setting  Indonesia  India  Thailand  Vietnam  China 
             
Cost analysis             
MMT 
(annual cost per patient) 
 Hospital clinic  347* ^^      261^  182 
VCT  
(cost per patient served) 
 Hospital  76**  3.6    39   
  HIV community clinic  41**      43   
  STI community clinic  59**  2.1^       
  Prison clinic  25**         
ART/HIV care 
(annual cost per patient) 
 Hospital  1,273***  270^  4,752^     
  HIV community clinic  1,482  434^       
             
Cost-effectiveness analysis (incremental ratios) 
 
MMT  Hospital clinic  $269/DALY  
or $7,000/ 
infection averted 
     $1,964/QALY  
or  
$3,224/ 
infection averted  
 $2,509 - 4,609/  
infection averted 
VCT  HIV community clinic  $9.17/DALY or  
$248/ infection 
averted 
        
* unit cost per MMT patient; ** excluding patient non-health care costs; ***unit cost based on patients across all CD4 cell counts at the first year of treatment per patient; ^ 
financial cost; ^^ $2.74 per visit 
Sources: [1–16] 
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What are the costs and effects of various voluntary counseling and testing 
(VCT) models? (Chapters 4 and 5) 
We estimated that the unit cost per VCT performed was highest in the hospital 
clinic ($74), followed by the STI community clinic ($65), the HIV community clinic 
($39), and the prison ($23). The hospital clinic diagnosed the highest number of 
HIV infections, but with the lowest average CD4 cell count and with the highest 
associated non-healthcare cost. The prison clinic detected fewer cases, but at an 
earlier stage, and all patients subsequently enrolled in HIV care. The community 
clinics detected the smallest number of cases but also at an earlier stage, although 
only 0-8% enrolled in HIV care.  
 
It seems most appropriate for the hospital clinic to be a referral center for 
treatment of late and/or complicated cases, and for treatment of opportunistic 
infections. VCT services may best be scaled up in community-based clinics for the 
broader population, to improve uptake and hence early detection of HIV/AIDS, 
taking into account the general barriers to VCT such as travel costs, lack of 
confidentiality of test results, and perceived lack of benefit of HIV testing [22]. 
These clinics may also initiate treatment of early/uncomplicated cases. However, a 
system should be developed to support community clinics in providing enrollment 
in care and referring patients with late cases and opportunistic infections to the 
hospital. The prison clinic has the lowest unit costs and can identify people living 
with HIV/AIDS (PLHIV) at earlier stage, but scaling up VCT to other prisons 
warrants further research. Also, there may be other settings which may also be 
appropriate in delivering VCT, but these are not covered in our analysis. 
 
Scaling up community-based VCT to 80% of the most-at-risk populations in West 
Java, as in the national strategy [23], could reduce the overall population prevalence 
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by 36% by 2030 and costs $248 per HIV infection averted or $9.17 per DALY 
saved. This amount per DALY is very cost effective, based on WHO criteria [17].  
 
However, scaling up community-based VCT will cost between $1.3 million in 2010 
and $3.8 million in 2030, respectively, and require the number of VCT clinics 
integrated at public community health centers from 73 in 2010 to 594 by 2030. 
Using HIV expenditure data from UNGASS [20], we calculate that the estimated 
amount of $1.3 million in 2010 was seven times higher than the total VCT 
expenditure in 2010, and around 15 times higher than the domestic VCT 
expenditure in the same year. Although VCT is cost effective, massively scaling up 
the service using our proposed scenario might not seem currently feasible given the 
large resource needs and the limited and internationally dominated national 
HIV/AIDS expenditure [20]. Special attention must be given to this if the 
government is planning to scale up VCT, as it is one of the key components in the 
national strategy [24].  
 
Table 1 shows that our estimated unit cost of VCT in the STI community clinic is 
comparable with the result from Vietnam, although our unit cost in the hospital 
setting is almost twice that of Vietnam [7,13].  Two factors may explain this: first, 
the number of patients served in the hospital clinic in Vietnam is higher than in 
Indonesia (although more PLHIV were detected in Indonesia, roughly 50% of 
those tested), and, second, the personnel cost component is higher in Indonesia. 
Therefore, we suspect that the number of personnel in hospital-based VCT clinics 
in Indonesia is much higher (the number of staff is not presented in both studies) 
[2,13]. Further study should analyze the ideal, efficient number of staff employed in 
the Indonesian hospital-based clinic.   
 
The VCT unit costs in India in both hospital and community clinics, however, are 
much lower. The number of patients undertaking VCT in hospital clinics in India 
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differs significantly from the annual number of patients in our study: around 2,898–
7,453 patients in each clinic in the years 2005-2006 [8]. This shows that a greater 
number of patients reduces the unit cost of VCT, and economic of scale is 
possible.  
 
 
 
 
 
 
 
 
 
 
 
 
What are the costs of providing antiretroviral treatment (ART)? (Chapter 6) 
Our study showed that treatment costs before the initiation of ART are dominated 
by laboratory tests, and after initiation by ARV drugs. The highest costs in the early 
phase of the treatment are due to the costs of hospitalization, OI treatment, and 
the onset of ART. These costs decrease over time due to the improvement of the 
patient’s health. 
 
Potential cost reduction can be achieved in two ways: by altering the current 
laboratory tests algorithm [25–29], and by providing early treatment. A relatively 
high CD4 cell count at treatment initiation relates to relatively low costs of ARV, 
laboratory tests, and OI drugs/treatment, showing the benefit of early treatment 
(this is comparable to the situation in Southern Africa [30]). In fact, early ART 
treatment has been proven to be cost effective in other countries [31,32], and can 
What are the costs and effects of various voluntary counseling and testing (VCT) models?  
Key messages: 
1. Testing in hospital only reaches the very advanced cases and will as such have a limited role in 
early detection and treatment 
2. Testing is more patient-friendly and cheaper in community clinics, but enrollment in HIV-care 
and ART for those tested positive in the community is extremely low. A system should be 
developed to support community clinics in providing HIV care and referring patients to the 
hospital; 
3. Prison is an extremely effective place for testing and treatment in the Indonesian setting where 
injecting drug use plays such an important role;  
4. Scaling up VCT at the community clinic to 80% of the most-at-risk populations in West Java 
would be highly cost effective, although the need to significantly increase the number of 
community-based clinics and the budget impact must be taken into consideration.. 
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reduce (one year) mortality [33]. However, as ART prolongs survival, the potential 
increase in the number of patients requiring life-long treatment should be taken 
into account [10,24]. 
 
Patients with CD4 cell count less than 200 cells/mm3 spent more than 10% of their 
monthly income to access ART (mostly for transportation costs), which potentially 
is a burden [34]. As such, the relatively low travel and waiting time associated with 
community clinics [2] indicates that scaling up ART at this level is preferable as it 
can reduce a patient’s transportation costs, increase adherence, and reduce barriers 
to accessing ART [35–38]. 
  
Other studies show that our estimated treatment costs are 3-4 times higher than 
those observed in Indian hospital and community clinics. The main reason is the 
much lower ARV drug costs in India: $72/visit1 in our study compared to $13 
(hospital) and $32 (community clinic) per visit in India [15,16]. More than 50% of 
ART patients in the hospital clinics in India used the combination of stavudine, 
lamivudine, and nevirapine, while 64% of the ART patients in the community clinic 
in India used the combination of zidovudine or stavudine plus lamivudine regimen 
[15,16]. We calculated the costs of this ARV drug combination using Indonesian 
prices and estimated it at around $55 and $44 per visit (instead of $13 and $32 per 
visit), respectively. Therefore, we suggest that further studies should examine the 
effectiveness of the cheaper ARV drugs in India and India's strategy to keep the 
ARV drug cost down. Our estimated treatment costs are much lower than those 
observed in Thailand, where costs are $280 per visit [10]. This difference might also 
be explained by differences in the type of drugs used. 
 
 
 
                                                          
1For patients with CD cell count below 50cells/mm3. 
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What are the implications of the findings for the policy on HIV/AIDS in 
Indonesia? 
Our findings have shown that all evaluated interventions are economically 
attractive. The cost effectiveness analysis of MMT and VCT has shown that both 
interventions are very cost effective, as their costs per DALY are below the 
international threshold of one-time GDP per capita [17]. However, our findings 
suggest that scaling up VCT is much more cost effective than scaling up MMT 
($9/DALY averted as opposed to $269/DALY averted).  
 
This raises the question to what extent MMT should still be considered a top-
priority. The face of the HIV/AIDS epidemic in Indonesia is changing - while the 
epidemic started among injecting drug users (IDU), it is now shifting towards the 
general population. The percentage of HIV transmission through IDU decreased 
from 53% in 2001-2005 to 34% in 2011, while through heterosexual transmission 
increased from 37% to71% [20]. It has also been found that former IDUs still have 
high HIV prevalence rates and high-risk sexual behavior, therefore contributing to 
What are the costs of providing antiretroviral treatment (ART)?  
Key messages: 
1. The costs of ART stabilize over the course of treatment and a higher CD4 cell count is 
associated with lower costs of treatment (e.g. lower OI and hospitalization costs); 
2. Alternative laboratory tests, early treatment, and providing alternative delivery models with 
involvement of community health services or less frequent hospital visits can create efficiency 
gains; 
3. Transportation costs dominate the patient cost to access ART and, for patients with lower 
CD4 cell count, access costs are more than 10% of income and potentially cause financial 
burden; 
4. Scaling up ART at the community level is best as it lowers waiting and travel time, lowers 
transportation costs, and may increase adherence and reduce barriers to access; 
5. Different ARV drug costs between countries has resulted in a striking difference in HIV 
treatment costs. Further studies should explore the appropriate and efficient price for ARV 
drugs, and the effectiveness of different (cheaper) ARV drugs. 
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the severity of the sexual HIV transmission [39]. Our modeling work in Chapter 3 
also suggests that the proportion of cases caused by IDUs is expected to decrease 
and to be replaced by infections caused by heterosexual transmission. MMT would 
only slightly reduce incidence (2.5% in our analysis) [5]. However, the HIV 
prevalence in IDUs over time is still high [20]. Therefore, IDUs are still an 
important key population (especially given their needle sharing and unsafe sexual 
behavior) and programs targeting this group, such as MMT, are still required. 
Putting a full stop to MMT will certainly result in an increase in HIV infection and 
boost the further development of the epidemic. Furthermore, getting the HIV(+) 
MMT patients to enroll in ART is also important. In fact, a study by Achmad, et al 
[40], conducted at the same hospital as in our study, has shown that MMT can also 
serve as an entry point for IDUs who are in need of ART (and other medical care). 
The MMT clinic in our study is closely linked to the HIV clinic within the same 
hospital. As such, HIV(+) MMT patients in need of ART are automatically 
admitted to ART, increasing their survival rate and reducing their chance of 
infecting others [40,41]. In addition, MMT is also known for its positive side effect 
of increasing the productivity and quality of life of its patients [40]. These points 
further emphasize the importance of MMT.  
 
Our cost effectiveness results suggest that the government should allocate more 
budget to the VCT program and scale up services. Indeed, scaling up VCT is an 
important component of the national response [20,24].  VCT has the potential to 
target a broad population and have a significant impact on the epidemic. Moreover, 
normalization of HIV testing (e.g., generalized HIV testing for pregnant women 
and TB patients) may further reduce new infections [42–44]. 
 
In the case of ART, it is an intervention acting as both prevention and treatment 
[45,46]: it has the benefit of reducing the transmission of HIV, like both MMT and 
VCT, and it is currently the only intervention which is able to treat the disease. 
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Although this thesis has not addressed its cost effectiveness, results from other 
studies show it is clearly cost effective and can even reduce costs in the longer run 
[31,47–49]. It can therefore be considered an absolute priority. The question on 
ART is merely on how to make the current ART delivery widely available and more 
efficient. Our findings suggest that there are several alternatives to gain efficiency, 
such as providing early treatment (higher CD4 cell count) and using alternative 
laboratory tests [3]. Reducing the number of visits of an already stable patient can 
also reduce the costs of treatment (i.e. reduce resources used) and patient costs (i.e. 
transportation and registration costs). 
 
In addition, Wisaksana et al. [50] have reported that the lost-to-follow-up rate at the 
hospital clinic is quite high (12% within first six months of treatment in 2008). 
Therefore, we strongly recommend that supporting programs such as partner 
notification and adherence counseling be thoroughly applied to ensure a high rate 
of adherence and treatment success.   
 
Moving to the community  
Early detection is important to allow early HIV treatment. Both the cost and cost 
effectiveness analyses of VCT have shown that providing VCT at the community 
level is economically attractive and supports early detection [2,6]. Providing 
universal voluntary HIV testing and early ART (with high adherence) is estimated 
to have a major effect on the HIV/AIDS epidemic and could save costs and 
increase early detection and treatment, although the exact impact varies depending 
on the methods [2,32,51–53]. It can avert the costs of treatment of new HIV 
infections and may potentially free resources to prevent more infections [54]. 
 
Furthermore, it also reduces the burden to the hospital and decreases waiting and 
travel time, which may lead to lower patient costs and better uptake and adherence 
of ART [2,35,36,38]. However, we also found that patients who are tested positive 
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at the community-based clinics rarely went to the hospital for follow up treatment. 
We strongly emphasize that a strong link between VCT and ART is needed to 
ensure the success of HIV care scale up, in line with a study by Srikantiah et al. [55]. 
Anecdotal evidence from the Integrated Management for Prevention and Control 
and Treatment of HIV/AIDS (IMPACT) program in Bandung, West Java suggests 
that developing such link is not without challenges. Presently, only the most 
adherent and stable patients are selected from a hospital clinic to receive ART at 
the community clinic and the progress is relatively slow. Yet, such a referral system 
in Bandung, although is still at its infancy, shows the opportunities for ART 
treatment at the community clinic [4].     
 
Currently, the Indonesian Ministry of Health has started a program called "Layanan 
Komprehensif Berkelanjutan" (comprehensive and continuous service), or LKB, in 
non-Papua regions (it had already been started in the Papua region). In LKB, one 
hospital is designated as a main referral hospital providing HIV/AIDS services 
supported by five community-based clinics acting as satellites [56]. This is in line 
with our findings that a main referral hospital should treat only severe cases 
whereas community-based clinics should treat less severe cases, while keeping a 
strong link between the two entities [2].  
 
Selection of the community clinic, however, should be based on several factors 
such as the location of the community clinic (i.e. in a high-prevalence area) and the 
demand for HIV service in the surrounding area. The community clinic’s efficiency 
in providing HIV services strongly depends on the number of patients: providing 
HIV services to only a few patients will result in an expensive cost of service per 
patient [4].  
 
We have observed two very distinct types of community clinics providing VCT, the 
community HIV and STI clinics. It is clear that the STI clinic has the advantage 
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over the HIV clinic in terms of number of patients taking VCT (784 patients at the 
STI clinic in 2008 compared to 28 patients at the HIV clinic in 2009, which only 
increased to 53 patients in 2011), although both perform early testing. We suspect 
this was due to the strategic location of the STI clinics very close to areas where 
both direct and indirect sex workers reside. The clinics also actively reach out to 
patients, allowing the possibility of approaching other high risk groups with 
relatively similar kinds of transmission (e.g. transgender and male having sex with 
male) [2]. Another type of clinic which has also been proven to be very efficient in 
providing HIV service is the prison clinic. The cost per patient of providing VCT 
in this type of clinic is the lowest compared to the other type of clinics in our study, 
while at the same time all prisoners in need of ART are enrolled in the treatment 
[2]. This shows that prison clinics is an excellent entry point for accessing ART 
[57]. 
 
Furthermore, the community HIV clinic studied is currently one of the satellites of 
the hospital clinic, delivering (first line) ART to four patients. A study in West Java 
has shown that this costs more than the hospital clinic ($1,482 per patient per year, 
using the fixed dose combination of ARV drugs). This unit cost, however, can be 
reduced by at least 20% by increasing the number of patients to more than 50 [4]. 
It is clear that capacity utilization is key. One study in Indonesia showed that it is 
indeed possible to increase capacity utilization - an HIV community clinic in Bali is 
able to serve ART to 24 patients (although the dropout rate is still an issue) [58], six 
times more than the number of ART patients in the HIV community clinic in our 
study. As an alternative, linking HIV services with traditional/faith-based treatment 
and behavior change programs can also increase capacity utilization [59,60]. 
Furthermore, utilizing nurses in providing HIV care in the community clinic may 
also increase treatment capacity and efficiency in resource use without 
compromising patient outcomes [61]. 
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Study limitations and future research 
The studies in this thesis have a number of limitations, and future studies should 
address these. Firstly, our study and policy recommendations focused mainly on 
economic analysis, neglecting other important factors such as cultural and religious 
acceptability and political interest, significant factors in Indonesia. We suggest that 
our results and recommendations should be accompanied by broader types of 
analyses that include these factors. This type of analyses can be in the form of 
Multi-Criteria Decision Analysis (MCDA), known for its potentially broader 
application in setting specific and generalized priorities in healthcare [62–64]. The 
process of MCDA is currently ongoing in Indonesia, used as the main tool to 
develop an HIV/AIDS strategic plan for West Java for the period 2014-2018, as 
the previous policy making process was considered insufficient to properly set 
priorities [65,66].  
 
Second, our scope of analysis is limited to Bandung or West Java and our analyses 
are done on some very contextualized services. This may hamper the 
What are the implications of the findings for the policy on HIV/AIDS in Indonesia?  
Key messages: 
1. Although MMT is less cost effective than VCT, MMT should still be implemented and scaled up 
given its importance in controlling HIV/AIDS epidemic in Indonesia; 
2. Scaling up HIV services at the community-based clinic is associated with early case finding, 
possibly leading to early treatment (and cost saving). It also reduces the hospital burden and 
patient access costs;  
3. When the capacity of the hospital to take care of HIV infected subjects is limited, scaling up of 
HIV services at community based clinic seems warranted. A strong referral and quality control 
system between the two should be established; 
4. Given the limited HIV domestic budget,  the budget implication of scaling up ART through the 
community should be carefully assessed.  
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generalizability of our results as the settings of West Java and other provinces in 
Indonesia may have a different context. For instance, community-based clinics are 
common in Papua, whereas in the non-Papua regions they remain a relatively new 
concept. This may be due to the different levels of the epidemic (2.4% in Papua 
compared to 0.27% in Indonesia excluding Papua [20]). However, the conceptual 
decision and methodological framework can be applied to other settings similar to 
West Java. Indeed, our approach can be useful in setting up or evaluating the 
programs by the Ministry of Health of Indonesia.  
 
Third, although our recommendations suggest to utilize community based clinics to 
provide HIV care, we realize that the local evidence supporting this is still limited. 
It is still unknown whether providing HIV care in the community is indeed cost 
effective as we are still lacking the evidence.  Future studies should evaluate 
whether providing HIV care at the community level is indeed favorable. A possible 
approach is to conduct a social experiment through randomization [67]. For 
instance, community clinics in a certain region can be randomly assigned to deliver 
HIV service, while others do not. By observing the two scenarios for a period of 
time (and controlling for other factors), we should be able to measure the cost 
effectiveness of providing HIV care at the community clinics.  The results of these 
two scenarios can then be a proof whether it is beneficial to provide HIV care at 
the community or not. This, however, require a significant amount of effort and 
resources. For example, an exceptionally careful method and framework must be 
developed as to not let other factors interfere with the conclusion of such studies. 
Regardless, it is an interesting approach to consider. 
 
Fourth, the epidemiological modelling in this thesis relied heavily on one model, 
the AEM. Upon closer inspection and based on our discussion with the National 
AIDS Commission of Indonesia (which use the model frequently for HIV/AIDS 
epidemic projection), it was found that AEM has its issues and limitations. For one, 
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the model required significant amount of data which is currently limitedly available 
in Indonesia. As such, in the case of missing data, the model relied on the default 
numbers which are derived from Thailand. Hence, the result of the model should 
be interpreted cautiously and extensive sensitivity analysis was needed. As such, 
further research on modelling the HIV/AIDS epidemic is urgently needed in 
Indonesia and this will then serve as a part of cost effectiveness analyses and 
provide more accurate results. This may provide more accurate HIV epidemic 
projections.    
 
Benefits of an integrated approach 
The work in this thesis is a part of a past program called Integrated Management 
for Prevention and Control and Treatment of HIV/AIDS (IMPACT), a five years 
collaboration (2007-2012) between Indonesian university (Universitas Padjadjaran) 
and three European universities (Radboud Universiteit Nijmegen, Maastricht 
University, and Universiteit Antwerpen), funded by the European Union (EU) 
(Sixth Framework Programme; Specific Targeted Research Project no.: 
318/10150A–EC SANTE/2005/105-033) and CORDAID contracted.  
 
This program (principle investigators Dr. B. Alisjahbana and Prof. Dr. A. van der 
Ven) utilized an integrated, comprehensive and multi-disciplinary approach 
comprising the following main activities: 1) integrating HIV-prevention and 
treatment, combining research and implementation; 2) utilizing biomedical, public 
health and sociobehavioral expertise for educational programs for adolescents; 3) 
scaling up HIV-testing, harm reduction strategies and care for HIV/AIDS in 
hospital, community and prison; 4) building the capacity of institutions and 
individuals in relation to IDU and HIV/AIDS [69,70]. This thesis is mainly based 
on the activities 1, 3, and 4. By the end of the program in late 2012, there are five 
working groups in this program, namely health promotion in school, 
comprehensive care in prison, addiction care, hospital care, and public health. In 
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the progression of this thesis, the work has benefited from and enriched by this 
integrated approach and collaboration between working groups.  
 
Data collection 
The data set used in this thesis is partly obtained from the work of other 
researchers/working group in the program. The collaboration with other disciplines 
and working groups has made possible for the studies in this thesis to obtain micro 
level data (costs, resources and patients related data) which are often considered as 
very sensitive information. The results of other studies within the IMPACT 
program has also been used throughout this thesis to support the findings. 
 
Studies interpretations 
The interpretations throughout this thesis has greatly benefited from the 
multidisciplinary approach. The collaborations with the colleagues from other 
disciplines has enriched the interpretation of the findings. These collaborations 
have expanded the analyses and discussions throughout this thesis to be beyond 
economic analysis, covering also the related public health and policy aspects.     
 
Academic and institutional partnership 
 The IMPACT program has created a network of academic and institutional 
partnership in which this thesis has derived certain advantages. The collaboration 
with other faculties in Universitas Padjadjaran, and with the three universities in 
Europe has improved the quality of this thesis. Furthermore, the program's 
partnership with other institutions such as government offices, NGOs and prison 
has given advantage for this thesis to obtain important (and sensitive) data. 
 
Research implication   
The integrated approach of IMPACT program has made it possible to produce 
policy recommendations which is of interest not only to economists, but also to 
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health care worker and policy makers in general at every level (government or grass 
root level). The policy implications of VCT studies in this thesis are currently 
implemented in four community clinics and one prison clinic in Bandung, West 
Java, as a part of IMPACT program activities. Providing community and prison 
based  HIV treatment is currently ongoing in two community based clinics and one 
prison clinic in Bandung, West Java, also as a part of IMPACT program activities. 
Although the community based clinics program is still at its infancy and face some 
issues, benefits are indeed felt by the patients [4]. Meanwhile, the HIV treatment in 
prison clinic has been more successful [57]. 
 
This thesis has greatly benefited from the IMPACT program. Although the 
program has ended in late 2011, the legacy left by the program such as network, 
academic and institutional partnerships, as well as institutional and individuals’ 
capacity improvement still perform significantly in the field of HIV/AIDS 
epidemic in Indonesia. In fact, the current HIV working group (formerly the 
IMPACT program) in Universitas Padjadjaran has expanded its work beyond the 
local institutions and work closely with both national and international entities. 
Owing much to the IMPACT program, HIV/AIDS  working group in Universitas 
Padjadjaran has now been considered as one of the strongest think-tank in the field 
of HIV/AIDS in Indonesia.  
 
Concluding remarks 
Our findings and recommendations support scaling up HIV services to the 
community to increase uptake as well as early detection and treatment, while at the 
same time increasing the effectiveness of HIV care by building a close network 
between community based clinics and hospitals [2,3,6,57]. We strongly suggest that 
moving HIV services to the community should be evidence based and carefully 
implemented given the potential budget implications [6,10,24,68]. We also suggest 
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that barriers to access HIV prevention and care programs (such as financial barrier) 
should be addressed [1–3] 
 
Furthermore, although the HIV/AIDS epidemic in Indonesia seems to change, 
IDUs are still a significant part of the epidemic [20]. Therefore, interventions such 
as MMT should still be prioritized, especially given its positive side effects [1,40]. 
These positive side effects are even further enhanced once MMT is linked with 
HIV care, increasing the survival rate of the patients [40,41]. 
 
In addition, as more heterosexual transmission occur, there is a need to test (and 
possibly treat) the low risk population (i.e. pregnant women, low risk 
men/women). Indeed the Hasan Sadikin hospital has announced that the hospital 
will soon test all pregnant women for HIV. This initiative has also been performed 
in another city in West Java.  
 
Finally, the integrated approach as implemented in the IMPACT program has 
provided many benefits, as illustrated in this thesis, and may set an example for 
future studies in this area.  
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The specific context of HIV/AIDS in Indonesia is characterized by an increasing 
overall prevalence led by high risk groups such as IDUs and sex workers, and a 
weak Indonesian health system. The low level of funding, mainly stemming from 
international sources, raises concerns on service coverage and their financial 
sustainability. In such a context, reliable, objective evidence on the costs and 
effectiveness of interventions to reduce the epidemic, is a key input into policy 
debates.  
 
Chapter 1 introduces the need for an effective and efficient use of resources 
through the broader application of economic analysis of HIV/AIDS control in 
Indonesia. The overall research question of this thesis is “what are the costs and 
effects of various strategies for HIV/AIDS control in Indonesia?”. Following this 
overall question, four research questions are identified and addressed in different 
chapters.   
 
What are the costs and effects of providing hospital-based methadone 
maintenance therapy (MMT)? (Chapter 2 and 3) 
Our study showed that the total cost of MMT per client visit is $7.50, of which 
65% is covered by the patients and the rest is covered by the central government 
and hospital. Patients spend almost 70% of their income to access MMT which 
may limit access to this intervention for substantial numbers of patients. The 
present government subsidy (40% of the clinical fee) or even higher is urgently 
needed to make MMT widely available and more easily affordable as injecting drug 
use is still an important factor in the HIV epidemic in Indonesia.  
 
Scaling up MMT from 5% coverage now to 40% coverage in 2019 could avert 
2,438 HIV infections at a cost of approximately $7,000 per HIV infection averted 
or around $269 per DALY. Based on WHO criteria [1], this can be considered 
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cost-effective as it is less than Indonesia’s one-time GDP per capita ($3,495 in 2011 
using 2012 U.S. dollars). 
 
What are the costs and effects of various voluntary counseling and testing 
(VCT) models? (Chapter 4 and 5) 
 Testing for HIV/AIDS in the hospital is relatively expensive (US$74 per test) and 
only reaches the very advanced cases and will as such have a limited role in early 
detection and treatment. Testing is more patient-friendly and cheaper in 
community clinics (US$39-65 per test), but enrollment in HIV-care and ART for 
those tested positive in the community is extremely low (only 0-8%). A system 
should be developed to support community clinics in providing HIV care and 
referring patients to the hospital. The prison clinic has the lowest unit costs 
(US$23) and it is an extremely effective place for testing and treatment in the 
Indonesian setting where injecting drug use plays such an important role.  
 
Scaling up VCT at the community clinic to 80% of the most-at-risk populations in 
West Java would be highly cost effective (US$248 per HIV infection averted or 
US$9.17 per DALY saved), although the need to significantly increase the number 
of community-based clinics and the budget impact must be taken into 
consideration. Scaling up community-based VCT requires the number of VCT 
clinics integrated at public community health centers to increase from 73 in 2010 to 
594 by 2030 and will cost between $1.3 million in 2010 and $3.8 million in 2030, 
respectively. The amount of $1.3 million in 2010 was seven times higher than the 
total VCT expenditure in 2010, and around 15 times higher than the domestic VCT 
expenditure in the same year. As such, although VCT is cost effective, massively 
scaling up the service using our proposed scenario might not seem currently 
feasible given the large resource needs and the limited and internationally 
dominated national HIV/AIDS expenditure. Special attention must be given to this 
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if the government is planning to scale up VCT, as it is one of the key components 
in the national strategy.  
 
What are the costs of providing antiretroviral treatment (ART)? (Chapter 6) 
Our study showed that treatment costs before the initiation of ART are dominated 
by laboratory tests, and after initiation by ARV drugs. The costs of ART stabilize 
over the course of treatment due to the improvement of the patient’s health, while 
a higher CD4 cell count is associated with lower costs of treatment (e.g. lower 
opportunistic infections and hospitalization costs). Alternative laboratory tests, 
early treatment, and providing alternative delivery models with involvement of 
community health services or less frequent hospital visits can create efficiency 
gains.  
 
Transportation costs dominate the patient cost to access ART and, for patients 
with lower CD4 cell count, access costs are more than 10% of their income and 
potentially cause financial burden. As such, scaling up ART at the community level 
seems best as it lowers waiting and travel time, lowers transportation costs, and 
may increase adherence and reduce barriers to access. However, important factors 
such as capacity of personnel, infrastructure, and budget implication need to be 
taken into account as these may be important barriers to effective implementation. 
 
What are the implications of the findings for the policy on HIV/AIDS in 
Indonesia? (Chapter 7) 
The last chapter synthesizes and discusses all of the findings of this thesis, and 
spells out the policy implications. We argue that although MMT is less cost 
effective than VCT, MMT should still be implemented and scaled up given its 
importance and positive effects in controlling HIV/AIDS epidemic in Indonesia.  
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When the capacity of the hospital to take care of HIV infected subjects is limited, 
scaling up of HIV services at community based clinics seems warranted. It is 
associated with early case finding, possibly leading to early treatment (and cost 
savings), and cost reductions for patients in accessing care. A strong referral and 
quality control system between hospital and community clinics, however, should be 
established. We strongly suggest that moving HIV services to the community 
should be evidence based and carefully implemented given the potential budget 
implications. We also suggest that barriers to access HIV prevention and care 
programs (such as financial barrier) should be carefully assessed. 
 
The policy recommendations in this thesis focused mainly on economic analysis, 
neglecting other important factors such as cultural and religious acceptability and 
political interest. We suggest that our results and recommendations should be 
accompanied by broader types of analyses that include these factors, such as the 
Multi-Criteria Decision Analysis (MCDA), known for its potentially broader 
application in setting priorities in healthcare. Our scope of analysis is limited to 
Bandung or West Java and our analyses evaluated highly contextualized services - 
this may hamper the generalizability of our results. However, the conceptual 
decision and methodological framework can be applied to other settings similar to 
West Java. We have also suggested further research on HIV epidemic modelling 
and the effectiveness of the community clinics in delivering HIV care.  
 
The work in this thesis has been carried out alongside a recently completed 
research and implementation program called Integrated Management for 
Prevention and Control and Treatment of HIV/AIDS (IMPACT). The integrated 
approach as implemented in the IMPACT program has provided many benefits, as 
illustrated in this thesis, and may set an example for future studies in this area.  
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De HIV/AIDS epidemie in Indonesië wordt gekenmerkt door een hoge HIV 
prevalentie onder risicogroepen als injecterende drugsgebruikers en prostituees en 
verspreid zich nu verder naar de algehele bevolking. Door het tekort aan gelden 
vanuit de overheid en de afhankelijk van internationale donorfinanciering zijn er 
zorgen over de lage dekking van programma’s en de financiële duurzaamheid. 
Gezien deze situatie is er grote behoefte aan gegevens over de kosten, effectiviteit 
en kosteneffectiviteit van HIV programma’s om beleidsmakers te informeren.  
 
In Hoofdstuk 1 komt ter sprake waarom het belangrijk is om schaarse middelen 
effectief en efficiënt in te zetten voor de HIV bestrijding en hoe economische 
analyse daaraan kan bijdragen.  
 
De hoofdvraag van dit proefschrift is dan ook: “Wat zijn de kosten en effecten van 
verschillende HIV programma’s in Indonesië?” Om deze vraag te kunnen 
beantwoorden zijn er drie deelvragen ontwikkeld die in de verschillende 
hoofdstukken worden behandeld.  
 
Wat zijn de kosten en effecten van een methadonprogramma in een 
ziekenhuis setting? (Hoofdstuk 2 en 3)  
Onze studie liet zien dat de totale kosten van het methadonprogramma US$ 7,50 
per patiënt per bezoek zijn, waarvan 65% betaald wordt door de patiënt en het 
resterende deel door de centrale overheid en het ziekenhuis. De kosten voor de 
patiënt bedraagt bijna 70% van het maandelijkse inkomen waardoor waarschijnlijk 
een groot deel van de patiënten geen of slechte toegang heeft tot 
methadonprogramma’s. De bestaande of indien mogelijk een hogere subsidie van 
de overheid (tot bijvoorbeeld 40% van de prijs voor patiënten) zal voor alle 
injecterende drugs gebruikers verstrekt moeten worden om ervoor te zorgen dat 
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het methadonprogramma betaalbaarder en daardoor toegankelijker wordt. Dit is 
belangrijk omdat druggebruikers nog steeds een belangrijke rol spelen in de HIV 
epidemie.  
 
Een opschaling van het methadonprogramma van een huidige dekking van 5% naar 
40% in 2019 zou 2438 nieuwe HIV infecties kunnen voorkomen en kost ongeveer 
US$ 7000 per voorkomen HIV infectie en ongeveer US$ 269 per gewonnen DALY 
(DisabilityAdjusted Life Years). Op basis van de criteria van de 
Wereldgezondheidsorganisatie (WHO) is deze opschaling kosteneffectief omdat 
het minder kost dan 1 keer het bruto binnenlands product van Indonesië (US$ 
3495 in 2011) per gewonnen DALY.  
 
Wat zijn de kosten en effecten van het counselen en testen op HIV in 
verschillende settingen? (Hoofdstuk 4 and 5)  
Het counselen en testen op HIV in een ziekenhuis setting is relatief duur (US$74 
per test) en bereikt alleen patiënten in een vergevorderd ziektestadium en kan 
daarom weinig bijdragen aan de vroege opsporing en behandeling van HIV.  
 
Het counselen en testen op HIV is patiëntvriendelijker en goedkoper in de 
eerstelijnsklinieken(US$39-65) maar tot nu toe zijn er nog maar weinig positief 
geteste patiënten onder behandeling met antiretrovirale middelen in deze klinieken 
(slechts 0-8%). Een systeem zal moeten worden opgezet om deze 
eerstelijnsklinieken te ondersteunen in het bieden van HIV zorg en het doorsturen 
van patiënten naar een ziekenhuis indien nodig.  
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Testen in klinieken in gevangenissen is het goedkoopste (US$23). Het is daarom 
een uitzonderlijk effectieve plek in Indonesië om patiënten te testen en te 
behandelen voor HIV, vooral ook omdat veel van de gevangen ook 
drugsgebruikers zijn en drugsgebruik een belangrijke rol speelt in de verspreiding 
van de epidemie. 
 
Het opschalen van het counselen en testen op HIV in de eerstelijnsklinieken naar 
een dekking van 80% van hoogste risicogroepen is zeer kosteneffectief (US$248 
per voorkomen HIV infectie en US$9.17 per gewonnen DALY). In dit scenario zal 
wel rekening gehouden moet worden met het grote aantal nieuwe 
eerstelijnsklinieken dat patiënten zal moeten gaan testen op HIV en de hoge totale 
kosten van het programma voor de overheid. Het totaal aantal klinieken zal moeten 
toenemen van 73 in 2010 naar 594 in 2030 en de totale kosten van dit programma 
zullen dan toenemen van US$ 1,3 miljoen in 2010 naar US$ 3,8 miljoen in 2030. 
Deze kosten van US$ 1.3 miljoen in 2010 bedragen al 7 keer zo veel als de totale 
uitgaven aan dit programma in Indonesië in hetzelfde jaar en 15 keer zoveel als het 
deel dat de overheid hieraan uit heeft uitgegeven Hoewel dit programma dus erg 
kosteffectief is zal een flinke opschaling op dit moment waarschijnlijk niet 
uitvoerbaar zijn omdat het veel middelen vraagt en de huidige financiering van HIV 
programma’s beperkt is en vooral afkomstig is van internationale donoren. Het 
opschalen van het programma is een belangrijk onderdeel van de nationale HIV 
strategie en de overheid zal dan ook rekening moeten houden met de genoemde 
barrières.  
 
Wat zijn de kosten van het aanbieden van behandeling met antiretrovirale 
middelen? (Hoofdstuk 6) 
Onze studie heeft laten zien dat voorafgaand aan het starten van de behandeling 
het grootste deel van de kosten bepaald worden door laboratoriumtesten - tijdens 
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de behandeling zijn dit de kosten voor antiretrovirale medicijnen. De kosten voor 
behandeling stabiliseren gedurende de behandeling vanwege een verbetering van de 
gezondheid van de patiënten, waarbij een hogere niveau van CD4 cellen in het 
bloed (dat wil zeggen, bij relatief gezonde patiënten) gerelateerd is aan lagere 
behandelingskosten (vanwege lagere kosten door minder opportunistische infecties 
en ziekenhuisopnames). Door het gebruik van alternatieve laboratoriumtesten, 
vroege behandeling, het verplaatsen van de zorg naar een andere setting zoals de 
eerstelijnsklinieken of minder ziekenhuisbezoeken zou een efficiëntieslag gemaakt 
kunnen worden.  
 
Kosten voor transport zorgen voor de grootste kosten voor patiënten om toegang 
te kunnen krijgen tot behandeling. Voor patiënten met een lage CD4 cel waarde in 
het bloed (dat wil zeggen, bij relatief zieke patiënten) zijn de kosten voor 
behandeling zijn zelfs meer dan 10% van hun inkomen en dit brengt ze in een 
moeilijke financiële situatie. Het opschalen van behandeling dichter bij de patiënten 
(bijvoorbeeld in de eerstelijnsklinieken) lijkt een goede oplossing omdat dat de 
wachttijd, reistijd en transportkosten verlaagt en daarmee de kans op uitval en 
barrières tot zorg vermindert. In dat geval moet er wel rekening gehouden worden 
met de capaciteit van het gezondheidszorgpersoneel, de infrastructuur en het totale 
benodigde budget omdat dit de implementatie kan hinderen.  
 
Wat zijn de implicaties van de bevindingen voor het HIV/AIDS beleid in 
Indonesië? 
In het laatste hoofdstuk worden alle resultaten van dit proefschrift samengevat en 
bediscussieerd. Wij bevelen aan dat hoewel het methadonprogramma minder 
kosteneffectief is dan het programma dat zich richt op het counselen en testen op 
HIV, het nog steeds geïmplementeerd en opgeschaald moet worden omdat het 
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belangrijke bijdrage levert aan het onder controle krijgen van de HIV epidemie in 
Indonesië.  
 
Omdat de capaciteit in het ziekenhuis beperkt is om zorg te bieden aan alle HIV 
patiënten bevelen wij aan om programma’s op te schalen op het niveau van de 
eerstelijnsklinieken. Hierdoor kunnen HIV patiënten eerder geidentificeerd worden 
wat leidt tot eerdere behandeling (en daardoor kostenbesparing) en het besparen 
van kosten van patiënten onder behandeling. Systemen tussen de ziekenhuizen en 
eerstelijnsklinieken om patiënten door te verwijzen en de kwaliteit te waarborgen 
zullen moeten worden opgezet. Het verplaatsen van de HIV zorg naar de 
eerstelijnsklinieken zal evidence-based moeten zijn en voorzichtig geïmplementeerd 
moeten worden gezien de hoge totale kosten die hierbij komen kijken. Ook zullen 
barrières voor toegang tot preventie- en zorgprogramma’s (zoals financiële 
barrieres) beter onderzocht moeten worden.  
 
Dit proefschrift richt zich vooral op de economische analyse en heeft daarbij 
minder aandacht voor belangrijke andere factoren zoals culturele en religieuze 
acceptatie. We bevelen aan dat onze resultaten daarom meegenomen worden in een 
bredere analyse, zoals Multi-Criteria Decision Analysis (MCDA), waarin meerdere 
factoren meegenomen kunnen worden in het stellen van prioriteiten in de 
gezondheidszorg. Onze analyse beperkt zich tot Bandung en West Java en 
analyseerde context-specifieke programma’s waardoor onze bevindingen wellicht 
niet generaliseert kunnen worden. Toch kunnen het conceptuele design en het 
methodologisch raamwerk van de studies worden gebruikt in andere gebieden die 
vergelijkbaar zijn met West Java. We bevelen ook aan dat meer onderzoek verricht 
moet worden naar het modelleren van de HIV epidemie en de effectiviteit van 
eerstelijnsklinieken om HIV zorg aan te bieden.   
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De studies in dit proefschrift zijn uitgevoerd tijdens een onlangs afgesloten 
onderzoeks- en implementatie project ‘Integrated Management for Prevention and 
Control and Treatment of HIV/AIDS (IMPACT). De geïntegreerde aanpak, zoals 
geïmplementeerd in het IMPACT project, heeft veel voordelen en kan een 
voorbeeld zijn voor verder onderzoek in dit vakgebied. 
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Pembahasan HIV/AIDS di Indonesia terkait dengan meningkatnya prevalensi yang 
banyak berhubungan dengan kelompok resiko tinggi seperti pengguna napza suntik 
(PENASUN) dan pekerja seks komersil (PSK), serta sistem kesehatan yang masih 
lemah. Rendahnya pembiayaan, yang masih banyak datang dari sumber 
internasional, menyebabkan adanya kekhawatiran pada cakupan layanan dan 
keberlangsungan dari pembiayaan tersebut. Dengan demikian, hasil penelitian cost 
dan effectiveness yang terpercaya terkait intervensi-intervensi yang ditujukan untuk 
menurunkan epidemi HIV/AIDS menjadi sangat penting dalam pembuatan 
kebijakan.  
 
Bab I mengemukakan perlunya penggunaan sumberdaya yang efektif dan efisien 
yang dikaji melalui analisis ekonomi terkait pengendalian HIV/AIDS di Indonesia. 
Pertanyaan utama penelitian tesis ini ialah "Berapakah biaya dan bagaimanakah efek 
dari berbagai strategi untuk pengendalian HIV/AIDS di Indonesia?". Berdasarkan 
pertanyaan utama ini,  empat pertanyaan penelitian lainnya telah dikembangkan dan 
dibahas pada bab-bab berikut.  
 
Berapakah biaya dan apakah efek dari penyediaan Program Terapi 
Rumatan Metadon (PTRM) di rumah sakit? (Bab 2 dan 3) 
Studi kami menunjukkan bahwa total biaya PTRM per kunjungan pasien ialah 
$7.50, dimana 65% dari biaya tersebut ditanggung oleh pasien dan sisanya 
ditanggung oleh pemerintah dan rumah sakit. Pasien menghabiskan sebanyak 70% 
dari pendapatan mereka untuk mengakses PTRM dimana hal ini mungkin dapat 
menghambat akses terhadap layanan ini bagi banyak pasien. Subsidi pemerintah 
saat ini (40% dari biaya penyediaan layanan) sangat diperlukan. Jumlah subdsidi ini 
bahkan dapat ditingkatkan agar layanan PTRM dapat disediakan secara lebih luas 
dan murah karena PENASUN masih merupakan faktor yang sangat penting terkait 
epidemi HIV di Indonesia.  
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Meningkatkan cakupan layanan PTRM dari 5% saat ini menjadi 40% di 2019 dapat 
menghindarkan 2,438 infeksi HIV dengan biaya $7,000 per infeksi HIV yang 
terhindarkan, atau sekitar $269 per DALY. Berdasarkan kriteria WHO, angka ini 
dapat dikategorikan sebagai cost effective karena lebih rendah dari satu kali 
Pendapatan Domestik Bruto (PDB) per kapita Indonesia ($3,495 di tahun 2011 
menggunakan US dollar tahun 2012). 
 
Berapakah biaya dan apakah efek dari penyediaan layanan berbagai model 
voluntary counseling and testing (VCT)? (Bab 4 dan 5) 
 Tes HIV/AIDS di rumah sakit mempunyai biaya yang relatif mahal (US$74 per 
tes) dan sebagian besar mencakup kasus-kasus yang sudah lanjut, sehingga 
mempunyai peran yang kecil pada deteksi dan perawatan dini. Pasien merasa lebih 
nyaman untuk melakukan tes di klinik-klinik komunitas, dan klinik ini juga 
mempunyai biaya yang lebih murah (US$39-65 per tes), tetapi keikutsertaan dalam 
layanan HIV dan antiretroviral treatment (ART) untuk mereka yang terdeteksi HIV 
positif di tingkat komunitas  sangatlah rendah (hanya 0-8%). Sebuah sistem harus 
dibangun untuk dapat mendukung klinik-klinik komunitas dalam menyediakan 
layanan HIV dan merujuk pasien ke rumah sakit. Klinik di penjara mempunyai unit 
cost terendah (US$23) dan merupakan tempat yang sangat efektif untuk 
menyediakan tes dan layanan HIV di Indonesia dimana PENASUN masih 
memegang peranan penting di dalam epidemi HIV.  
 
Peningkatan layanan VCT melalui klinik komunitas hingga mencakup 80% 
kelompok resiko tinggi di Jawa Barat sangatlah cost effective (US$248 per infeksi HIV 
terhindarkan atau US$9.17 per DALY terselamatkan), walaupun kebutuhan 
peningkatan jumlah klinik dan dampak biaya yang signifikan perlu 
dipertimbangkan. Meningkatkan layanan VCT berbasis komunitas memerlukan 
layanan VCT yang terintegrasi dengan puskesmas untuk meningkat dari 73 klinik di 
tahun 2010 menjadi 594 di 2030, dan memerlukan biaya sebanyak US$1.3 juta di 
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2010 dan US$3.8 juta di 2030. Jumlah US$1.3 juta di tahun 2010 ialah jumlah yang 
tujuh kali lebih tinggi dibandingkan dengan pengeluaran untuk VCT di 2010, dan 
15 kali lebih tinggi dari jumlah pengeluaran domestik untuk VCT di tahun yang 
sama. Dengan demikian, walaupun VCT sangatlah cost effective, peningkatan jumlah 
layanan secara besar-besaran dengan menggunakan skenario yang kami tawarkan 
nampaknya belum bisa dilaksanakan karena memerlukan sumber daya yang sangat 
besar dan pembiayaan HIV/AIDS di Indonesia saat ini masih didominasi oleh 
pembiayaan internasional. Perhatian khusus harus diberikan pada usulan ini apabila 
pemerintah berencana untuk meningkatkan jumlah layanan VCT, karena VCT ialah 
salah satu komponen kunci di dalam strategi nasional.    
 
Berapakah biaya dari penyediaan layanan antiretroviral  treatment (ART)? 
(Bab 6) 
Study kami memperlihatkan bahwa biaya layanan sebelum ART didominasi oleh  
tes laboratorium, dan setelah ART didominasi oleh obat antiretroviral. Biaya ART 
akan menjadi lebih stabil dengan berjalannya perawatan yang disebabkan oleh 
membaiknya keadaan pasien, sementara tingginnya jumlah sel CD4 diasosiasikan 
dengan lebih rendahnya biaya perawatan (disebabkan oleh rendahnya biaya infeksi 
oportunistik dan rawat inap). Tes laboratorium alternatif, perawatan dini, 
penyediaan bentuk alternatif layanan dengan melibatkan layanan kesehatan berbasis 
komunitas atau pengurangan kunjungan ke rumah sakit dapat meningkatkan 
efisiensi.     
 
Biaya transportasi mendominasi biaya pasien untuk mnegakses ART dan, untuk 
pasien dengan jumlah sel CD4 yang lebih rendah, biaya akses menghabiskan 10% 
dari pendapatan mereka dan berpotensi untuk menjadi beban finansial. Dengan 
demikian, meningkatkan ART di tingkat komunitas nampaknya merupakan solusi 
terbaik karena  berpotensi menurunkan waktu tempuh menuju layanan dan waktu 
tunggu, menurunkan biaya transportasi, dan dapat meningkatkan kepatuhan dalam 
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menjalani ART dan mengurangi halangan untuk mengakses layanan. Akan tetapi, 
faktor-faktor penting seperti kapasitas petugas, infrastruktur, dan implikasi biaya 
perlu diperhatikan karena faktor-faktor ini dapat menjadi halangan terhadap 
implementasi yang efektif.    
 
Apa implikasi dari hasil penelitian yang didapat pada kebijakan HIV/AIDS 
di Indonesia?  
(Bab 7) 
Bab terakhir merangkum dan mendiskusikan seluruh temuan dari tesis ini, dan 
mengemukakan beberapa implikasi kebijakan. Kami menekankan bahwa walaupun 
VCT lebih cost effective dari PTRM, layanan PTRM harus tetap diimplementasikan 
dan diperbanyak karena mempunyai posisi yang sangat penting dan efek positif 
dalam mengendalikan epidemi HIV/AIDS di Indonesia.  
 
Dimana terdapat keterbatasan kapasitas dari rumah sakit untuk merawat pasien 
HIV, meningkatkan jumlah layanan HIV di tingkat komunitas nampaknya 
merupakan solusi yang baik. Hal tersebut dapat diasosiasikan dengan deteksi dini, 
yang dapat mengarah ke perawatan dini (dan penghematan biaya), dan pengurangan 
biaya bagi pasien dalam mengakses layanan. Gagasan ini sangat memerlukan 
kestabilan sistem rujukan dan kontrol yang ketat terhadap kualitas antara rumah 
sakit dan klinik komunitas. Kami sangat menganjurkan bahwa untuk memindahkan 
layanan HIV ke tingkat komunitas harus didasarkan pada penelitian dan 
diimplementasikan dengan penuh pertimbangan terkait dengan implikasi biaya dari 
pemindahan tersebut. Kami juga menyarankan untuk secara seksama mempelajari 
halangan untuk mengakses program pencegahan dan layanan HIV. 
 
Rekomendasi kebijakan tesis ini terfokus pada analisis ekonomi, dan tidak 
mengikutsertakan faktor penting lainnya seperti budaya, agama, dan kepentingan 
politik. Kami menyarankan hasil penelitian kami haruslah disertai dengan tipe 
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analisis yang lebih luas lagi yang mengikutsertakan ketiga faktor tersebut, seperti 
Multi-Criteria Decision Analysis (MCDA), dikenal dengan potensinya untuk aplikasi 
yang lebih luas lagi dalam menentukan prioritas untuk layanan kesehatan. Analisis 
kami terbatas pada Bandung atau Jawa Barat dan analisis kami mengevaluasi 
layanan-layanan yang sangat spesifik - dengan demikian generalisasi dari hasil-hasil 
penelitian kami haruslah dilakukan dengan pertimbangan. Akan tetapi, konsep dan 
kerangka metode dapat diaplikasikan pada tempat lain yang serupa dengan Jawa 
Barat. Kami juga menyarankan perlunya penelitian lebih lanjut terkait pemodelan 
epidemi HIV dan efektifitas daripada klinik komunitas dalam memberikan layanan 
HIV.  
 
Pengerjaan tesis merupakan bagian dari sebuah program penelitian dan 
implementasi bernama Integrated Management for Prevention and Control and Treatment of 
HIV/AIDS (IMPACT) yang baru saja selesai di tahun 2011. Pendekatan 
terintegrasi program ini telah menyediakan banyak keuntungan, sebagaimana 
tergambar dari tesis ini, dan dapat menjadi sebuah contoh bagi studi selanjutnya di 
bidang ini.  
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